

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
**WO 2004/017810 A2**

- (51) International Patent Classification<sup>7</sup>: **A61B**
- (21) International Application Number:  
PCT/FI2003/000615
- (22) International Filing Date: 20 August 2003 (20.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
PCT/FI02/00681 20 August 2002 (20.08.2002) FI
- (71) Applicant (for all designated States except US): **BIOTIE THERAPIES CORP.** [FI/FI]; Tykistökatu 6, FIN-20520 Turku (FI).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **NATUNEN, Jari** [FI/FI]; Oolannintie 10 E 18, FIN-01520 Vantaa (FI). **TENEBERG, Susann** [SE/SE]; Postbox 1639, S-43063 Hindås (SE). **KARLSSON, Karl-Anders** [SE/SE]; Nilssonsberg 37, S-41143 Göteborg (SE). **SATOMAA, Tero** [FI/FI]; Maakaari 6 A 11, FIN-00710 Helsinki (FI). **HEISKANEN, Annamari** [FI/FI]; Trumpettitie 8 E 93, FIN-00420 Helsinki (FI).
- (74) Agent: **OY JALO ANT-WUORINEN AB**; Iso Roobertinkatu 4-6 A, FIN-00120 Helsinki (FI).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF

(57) Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.

WO 2004/017810 A2

*Tumor specific oligosaccharide epitopes and use thereof*

## FIELD OF THE INVENTION

5 The present invention relates to oligosaccharide sequences, which are specifically expressed by human tumors. The present invention describes methods for the detection of the tumor specific oligosaccharide structures disclosed in the invention as well as methods for the production of reagents binding to said oligosaccharide sequences. The invention is also directed to the use of said oligosaccharide sequences and reagents binding to them for  
10 diagnostics of cancer and malignancies. Furthermore the invention is directed to the use of said oligosaccharide sequences and reagents binding to them for the treatment of tumors, cancers and malignancies.

## BACKGROUND OF THE INVENTION

15

Various tumors express oligosaccharide sequences which are different from the non-malignant glycosylation of the same cell or tissue type. Examples of the known or speculated cancer associated oligosaccharide structures include: glycolipid structures such as globo-H (Fuc $\alpha$ 2Gal $\beta$ 3GalNAc $\beta$ 3Gal $\alpha$ 4Lac $\beta$ Cer), gangliosides: GM1  
20 Gal $\beta$ 3GalNAc $\beta$ 4(NeuNAc $\alpha$ 3)Lac $\beta$ Cer or GD2 GalNAc $\beta$ 4(NeuNAc $\alpha$ 8NeuNAc $\alpha$ 3)Lac $\beta$ Cer; Lewis-type fucosylated structures such as Lewis a and x: Gal $\beta$ 3/4(Fuc $\alpha$ 4/3)GlcNAc, Lewis y: Fuc $\alpha$ 2Gal $\beta$ 4(Fuc $\alpha$ 3)GlcNAc, sialyl-Lewis x: NeuNAc $\alpha$ 3Gal $\beta$ 4(Fuc $\alpha$ 3)GlcNAc, and some combinations of these on poly-lactosamine chains; O-glycan core structures, such as T-antigen  
25 Gal $\beta$ 3GalNAc $\alpha$ Ser/Thr-Protein, Tn-antigen GalNAc $\alpha$ Ser/Thr-Protein or sialyl Tn-antigen NeuNAc $\alpha$ 6GalNAc $\alpha$ Ser/Thr-Protein. Presence of non-human structures such as N-glycolyl-neuraminic acid in cancers has also been indicated. Association and specificity of oligosaccharide structures with regard to cancers have been well established only in few cases, some of the structures are present in normal cells and tissues and are possibly only  
30 more concentrated in cancers.

One report has indicated that structures with terminal GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc sequence are present in human leukaemia cells (Hu et al., 1994). The structures may also be equally present on normal leukocytes. Thus, the relation of the finding to glycosylation patterns  
35 generally present in solid tumors was not indicated. This type of saccharide structures may be a part of rare normal glycosylations of human tissues: GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6 sequence linked on O-glycans is probably present on human gastric mucin. A study shows that a monoclonal antibody recognizing GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 6 sequence may

possibly recognize similar structures on malignant tissues, such as mucinous ovarian neoplasms, pseudopyloric metaplasia of gallbladder and pancreatic epithelia, gastric differentiated carcinoma of stomach, gallbladder and pancreas, and on non-malignant tissues, such as human amniotic fluid, but, however, the structures from malignant tissues were not characterized (Hanisch et al., 1993). The antibody did not recognize neoglycolipid structure GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Gal $\beta$ 4 nor carcinomas of lung, colorectum, endometrium or other organs. Another monoclonal antibody raised against testicular cells probably recognizes branched N-acetylactosamines such as GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4GlcNAc- (Symington et al., 1984). Terminal GlcNAc has also been reported from mucins of human foetal mucin (Hounsell et al., 1989). In normal tissues terminal GlcNAc may be present in minor amounts as biosynthetic intermediates in the biosynthesis of poly-N-acetylactosamines.

Several monoclonal antibodies has been raised against a semisynthetic glycolipid GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$ 3Lac $\beta$ Cer, these antibodies were shown to recognize glycolipids from cultured colon cancer cell lines and tumors (Holmes et al., 1991). However, the antibodies recognized several structures and the binding data was contradictory. Moreover the glycolipids were not recognized by all of the antibodies and the glycolipid structures from cancer cells or tumors were not characterized. Therefore the presence of terminal GlcNAc structures on tumors were not established. Another study showed production of a monoclonal antibody against GlcNAc $\beta$ 3Lac $\beta$ Cer (Nakamura et al., 1993). This antibody also weakly recognized the pentasaccharide structure described above. Moreover, the antibody recognized a protease sensitive epitope on COS-1 cells, which cell line is not of human origin. The immunization protocols of these studies did not describe induced antibody responses against polyvalent conjugates of the saccharides, but immunization by glycolipids.

Normally there are large amounts of antibodies recognizing terminal GlcNAc structures in human serum. There are also a class of natural antibodies recognizing terminal Gal $\alpha$ 3Gal $\beta$ 4GlcNAc- structures. The Gal $\alpha$  antigen is not naturally present in man and recently it was also shown that the natural antibodies bind structures such as GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc, and GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc (Teneberg et al., 1996). The X2-structure, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc, is a normal antigen on human tissues and structures GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc and Gal $\alpha$ 3Gal $\beta$ 4GlcNAc have not been described from normal or cancer tissues. Thus, the present finding that the terminal GlcNAc structure is a tumor antigen indicates that the actual function of the natural antibodies might be the prevention of cancers having terminal GlcNAc structures.

The following patents describe cancer antigens and their use for making antibodies for therapeutic and diagnostic uses and for cancer vaccines. The antigen structures are not related to saccharides of the present invention:

- 5 Cancer vaccines: US patent Nos. 5,102,663; 5,660,834; 5,747,048; 5,229,289 and 6,083,929.

Therapeutic antibodies: US patent Nos. 4,851,511; 4,904,596; 5,874,060; 6,025,481 and 5,795,961.

10

Diagnostics: US patent Nos. 4,725,557; 5,059,520; 5,171,667; 5,173,292; 6,090,789; 5,708,163; 5,679,769; 5,543,505; 5,902,725 and 6,203,999.

15

In the prior art tumor diagnostic and therapeutic antibodies recognizing chitobiose-mannose trisaccharides has been described in DE 38 07 594 A1. The application also describes other N-glycans with numerous varying terminal structures some of which may comprise also non-reducing terminal N-acetyl glucosamine. Several of the desired structures have been characterized as normal glycans and not cancer specific structures. The application claims to describe structures useful for cancer applications. However, it is not clear from the invention what the structure of the desired glycan is. Formel (I) may indicate presence of non-reducing terminal GlcNAc, if it is unconventionally read from right to left. However the Formel (I) does not indicate the linkage structure of the terminal GlcNAc. The Formel (III) indicates that the GlcNAc residues are  $\alpha 2$ ,  $\alpha 4$ , or  $\alpha 6$ -linked. The present invention is not directed to such unusual structures. The present invention is directed to human tumor specific glycans comprising non-reducing end terminal  $\beta$ -linked GlcNAc residues.

20

25

30

35

Patent application WO 00/21552 claims several unusual O-glycan structures isolated from bovine submaxillary mucin. Two of the structures such as  $\text{GlcNAc}\beta 6\text{GalNAc}\alpha 6\text{GalNAc}$  and  $\text{GalNAc}\beta 3(\text{GlcNAc}\beta 6)\text{GalNAc}$  comprise terminal GlcNAc-residues. The application did not indicate that said structures would also be related to bovine or human cancers. The present invention is not directed to these structures comprising two GalNAc-residues. The application contains speculation about potential therapeutic use of the structures as antigens related to cancer. However, it has not been shown that the structures are related to bovine cancer when these are present in bovine normal submaxillary secretion. Moreover, it is even less probable that the structures would be present in human tissues, the glycosylations are species specific and vary between human and bovine, e.g. bovine and human glycosyltransferase and glycosylation profiles are different. The human genome is



also known and thus glycosyltransferases which could be related to synthesis of the claimed bovine structures should have been now produced and characterized from human. So far none of these has been described in human, or human cancer.

- 5 Meichenin et al, 2000 shows a murine monoclonal antibody which can bind to some oligosaccharides containing terminal GlcNAc $\beta$  and to certain human tissue cancer samples. The antibody was produced in mouse using the endo-beta-galactosidase treated red cells. However, the article does not establish any human specific immunotherapy with a specific antibody or other carbohydrate specific binding substance binding to an
- 10 immunogenic carbohydrate. Moreover, the fact that such an antibody with limited specificity was formed in mouse does not indicate that similar antibody would be formed in human, or it would be tolerable in human, or be useful in context of individual human tumors of specific kind, since immune reactions to carbohydrates are species specific. Endo et al, 1996 describes N-glycan type oligosaccharides from soluble protein alkaline
- 15 phosphatase of rat hepatoma AH-130 cell line. Again, material of animal origin is speculated in view of cancer specificity. Therefore, no diagnostics or therapy of human cancer is disclosed.

- Patent application FI20011671 described the general useability of terminal GlcNAc-
- 20 structures in tumor therapy. The application described specific polylactosamine type oligosaccharide sequences containing terminal GlcNAc linked to Gal especially found from glycolipid. The application indicated that the structures can be part of N-linked glycan or O-linked glycans, and that the tumorspecific oligosaccharide sequences can also be linked to O-glycosidic GalNAc. The application did not disclose exact structures of the
- 25 O-linked or N-linked glycans

- The present invention describes preferred treatment of cancer when the oligosaccharide sequences have been detected from cancer but not from normal tissues. The present invention is directed to the combination of the analysis and treatment of a cancer. The
- 30 present application also show for the first time the useability of the oligosaccharide sequences of the terminal beta-GlcNAc sequences for cancers of lung, stomach, colon, larynx and mucinous carcinomas, especially mucinous ovarian carcinomas, forming a group of epithelial type and/or mucin secreting cancers. The present invention is further especially directed to human cancer specific protein linked GlcNAc $\beta$ -structures. The
- 35 present invention is also further especially directed to the specified N-glycans and O-glycans and protein linked GlcNAc. The preferred structures form a specific family of terminal specifically "protein linked GlcNAc $\beta$ -structures" which are human protein linked defective glycosylation present in human cancer. Particularly, the preferred terminal beta-

GlcNAc O-glycans and N-glycans form a specific family of human cancer specific "protein linked GlcNAc $\beta$ -glycan cores" which are result of defective galactosylation of cancer or tumor tissue.

- 5 The present application further describes human natural antibodies and more specifically human cancer associated antibodies specifically recognizing preferred human terminal beta-linked GlcNAc structures. The present invention also describes an enzyme based targeting of the cancer antigens by transferring a modified monosaccharide derivative on cancer cells. The presence of the human natural cancer associated antibodies shows that it
- 10 is possible to use the structures as targets for cancer therapy in human in vivo. The invention is specifically further directed to antibody and other cancer targeting therapies and therapeutic immune reactions such as cancer vaccination and reagents useful for these directed to the preferred specifically protein linked GlcNAc $\beta$ -structures. The present invention is specifically further directed to antibody and other cancer targeting therapies
- 15 and therapeutic immune reactions such as cancer vaccination and reagents useful for these directed to human cancer specific protein linked GlcNAc $\beta$ -glycan cores.

- Current therapies for cancer and numerous infectious diseases are not effective enough. Cancers are major cause of deaths in industrialized countries and devastating infectious
- 20 diseases kill children and adults especially in developing countries. Infections are probably behind numerous life-style and other diseases of the industrialized world, like gastric ulcers caused by *Helicobacter pylori*.

- Previous *in vitro* studies have described the transfer of sialyl-Lewis x-oligosaccharides on surface of a cultured cell type. The cells were used to study the binding of human selectins to the sialyl- Lewis x oligosaccharides. Similarly, a blood group B-antigen has been transferred to human erythrocytes, and it was shown to be recognized by anti-blood group B antibodies. Because of the unnatural structure of the GDP-Fuc(-B-antigen), the authors stated that the structure was unsuitable for *in vivo* use. According to present invention, it is
- 30 possible to use the unnatural structures as modified monosaccharides to target microbial pathogens, viruses, tumors or cancers.

- A galactosyltransferase has been used to label human endo-beta-galactosidase modified erythrocytes (Viitala and Finne, 1984) and mouse teratocarcinoma cells (Spillmann and Finne, 1994) under *in vitro* conditions. Cell surface galactosyltransferases has been also studied in connection of various biological conditions. These studies do not describe diagnostics or therapy for any disease. The carbohydrates transferred are not monosaccharide conjugates according to the invention. The old studies utilized
- 35

radioactively labeled UDP-Gal, the chemical structure of the Gal-residue is not changed but it contains atoms enriched with  $^{14}\text{C}$  or  $^3\text{H}$ .

A fluorescently labelled muramic acid has been transferred on bacteria and the method was speculated to be used to study vaccination against the compound transferred or for interaction studies between bacteria, the transfer reaction was not specific for a type of a bacterium. The method was aimed to be used *in vitro* and the cells had to be permeabilized to achieve very weak reactions by the peptidoglycan precursor molecules (Sadamoto, R. et al 2001). In contrast the transfer reactions described by the present invention for bacteria are targeted to transfer of the carbohydrates directly to the cell surface. Preferentially the present invention is directed to *in vivo* use in the patient, which can be a human patient. Preferentially the invention is directed to use of transferring enzymes from the patients serum or transferring enzyme on the very surface of the pathogenic entity. As a separate embodiment the present invention is directed to direct cell surface vaccination against the pathogenic entity when a carbohydrate epitope is transferred.

Moreover the previous technology describes *in vitro* transfer of Gal on acceptors of a cancer cell by  $\alpha 1$ -3galactosyltransferase. The monosaccharide to be transferred is not modified nor aimed for blocking of a pathogenesis-inducing carbohydrate receptor. The invention does not describe transfer of immunologically active or toxic monosaccharide conjugates, but the terminal structure formed is reactive to anti Gal $\alpha 1$ -3Gal-antibodies. The epitope was aimed for increasing immunoreactivity of cancer cells to be injected as cancer vaccine.

Previous art also described transfer of 6-biotinylated Gal to GlcNAc-BSA or hen egg white ovalbumin or transfer of fluoresceinyl-NeuNAc to glycoproteins of golgi apparatus. The studies did not describe the therapy or diagnostics according to the invention (Bulter T. et al. 2001).

Various cell types express oligosaccharide sequences which are different from the non-malignant glycosylation of the same cell or tissue type. Association and specificity of oligosaccharide structures with regard to cancers have been well established only in few cases, some of the structures are present in normal cells and tissues and are possibly only more concentrated in cancers. The present patent application also describes terminal N-acetylglucosamine containing tumor specific oligosaccharide sequences. Priority of the recognition of the tumor specific oligosaccharide sequences by glycosyltransferases is claimed from the patent application.

Normally there are large amounts of antibodies recognizing terminal GlcNAc structures in human serum. Thus, the previous finding that the terminal GlcNAc structure is a tumor antigen indicates that the actual function of the natural antibodies might be the prevention of cancers having terminal GlcNAc structures.

5

## SUMMARY OF THE INVENTION

The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a pharmaceutical composition comprising a substance binding to a human tumor specific oligosaccharide sequence containing a terminal beta-linked N-acetylglucosamine residue, GlcNAc $\beta$ , for the treatment of human cancer. The present invention is also related to a method of determining an oligosaccharide sequence, which comprises a human tumor specific terminal beta-linked N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention also provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.

10  
15  
20

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1.** An autoradiogram of a thin-layer assay after overlaying and binding of GlcNAc $\beta$ -specific *E. coli* bacterium demonstrating the tumor specificity of the oligosaccharide sequences containing terminal GlcNAc residue: non-acidic glycosphingolipids from hypernephroma tumor (first lane) and corresponding glycosphingolipid fraction from normal kidney (second lane).

25

**Figure 2.** Thin-layer overlay assays A) using [ $^{35}$ S]-labelled, GlcNAc $\beta$ -specific *E. coli* and B) [ $^{125}$ I]-labelled Gal $\beta$ 4GlcNAc $\beta$ -specific lectin from *Erythrina cristagalli*. Lanes 1-8: Subfractions of non-acid glycosphingolipids from human hypernephroma. Lane 9: Reference glycosphingolipid GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ 1Cer. Lane 10: Reference glycosphingolipid globoside GalNAc $\beta$ 3Gal $\alpha$ 4Gal $\beta$ 4Glc $\beta$ 1Cer.

30

**Figure 3A.** Positive ion reflector mode MALDI-TOF mass spectrum of lung adenocarcinoma sample neutral glycans.

35

**Figure 3B.** Positive ion reflector mode MALDI-TOF mass spectrum of healthy lung sample neutral glycans.

**Figure 3C.** Positive ion reflector mode MALDI-TOF mass spectrum of lung adenocarcinoma sample neutral glycans after *S. pneumoniae*  $\beta$ -N-acetylglucosaminidase digestion.

**Figure 3D.** Positive ion reflector mode MALDI-TOF mass spectrum of lung adenocarcinoma neutral glycans after *S. pneumoniae*  $\beta$ -N-acetylglucosaminidase and jack bean  $\alpha$ -mannosidase digestions.

**Figure 4A.** Negative ion linear mode MALDI-TOF mass spectrum of purified nucleotide sugars after UDP-galactosamine synthesis reaction.

**Figure 4B.** Negative ion linear mode MALDI-TOF mass spectrum of purified nucleotide sugars after the UDP-GalN-biotin synthesis reaction.

**Figure 5.** Structure of UDP-GalN-biotin, uridine 5'-diphospho-N-(6-biotinamidohexanoyl)galactosamine.

**Figure 6.** Autoradiography of [ $^{14}\text{C}$ ]Gal labelled lung adenocarcinoma (a.) and healthy lung tissue (b.) sections.

**Figure 7A.** [ $^{14}\text{C}$ ]Gal labelled oligosaccharides from N-glycosidase F digested lung adenocarcinoma sample. Glycans were subjected to gel filtration HPLC with a Superdex Peptide HR 10/30 column (Pharmacia, Sweden) in 50 mM  $\text{NH}_4\text{HCO}_3$  (pH about 8.3) at a flow rate of 1 ml/min. 1 ml fractions were collected and counted for radioactivity. Fractions at 12 - 15 min were pooled.

**Figure 7B.** [ $^{14}\text{C}$ ]Gal labelled oligosaccharides from N-glycosidase F digested lung adenocarcinoma sample. The 12 - 15 min pool from Superdex Peptide gel filtration HPLC (Fig. 10A) was subjected to HPLC with a 4.6x250 mm Hypercarb 5u column (Thermo Hypersil, USA) in 10 mM  $\text{NH}_3$  at a flow rate of 0.7 ml/min, with a linear gradient of 0 % to 40 % acetonitrile in the mobile phase in 100 minutes. 0.7 ml fractions were collected and counted for radioactivity.

**Figure 7C.** [ $^{14}\text{C}$ ]Gal labelled material released by nonreductive  $\beta$ -elimination from lung adenocarcinoma sample. The material was subjected to gel filtration HPLC with a

Superdex Peptide HR 10/30 column (Pharmacia, Sweden) in 50 mM  $\text{NH}_4\text{HCO}_3$  at a flow rate of 1 ml/min. 1 ml fractions were collected and counted for radioactivity. Fractions at 8 - 15 min (pool 1) were pooled as well as at 15 - 18 min (pool 2).

- 5 **Figure 8.** Coomassie Blue stained reducing SDS-PAGE gels. Arrowheads indicate the positions of IgG heavy and light chains, respectively. (A.) Serum from a person who had recovered from mucinous ovarian adenocarcinoma, GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  Sepharose; left: 0.5 M GlcNAc elution, right: acidic elution. (B.) IgG from pooled human sera, GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  Sepharose; left: 0.5 M GlcNAc elution, right: acidic elution. (C.) Silver stained gel.
- 10 Serum from a person who had recovered from mucinous ovarian adenocarcinoma, Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  Sepharose; left: 0.5 M GlcNAc elution, right: acidic elution.

**Figure 9.** The chemical structure of UDP-GalN-PEG-fluorescein reagent.

- 15 **Figure 10.** Fluorescence microscopy of GalN-PEG-fluorescein labeled tumor tissue sections. A. Control reaction without the enzyme at 460-490 nm. B. Control reaction without the enzyme at 530-550 nm. C. Reaction with the enzyme at 460-490 nm. D. Reaction with the enzyme at 530-550 nm. E. Reaction with the enzyme at 460-490 nm. F. Reaction with the enzyme at 530-550 nm.

## 20 DETAILED DESCRIPTION OF THE INVENTION

- The present invention is directed to terminal  $\beta$ -linked N-acetylglucosamine oligosaccharide chain structures and protein linked monosaccharide N-acetylglucosamine which are presented by human tumors. The present invention realizes specific defects in human tumors, which leads to cell surface and extracellular presentation of unusual
- 25 carbohydrates comprising terminal N-acetylglucosamines. In general the terminal GlcNAc-structures are very rare in human normal tissues. The expression of the structures are caused by two factors. For the first the biosynthesis and degradation machinery in the tumor cells does not work properly. Many terminal structures in normal tissues comprise galactose on GlcNAc-residues, these structures are capped by sialic acids, blood group
- 30 antigens and the like. The present data indicates that the cancer or tumor carbohydrates are exposed to unusual glycosidase activities and the defective glycosylation reactions by  $\beta$ 4- and possibly also by  $\beta$ 3-galactosyltransferases. Defects were observable in all 3 types of  $\beta$ -galactosylated oligosaccharide sequences. Secondly, the intracellular targeting and quality control of glycosylation including glycoprotein and glycolipid structures seem to
- 35 be defective. In normal cells the glycosylation is under quality control which recirculates underglycosylated proteins and glycolipids to complete the natural glycosylation, so that in normal cells the amount of the structures disclosed in the invention are very rare on cell surfaces. In normal cells or tissues the oligosaccharide structures described by the invention are present in low amounts in human golgi apparatus, the known protein linked

GlcNAc is considered to be almost exclusively a cytoplasmic nuclear protein modification. The defects in organization of the golgi apparatus leads to partial cell surface expression of the tumor specific structures described by the present invention. Even intracellularly overexpressed structures according to the present invention are directly useful for diagnostic applications.

The defects in galactosylation and presence of unusual glycosidase activities and loss of intracellular quality control lead to three types of tumor associated glycosylations:

1. incomplete, undergalactosylated protein linked N-glycan and incomplete, undergalactosylated
2. O-glycan core structures,
3. moreover polylactosamines are also undergalactosylated as exemplified by poly-N-acetylactosamine type glycolipid from human hypernephroma.

These defects lead to several unusual terminal epitopes on glycoproteins. The present invention is directed to the three groups of oligosaccharide epitopes. The current invention notices for the first time similar general defect on all three types of glycan chains carrying normally  $\beta$ -galactosylated oligosaccharide sequences. Terminal  $\beta$ -linked GlcNAc is present as terminal structure. The structures indicate defects in enzymatic steps directly modifying the terminal GlcNAc-residues including  $\beta$ 1,4(3)-Gal-transferase reactions and on the other hand increased glycosidase activities in the Golgi-pathway which could degradate terminal structures. However, the generality of the defect in 3 types of carbohydrates would indicate that organization of the golgi apparatus is so disturbed that terminally modifying enzymes located in late golgi cannot effectively modify all glycans expressed by tumor cells.

Furthermore present invention is directed to

4. missdirected expression of protein linked N-acetylglucosamine monosaccharide on cancers and tumors.

The protein linked N-acetylglucosamine is in general present in so called O-GlcNAc-structures intracellularly. The present invention notices strong overexpression of the protein linked N-acetylglucosamine. The overexpression leads to even some cell surface associated labeling of the O-linked GlcNAc on human tumors.

Though the terminal  $\beta$ -linked GlcNAc is common to the all three groups 1-3 above, it is realized that the subterminal structures have effect on the structures which should be recognized in diagnostic or therapy of tumors or cancers. The present invention is specifically directed to therapeutic and diagnostic uses of terminal oligosaccharide sequences comprising the terminal GlcNAc and one to several neighboring

monosaccharide residues in the three defective oligosaccharide sequence groups. The present invention is directed to the oligosaccharide sequences comprising nonreducing end terminal  $\beta$ -GlcNAc oligosaccharide sequences on polylactosamines, or O-glycans or N-glycans. The invention is directed to all of the defective glycosylation types when an analysis of normal glycosylation and potential general glycosylation defect is used together. The invention is further directed to the use of combinations of at least two of the four terminal GlcNAc type structures, especially the use of the polylactosamine type terminal GlcNAc-sequence in combination with the other terminal GlcNAc-structures as

General galactosylation defect and specific protein galactosylation defect

The present invention discovered that the defect of the glycosylation may be general and affect at least two classes of the four defective classes of terminal GlcNAc $\beta$ -glycosylations disclosed in the invention: O-glycans, N-glycans, polylactosamines and protein linked GlcNAc. In a specific embodiment the general defect of galactosylation affects both specific protein linked glycosylations and glycolipid linked glycosylations, especially polylactosamine type terminal GlcNAc-structures of glycolipids. The present invention is specifically directed to detecting presence of general galactosylation defect from a cancer sample and/or from normal tissue sample of a person. The present invention is directed to the analysis of the general glycosylation defect producing the multiple types of terminal GlcNAc structures. The defect may be analyzed by an analysis of the carbohydrate samples as described by the invention. The galactosylation defect may be analyzed also by, for example, genetic or biochemical or cell biological means by analyzing production and/or activity and/or localization of enzymes or other proteins or biochemical mediators capable of producing the general glycosylation defect. The invention is directed to detecting general glycosylation defect when the intracellular structures involving glycan biosynthesis and/or degradation are defective. The present invention is especially directed to the analysis of the general glycosylation defect by genetic and/or biochemical and/or cell biological means when the method is verified with the analysis of carbohydrate structures, preferably the carbohydrate structures are analyzed by mass spectrometry and/or with known chemical and/or enzymatic methods and/or by substances according to the invention specifically binding and/or modifying the terminal GlcNAc $\beta$ -structures disclosed in the invention.

The analysis of the general glycosylation defect in cancer sample and/or normal tissues of patient is preferably used for selecting patients for treatment of cancer disclosed in the invention. The analysis of the general glycosylation defect in normal tissue(s) is according to the invention directed to be also used for predicting susceptibility or risk for a person



for getting cancer and/or selecting persons for additional screening for cancer. The individual analysis of the normal tissue glycosylations and/or the general galactosylation defect disclosed in the invention is preferable as the normal glycosylation was noticed to vary in some cancer patients as described in the examples. In a preferred embodiment the invention is directed to the prediction of a high risk for cancer, especially for a person with "cancer type" terminal GlcNAc structures present in high amounts in normal tissue.

The present invention is especially directed to therapies targeting structures from at least two classes of defective glycosylations, i.e. terminal GlcNAc $\beta$ -glycosylations disclosed in the invention: O-glycans, N-glycans, polylactosamines and protein linked GlcNAc. In a preferred embodiment at least three classes or all four terminal GlcNAc-type structures are targeted. The invention is specifically directed to the targetting of the polylactosamine type structures together with the any other of the terminal GlcNAc $\beta$ -structures. In a preferred embodiment the polylactosamine type structures are targetted together with the protein specific N-glycan structures.

Specific glycosylation defect, especially protein glycosylation defect

The present invention further discloses a glycosylation defect wherein the intracellular structures involving glycan biosynthesis and/or degradation are defective. When a specific class of terminal GlcNAc $\beta$ -structures is defective, the specific glycosylation defect may be detected by analyzing alteration in activity and/or localization of specific enzymes synthesizing or degrading glycan structures to create terminal GlcNAc-structures. The present invention is especially directed to the analysis of the specific glycosylation defect by genetic and/or biochemical and/or cell biological means when the method is verified with the analysis of carbohydrate structures disclosed in the invention, preferably the carbohydrate structures are analyzed by mass spectrometry and/or with known chemical and/or enzymatic methods and/or by substances disclosed in the invention specifically binding and/or modifying the terminal GlcNAc $\beta$ -structures disclosed in the invention.

Tumor and cancer specific defective terminal protein linked GlcNAc $\beta$ -structures

The present invention is especially directed to human cancer specific protein linked GlcNAc $\beta$ -structures. The data of the present application shows that protein fractions isolated from certain tumors express many terminal GlcNAc-structures on N-glycan and O-glycan type, especially "specifically protein linked GlcNAc $\beta$ -structures", which means that the GlcNAc-structures are present in core structures of N-glycans or O-glycans and not elongated as lactosamine structures. For example the experiment about the protein fraction from the same hypernephroma tumor previously shown to contain glycolipid linked GlcNAc $\beta$ Gal-structures, was now shown to express much of the specifically protein

linked GlcNAc $\beta$ -structures such as N-glycan with terminal GlcNAc $\beta$ 2Man-terminals. The present invention is thus especially directed to the specified N-glycans and O-glycans and protein linked GlcNAc structures as "specifically protein linked GlcNAc structures". The preferred structures form a specific family of terminal protein linked GlcNAc $\beta$ -structures which are human protein linked defective glycosylations present in human cancer. The present invention further disclose specific preferred N-glycan structures and O-glycan structures. The preferred terminal beta-GlcNAc O-glycans and N-glycans form a specific family of human cancer specific "protein linked GlcNAc $\beta$ -glycan cores" which are result of defective galactosylation of cancer or tumor tissue.

The present application further describes human natural antibodies and more specifically human cancer associated antibodies specifically recognizing preferred human terminal beta-linked GlcNAc structures. The application also describes an enzyme based targeting of the cancer antigens by transferring a modified monosaccharide derivative on cancer cells. The presence of the human natural cancer associated antibodies shows that it is possible to use the structures as targets for cancer therapy in human *in vivo*. The invention is specifically further directed to antibody and other cancer targeting therapies and therapeutic immune reactions such as cancer vaccination and reagents useful for these directed to the preferred specifically protein linked GlcNAc $\beta$ -structures. The present invention is specifically further directed to an antibody and other cancer targeting therapies and therapeutic immune reactions such as cancer vaccination and reagents useful for these directed to human cancer specific protein linked GlcNAc $\beta$ -glycan cores.

1. Incomplete, undergalactosylated or degraded N-linked glycans.

The N-glycans described here belong to specifically protein linked GlcNAc $\beta$ -structures and protein linked GlcNAc $\beta$ -glycan cores disclosed in the invention. The structures include the natural N-glycans and terminal structure containing fragments thereof useful as for immunization or as a binding epitope for targeting substances. All structures contain specific GlcNAc $\beta$ 2Man-structure.


The inventors have characterized by mass spectrometry several N-glycan structures comprising terminal GlcNAc residues from tumors such as larynx, stomach, colon and lung tumors. The present invention shows that the overexpression of the N-glycans on tumors is common. The novel N-glycan type tumor antigens were also detected specifically by novel glycosyltransferase methods from tissue sections of tumors but not or in lower amounts in corresponding normal or non-malignant tissues.

The present invention is directed to N-glycan structure

GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc $\beta$ Asn

and oligosaccharide substructures thereof carrying non-reducing end protein or peptide linked terminal GlcNAc. Asn indicates asparagine amino acids directly linked to the protein in the natural antigen. The natural protein linked oligosaccharide should contain the reducing end GlcNAc $\beta$ Asn- structure and at least one of the branches carrying the terminal GlcNAc $\beta$ 2Man. When the N-glycan structure is used for making antigenic epitopes, the present invention is directed to at least one of natural oligosaccharide sequence structures and structures truncated from the reducing end of the N-glycan according to the following

Formula



wherein

$r1, r2, r3, r4, r5,$  and  $r6$  are either 0 or 1,

with the proviso that at least  $r1$  is 1 or  $r2$  is 1.

- GN is GlcNAc, with the proviso that when both  $r1$  and  $r2$  are 1, one GN $\beta$ Man can be further elongated by one or several other monosaccharide residues such as galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6-residue and or Man $\alpha$ 3 residues can be further substituted by GN $\beta$ 6 or GN $\beta$ 4, and/or Man $\beta$ 4 can be further substituted by GN $\beta$ 4.

The structures represent truncated forms of known N-linked glycan structures on human N-glycans. Such structures are rare on normal tissues and thus the structures are suitable for immunodiagnostics.

- A group of more preferred structures are represented by formula:



wherein

- $r1, r2, r5,$  and  $r6$  are either 0 or 1,

with the proviso that at least  $r1$  is 1 or  $r2$  is 1.

- GN is GlcNAc, with the proviso that when both  $r1$  and  $r2$  are 1, one GN $\beta$ Man can be further elongated by one or several other monosaccharide residues such as galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6-residue and/or Man $\alpha$ 3 residues can be further substituted by GN $\beta$ 6 or GN $\beta$ 4, and/or Man $\beta$ 4 can be further substituted by GN $\beta$ 4.

In a more preferred embodiment GN is GlcNAc, with the proviso that when both r1 and r2 are 1, one GN $\beta$ Man can be further elongated by one or several other monosaccharide residues such as galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6-residue,

5 and most preferably GN is GlcNAc.

The preferred non-elongated structures include:

GlcNAc $\beta$ 2Man, GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
10 GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man, GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc,  
15 Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man, Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man,  
20 GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc.

More preferred N-glycan oligosaccharide sequences include:

GlcNAc $\beta$ 2Man, GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
25 GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc, Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man,  
GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc.

30

And most preferred N-glycan oligosaccharide sequences include:

GlcNAc $\beta$ 2Man, GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc, Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
35 Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc.

2. Incomplete, undergalactosylated or degraded O-linked glycans.

The O-glycans described here belong to specifically protein linked GlcNAc $\beta$ -structures and protein linked GlcNAc $\beta$ -glycan cores disclosed in the invention. The structures include the natural O-glycans and terminal structure containing fragments thereof useful as  
5 for immunization or as a binding epitope for targeting substances. All structures contain specific GlcNAc $\beta$ GalNAc, preferably GlcNAc $\beta$ GalNAc $\alpha$ -structure.

The inventors have also found out that O-glycans of tumors contain structures carrying terminal  $\beta$ -linked GlcNAc. The O-glycan specificity for tumor is demonstrated in the  
10 examples by describing specific natural cancer associated antibody from a person recovered from ovarian cancer and by absence of the antibody in a pool of sera from persons without cancer background.

The present invention is specifically directed to human tumor specific O-glycan core  
15 structures comprising terminal  $\beta$ -linked GlcNAc residues, preferably with the provision that the O-glycan sequences do not comprise GalNAc-GalNAc sequence. The preferred O-glycan oligosaccharide sequences comprise at least one oligosaccharide sequence according to the formula:



wherein s1, s2, and s5 are independently 0 or 1, with proviso that at least s1 is 1 or s5 is 1. When there is two GlcNAc structures, one may be substituted with Gal, NeuNAc $\alpha$ Gal or other natural oligosaccharide sequences. The Gal-residue may be further substituted with  
25 sialic acid or other natural oligosaccharide sequences, in a preferred embodiment the Gal-residue is sialylated.

Preferred O-glycan oligosaccharide sequences include:

30 GlcNAc $\beta$ 3Gal $\beta$ 3(Gal $\beta$ 4GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3Gal $\beta$ 3GalNAc, Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 6GalNAc, GlcNAc $\beta$ 3GalNAc, and SA $\alpha$ Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, wherein SA is sialic acid, preferably Neu5Ac or Neu5Gc or derivative such as O-acetylated derivative thereof which may be  $\alpha$ 3- or  $\alpha$ 6-linked to Gal.

35 More preferably O-glycan oligosaccharide sequences include:

GlcNAc $\beta$ 3Gal $\beta$ 3GalNAc, Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 6GalNAc and GlcNAc $\beta$ 3GalNAc and NeuNAc $\alpha$ Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc.

Most preferred O-glycan sequences include Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3GalNAc, GlcNAc $\beta$ 6GalNAc and NeuNAc $\alpha$ 3Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc.

The O-glycan means that the original antigen is protein/peptide linked from the reducing end to serine or threonine, preferably alpha linked to serine or threonine, or conjugate or analog thereof. The oligosaccharide may also be linked to other carrier aglycon or aglycon spacer structures. Linkage to aglycon or aglycon spacer means that the epitopes are not, at least not directly, linked to carbohydrate, especially not linked to GalNAc $\alpha$ . Aglycon preferably comprises at least one CH<sub>2</sub>-group like in serine or threonine, giving preferred structures OS $\alpha$ -O-CH<sub>2</sub>-R, wherein OS is an oligosaccharide according to the invention and R is rest of the aglycon or spacer, preferably comprising additional methylene or acyclic alkyl-structures. In a separate embodiment the O-glycan is linked by a beta linkage as described above.

The present invention is specifically directed to human antibodies recognizing O-glycan oligosaccharide sequence structures Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, and/or GlcNAc $\beta$ 6GalNAc but not Gal $\beta$ 3(Gal $\beta$ 4GlcNAc $\beta$ 6)GalNAc, and/or Gal $\beta$ 4GlcNAc $\beta$ 6GalNAc and therapeutic and diagnostic uses of these as described by the present invention. In a preferred embodiment the present invention is directed to human antibody recognizing effectively oligosaccharide sequence Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc but not oligosaccharide sequence Gal $\beta$ 3(Gal $\beta$ 4GlcNAc $\beta$ 6)GalNAc. GlcNAc $\beta$ 3GalNAc is also preferred O-glycan type target for human antibodies. In preferred embodiment the human antibody is natural antibody. In another embodiment the antibody is induced by a cancer vaccine. In more preferred embodiments the human antibody is an IgG or IgA or IgM antibody, most preferably a IgG antibody.

As separate embodiment the present invention is directed to uses of to rare sialylated variants of the O-glycan core structures such as GlcNAc $\beta$ 3(NeuNAc $\alpha$ 6)GalNAc or NeuNAc $\alpha$ 3Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc.

### 3. Poly-N-acetylactosamine type sequences containing terminal GlcNAc $\beta$ 3 and /or GlcNAc $\beta$ 6

The polylactosamine sequences described here do not belong to specifically protein linked GlcNAc $\beta$ -structures and protein linked GlcNAc $\beta$ -glycan cores according to the invention.

The structures are useful in combination with the protein specific structures and other specific methods described by the invention.

The present invention describes the presence of terminal N-acetylglucosamine (GlcNAc) on poly-N-acetyllactosamine type structures on human tumors. The structures were first found in large amounts from a human hyper nephroma tumor in one out of four tumors studied. The glycolipid fraction of the tumor was characterized to contain terminal N-acetylglucosamines by a specific radiolabelled *Escherichia coli* strain and FAB-mass spectrometry of permethylated sample. The glycolipid fraction also contained terminal N-acetyllactosamines, which could be detected by using a specific lectin. Screening of normal kidney glycolipids by the bacterium showed that the terminal GlcNAc was not present in the corresponding normal tissue, as it was not present in several other control tissues.

One embodiment of the present invention describes detection or isolation of an oligosaccharide sequence or oligosaccharide sequences comprising a terminal N-acetylglucosamine residue from tumor.

Following saccharide sequences are among the tumor specific structures to be isolated or detected: GlcNAc $\beta$ 3Gal, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcNAc $\beta$ 6Gal, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4GlcNAc, GlcNAc $\beta$ 6Gal or GlcNAc $\beta$ 6Gal $\beta$ 4GlcNAc, the sequences are part of poly-N-acetyllactosamine chains so that the chains comprise at least one terminal  $\beta$ -linked GlcNAc.

In a more preferred embodiment the present invention is directed to non- $\beta$ 6- containing linear polylactosamine sequences: GlcNAc $\beta$ 3Gal, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc3Gal $\beta$ 4GlcNAc.

In a separate embodiment the present invention is directed to  $\beta$ 6- containing non-branched polylactosamine sequences: GlcNAc $\beta$ 6Gal, GlcNAc $\beta$ 6Gal $\beta$ 4GlcNAc, GlcNAc $\beta$ 6Gal $\beta$ 4GlcNAc3Gal $\beta$ 4GlcNAc.

A preferred group of poly-N-acetyllactosamine type sequences are  $\beta$ 3-,  $\beta$ 6-branched structures, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4GlcNAc, Gal $\beta$ 4GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4GlcNAc. Then branched structures resemble branched O-glycan structures.

Structures with type one N-acetyllactosamine, GlcNAc $\beta$ 3Gal $\beta$ 3GlcNAc, or GlcNAc $\beta$ 6Gal $\beta$ 3GlcNAc are also among the compounds within the scope of the invention.

#### 4. Protein linked N-acetylglucosamine

The protein linked GlcNAc described here belong to specifically protein linked GlcNAc $\beta$ -structures according to the invention. The inventors have characterized protein linked GlcNAc residues from tumors such as larynx, stomach, colon and lung tumors. The

present invention shows that the overexpression of the protein linked GlcNAc expression on tumors is common. The novel N-glycan type tumor antigens were also detected specifically by novel glycosyltransferase methods from tissue sections of tumors but not or in lower amounts in corresponding normal or non-malignant tissues. The analysis of the protein linked GlcNAc indicated presence of several forms of protein linked GlcNAc

In a specific embodiment the present invention is directed according to the present invention to therapeutic, and diagnostic uses, and pharmaceutical compositions, comprising beta linked N-acetylglucosamine monosaccharide residue, GlcNAc $\beta$ . Most of the tumors cells carry the O-glycan like GlcNAc releasable by  $\beta$ -elimination.

The present invention is in a preferred embodiment directed to the uses according to the present invention using O-glycosidic structures GlcNAcSer and/or GlcNAcThr,

wherein the hydroxyl groups serine and threonine residues are glycosidically linked to the GlcNAc residue. The serine (Ser) and threonine (Thr) amino acid residues are in a preferred embodiments parts of peptides or peptide conjugates or derivatized from amino- and/or carboxylic acid groups.

In another preferred embodiment the present invention is directed to the uses of GlcNAcX, wherein X is aglycon preferably mimicking serine or threonine amino acid residues described above.

In a preferred embodiment GlcNAc $\beta$ Ser and/or GlcNAc $\beta$ Thr, GlcNAc $\beta$ X is linked to polyvalent carrier according to the present invention for uses described by the invention, preferably to a carrier useful for vaccination, and most preferably to a carbohydrate carrier as described by the present invention.

In another preferred embodiment GlcNAc $\alpha$ Ser and/or GlcNAc $\alpha$ Thr, GlcNAc $\alpha$ X is linked to polyvalent carrier according to the present invention, preferably to a carrier useful for vaccination, and most preferably to a carbohydrate carrier as described by the present invention.

The present invention is also directed to  $\beta$ -linked N-glycosidic analogs of the O-glycan type structures described above, for example GlcNAc $\beta$ -Asn and peptide derivatives and analogs thereof. In biological samples such structures are formed by exoglycosidases or by endo-N-acetylglucosaminyltransferase.

#### Preferred human specific immune reactions

The present invention describes novel natural immune reactions found from persons having cancer or which have been cured from cancer. Possibility of human immune reaction against a novel carbohydrate cannot be guessed from animal data due to species



specificity of glycosylation, The invention is especially directed novel human cancer associated immune reactions and human cancer associated antibodies including corresponding humanized antibodies against O-glycan structures GlcNAc $\beta$ 3GalNAc, GlcNAc $\beta$ 6(Gal $\beta$ 3)GalNAc, N-glycan structures comprising terminal GlcNAc $\beta$ 2Man, especially ones binding GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man, and the protein linked GlcNAc-structure, especially when the antibody binds to GlcNAc $\beta$ -O-CH<sub>2</sub>-R, where in the structure is O-glycosidically linked to serine or threonine or an aglycon represented by R as described for O-glycans. The antibody reactions were especially effective against O-glycan structures. Both IgM and IgG antibodies against all structures were observed. The invention is targeted both human IgG and IgM antibodies recognizing the preferred structures.

#### General structures representing oligosaccharide sequences

The oligosaccharide sequences of the invention can be a part of a glycolipid, a part of a glycoprotein, and/or a part of a N-acetylactosamine chain. The tumor specific oligosaccharide sequences can also be a part of glycolipids, a part of N-linked glycans or O-linked glycans of glycoproteins. The tumor associated oligosaccharide sequences can also be directly linked to O-glycosidic GalNAc. Defects or changes in biosynthetic and/or biodegradative pathways of tumors lead to the synthesis of the oligosaccharide sequences of the invention both on glycolipids and glycoproteins. Terminal N-acetylglucosamine means that the non-reducing end GlcNAc residue in an oligosaccharide chain is not substituted by any other monosaccharide. The term oligosaccharide sequence indicates that the monosaccharide residue/residues in the sequence are part of a larger glycoconjugate, which contains other monosaccharide residues in a chain, which may be branched, or natural substituted modifications of oligosaccharide chains. The oligosaccharide chain is normally conjugated to a lipid anchor or to a protein. In a preferred embodiment the oligosaccharide sequences according to the present invention are non-reducing terminal oligosaccharide sequences, which means here that the oligosaccharide sequences are not linked to other monosaccharide or oligosaccharide structures except optionally from the reducing end of the oligosaccharide sequence. The oligosaccharide sequence when present as conjugate is preferably conjugated from the reducing end of the oligosaccharide sequence, though other linkage positions which are tolerated by the antibody/binding substance binding can also be used. In a more specific embodiment the oligosaccharide sequence according to the present invention means the corresponding oligosaccharide residue which is not linked by natural glycosidic linkages to other monosaccharide or oligosaccharide structures. The oligosaccharide residue is preferably a free oligosaccharide or a conjugate or derivative from the reducing end of the oligosaccharide residue.

Minor species of ganglio- or galactosylglobosides can also represent the tumor specific terminal GlcNAc: terminal Gal $\beta$ 4GlcNAc $\beta$ 3/ $\beta$ 6 structures are linked to the glycolipid cores in some tissues and under low galactosylation conditions described by the invention  
5 terminal GlcNAcs can be revealed.

In another embodiment of the invention the tumor specific oligosaccharides are detected for the diagnostics of cancer or tumor.

- 10 Preferably the tumor specific oligosaccharide sequence is detected by a specific binding substance which can be an aptamer, lectin, peptide, or protein, such as an antibody, a fragment thereof or genetically engineered variants thereof. More preferably the specific binding substance is divalent, oligovalent or polyvalent. Most preferably the binding substance is a lectin or an antibody.

15 Specific binding combinatorial chemistry libraries can be used to search for the binding molecules. Saccharide binding proteins, antibodies or lectins can be engineered, for example, by phage display methods to produce specific binders for the structures of the invention. Labelled bacteria or cells or other polymeric surfaces containing molecules  
20 recognizing the structures can be used for the detection. Oligosaccharide sequences can also be released from cancer or tumor cells by endoglycosidase enzymes. Alternatively oligosaccharides can be released by protease enzymes, such as glycopeptides. Chemical methods to release oligosaccharides or derivatives thereof include, e.g., otsonolysis of glycolipids and beta-elimination or hydrazinolysis methods to release oligosaccharides  
25 from glycoproteins. Alternatively the glycolipid fraction can be isolated. A substance specifically binding to the tumor specific oligosaccharide sequences can also be used for the analysis of the same sequences on cell surfaces. Said sequences can be detected, e.g., as glycoconjugates or as released and/or isolated oligosaccharide fractions. The possible methods for the analysis of said sequences in various forms also include NMR-  
30 spectroscopy, mass spectrometry and glycosidase degradation methods. Preferably at least two analysis methods are used, especially when methods of limited specificity are used.


Analysis of multiple cancer specific structures simultaneously from mass spectrometric profiles

- 35 The present invention is especially directed to the analysis and/or comparison of several analytical signals, preferably mass spectrometry signals produced from a sample comprising total fraction of oligosaccharides released from a cancer or a tumor sample. A single mass spectrum of an oligosaccharide fraction comprise a profile of glycosylation

and multiple peaks indicating the potential presence of the oligosaccharide sequences and potential presence of cancer specific oligosaccharide sequences and altered levels thereof in comparison to normal tissue sample. The profiles are determined preferably by MALDI-TOF spectrometry as described in Examples. The total oligosaccharide fraction

5 corresponds preferably total fraction of protein oligosaccharides, preferably comprising at least one cancer or tumor specific oligosaccharide sequence according to the invention. In another preferred embodiment the total oligosaccharide fraction comprises at least one cancer or tumor specific O-glycosidic and one N-glycosidic oligosaccharide according to the invention. The present invention is further directed to analysis of the multiple mass  
10 spectrometric signals when the total oligosaccharide fraction released from a cancer or tumor sample after an enzymatic or a chemical digestion step. The enzymatic digestion is preferably performed by a glycosidase enzyme, preferably selected from the group: galactosidase, sialidase, N-acetylhexosaminidase, N-acetylglucosaminidase, fucosidase or mannosidase.

15 The present invention is also directed to the use of the tumor specific oligosaccharide sequences or analogs or derivatives thereof to produce polyclonal or monoclonal antibodies recognizing said structures using following process: 1) producing synthetically or biosynthetically a polyvalent conjugate of an oligosaccharide sequence of the invention or analogue or derivative thereof, the polyvalent conjugate being, for instance, according  
20 to the following structure: position C1 of the reducing end terminal of an oligosaccharide sequence (OS) comprising the tumor specific terminal sequence of the invention is linked (-L-) to an oligovalent or a polyvalent carrier (Z), via a spacer group (Y) and optionally via a monosaccharide or oligosaccharide residue (X), forming the following structure



25 where integer m have values  $m > 1$  and n is independently 0 or 1; L can be oxygen, nitrogen, sulfur or a carbon atom; X is preferably lactosyl-, galactosyl-, poly-N-acetyl-  
30 lactosaminy, or part of an O-glycan or an N-glycan oligosaccharide sequence, Y is a spacer group or a terminal conjugate such as a ceramide lipid moiety or a linkage to Z; 2) immunizing an animal or human with polyvalent conjugate together with an immune response activating substance. Preferably the oligosaccharide sequence is polyvalently conjugated to an immune response activating substance and the conjugate is used for  
35 immunization alone or together with an additional immune response activating substance. In a preferred embodiment the oligosaccharide conjugate is injected or administered mucosally to an antibody producing organism with an adjuvant molecule or adjuvant molecules. For antibody production the oligosaccharide or analogs or derivatives thereof

can be polyvalently conjugated to a protein such as BSA, keyhole limpet hemocyanin, a lipopeptide, a peptide, a bacterial toxin, a part of peptidoglycan or immunoactive polysaccharide or to another antibody production activating molecule. The polyvalent conjugates can be injected to an animal with adjuvant molecules to induce antibodies by routine antibody production methods known in the art.

Antibody production or vaccination can also be achieved by analogs or derivatives of the tumor specific oligosaccharide sequences. Simple analogs of the N-acetyl-group containing oligosaccharide sequences include compounds with modified N-acetyl groups, for example, N-alkyls, such as N-propanyl.

Analogues that can be used for the production of antibodies binding GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc include sequences Hex(NAc) $_{0-1}\alpha$ 3Gal $\beta$ 4GlcNAc, Hex(NAc) $_{0-1}\beta$ 3Gal $\beta$ 4GlcNAc, where Hex is hexose, preferably Gal or Glc. The analogs may also comprise molecules where GlcNAc is replaced by a close isomer such as ManNAc.

According to the invention it is possible to use the tumor specific oligosaccharide sequences for the purification of antibodies from serum, preferably from human serum. Normally there are large amounts of antibodies recognizing terminal GlcNAc structures in human serum. There is also a class of natural antibodies recognizing terminal Gal $\alpha$ 3Gal $\beta$ 4GlcNAc structures. The Gal $\alpha$  antigen is not naturally present in human and recently it was shown that the natural antibodies also bind *in vitro* structures GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc, and GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc (Teneberg et al., 1996). The X2-structure, GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc, is a normal antigen on human tissues and structures GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc and Gal $\alpha$ 3Gal $\beta$ 4GlcNAc have not been described from human normal or cancer tissues. Thus, the present finding that the terminal GlcNAc-structure is a tumor antigen indicated that it is possible that the actual function of the natural antibodies is to prevent cancers and destroy tumors having terminal GlcNAc-structures. The tumor specific oligosaccharides or derivatives or analogs, such as a close isomer, can also be immobilized for the purification of antibodies from serum, preferably from human serum. The present invention is directed to natural human antibodies which bind strongly to the tumor specific oligosaccharide sequences according to the present invention.

The tumor specific oligosaccharide sequences can also be used for detection and or quantitation of the human antibodies binding to the tumor specific oligosaccharide sequences, for example, in enzyme-linked immunosorbent assay (ELISA) or affinity chromatography type assay formats. The detection of human antibodies binding to the

tumor specific oligosaccharide sequences is preferably aimed for diagnostics of cancer, development of cancer therapies, especially cancer vaccines against the oligosaccharide sequences according to the present invention, and search for blood donors which have high amounts of the antibodies or one type of the antibody.

5

Furthermore, it is possible to use human antibodies or humanized antibodies against the tumor specific oligosaccharide sequences to reduce the growth of or to destroy a tumor or cancer. Human antibodies can also be tolerated analogs of natural human antibodies against the tumor specific oligosaccharide sequences; the analogs can be produced by  
10 recombinant gene technologies and/or by biotechnology and they may be fragments or optimized derivatives of human antibodies. Purified natural anti-tumor antibodies can be administered to a man without any expected side effect as such antibodies are transferred during regular blood transfusions. This is true under conditions that the tumor specific structures are not present on normal tissues or cells and do not vary between individuals as  
15 blood group antigens do, however, such blood-group-like variations are not known for the structures with terminal GlcNAc. In another embodiment of the invention species specific animal antibodies are used against a tumor or cancer of the specific animal. The production of specific humanized antibodies by gene engineering and biotechnology is also possible: the production of humanized antibodies has been described in US patents  
20 Nos. 5,874,060 and 6,025,481, for example. The humanized antibodies are designed to mimic the sequences of human antibodies and therefore they are not rejected by immune system as animal antibodies are, if administered to a human patient. It is realized that the method to reduce the growth of or to destroy cancer applies both to solid tumors and to cancer cells in general. It is also realized that the purified natural human antibodies  
25 recognizing any human cancer specific antigen, preferably an oligosaccharide antigen, can be used to reduce the growth of or to destroy a tumor or cancer. In another embodiment species specific animal antibodies are used against a tumor or cancer of the specific animal.

30

According to the invention human antibodies or humanized antibodies against the tumor specific oligosaccharides, or other tolerated substances binding the tumor specific oligosaccharides, are useful to target toxic agents to tumor or to cancer cells. The toxic agent could be, for example, a cell killing chemotherapeutics medicine, such as doxorubicin (Arap et al., 1998), a toxin protein, or a radiochemistry reagent useful for  
35 tumor destruction. Such therapies have been demonstrated and patented in the art. The toxic agent may also cause apoptosis or regulate differentiation or potentiate defence reactions against the cancer cells or tumor. In another embodiment of the invention species specific animal antibodies are used against a tumor or cancer of the specific animal. The

cancer or tumor binding antibodies according to the present invention can be also used for targeting prodrugs active against tumor or enzymes or other substances converting prodrugs to active toxic agents which can destroy or inhibit tumor or cancer, for example in so called ADEPT-approaches.

5

The therapeutic antibodies described above can be used in pharmaceutical compositions for the treatment or prevention of cancer or tumor. The method of treatment of the invention can also be used when patient is under immunosuppressive medication or he/she is suffering from immunodeficiency.

10

The terminal GlcNAc, or preferably GlcNAc $\beta$ 3/6Gal $\beta$ 4GlcNAc-type cancer or tumor glycosylation, may be more common in tumors occurring in patients suffering from immunodeficient conditions, e.g., immunodeficiency causing diseases, such as AIDS, or immunodeficiency caused by immunosuppressive medication. Kaposi's sarcoma is a common cancer related to AIDS and immunodeficiency. Immunosuppressive medications are used, for instance, with organ transplantations to prevent rejection during kidney, heart, liver or lung transplantations. Malignancies arising during such therapies are in general benign, but they cause often the loss of the precious organ transplant. Some of the potential natural anticancer antibodies may probably also recognize following epitopes: GalNAc $\beta$ 3Gal $\beta$ 4GlcNAc, GalNAc $\alpha$ 3Gal $\beta$ 4GlcNAc, and Gal $\alpha$ 3Gal $\beta$ 4GlcNAc, which have been shown to be similar. The first structure, X<sub>2</sub>, is more common in persons who belong to a rare variant of p-blood group, these persons may also have less antibodies recognizing GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc structure. Capability to produce antibodies against tumor or cancer specific antigens may vary according to individual differences in immune system. Persons who have recovered from cancer may have especially high amounts of natural anti-cancer antibodies.

15

20

25

A possible example from the antibody mediated immune reaction against tumor tissue is a total recovery from hypernephroma after surgery of the majority of the tumor. The oligosaccharide sequences with terminal GlcNAcs are potential targets of such immune response.

30

#### Other methods for therapeutic targeting of tumors

It is realized that numerous other agents beside antibodies, antibody fragments, humanized antibodies and the like can be used for therapeutic targeting cancer or tumors similarly with the diagnostic substances. It is specifically preferred to use non-immunogenic and tolerable substances to target cancer or tumor. The targeting substances binding to the

35

cancer or tumor comprise also specific toxic or cytolytic or cell regulating agents which leads to destruction or inhibition of cancer or tumor. Preferably the non-antibody molecules used for cancer or tumor targeting therapies comprise molecules specifically binding to the cancer or tumor specific oligosaccharide sequences according to the present invention are aptamers, lectins, genetically engineered lectins, enzymes recognizing the terminal GlcNAc-structures such as glycosidases and glycosyltransferase and genetically engineered variants thereof. Labelled bacteria, viruses or cells or other polymeric surfaces containing molecules recognizing the structures can be used for the cancer or tumor targeting therapies. The cancer or tumor binding non-antibody substances according to the present invention can also be used for targeting prodrugs active against cancer or tumor to cancer or tumor or for targeting enzymes or other substances converting prodrugs to active toxic agents which can destroy or inhibit cancer or tumor.

Targetting terminal GlcNAc-comprising tumor antigens by glycosyltransferases

The present invention is also directed to novel method to transfer a modified monosaccharide derivative on cancer cells or tumor for treatment or diagnostics. We disclose a method of generating a covalent bond between a toxic agent, label, drug or immunologically active carbohydrate and the surface of a pathogenic cell of a patient, which surface comprises an acceptor structure recognized by a transferase enzyme, comprising the steps of

- conjugating said toxic agent, label, drug or immunologically active carbohydrate with a donor molecule of the transferase enzyme, and
- (a) administering the conjugate obtained and optionally said transferase enzyme to the patient for the treatment of tumor
- or (b), for tumor diagnostics, contacting the conjugate obtained to a tumor sample and detecting said label.

The monosaccharide derivatives to be transferred by glycosyltransferases also comprise a glycosidically linked nucleotide residue. The preferred monosaccharide derivatives are 2-modified such as amide derivatives of UDP-galactosamine

A preferred theraphautic or diagnostic monosaccharide derivative is UDP-GalN[-S]-D,

wherein

S is an optional spacer group

D is derivatizing group including molecular labels such as for example biotin or a fluorecent molecule including, or a toxic agent, prodrug or prodrug releasing substance as described for other cancer or tumor targetting methods.

The spacer is preferably flexible enough to allow the binding of the modified nucleotide monosaccharide to the transferase.

A preferred monosaccharide derivative is UDP- N-(6-biotinamidohexanoyl)galactosamine.

A preferred enzyme to be used is a galactosyltransferase which is engineered to transfer effectively 2-modified monosaccharides. Also natural GalNAc/GlcNAc-transferases with similar specificity from animals for example, may also be used.

The present invention is especially directed to method to label tumor tissue by biotin by incubating the tissue with UDP-GalN-spacer-biotin and a modified galactosyltransferase.

10 The present invention is in a separate embodiment directed to a diagnostic method in which

1. radiolabelled Gal is transferred from radiolabelled UDP-Gal to human tumor tissue by galactosyltransferase, preferably by  $\beta$ 4-galactosyltransferase and

2. the radioactivity incorporated to the tissue is used to determine amount of terminal GlcNAc residues on the tumor.

The methods using galactosyltransferases for labelling are effective for all types of terminal  $\beta$ -GlcNAc structures of the present invention.

20 Transfer of modified galactose residue to cancer for therapy or diagnosis of terminal GlcNAc $\beta$ -structures

The present invention is further directed to enzyme based therapeutic and diagnostic targeting and/or labeling terminal GlcNAc-residues *in vivo* or *ex vivo* by transferring a labeled monosaccharide covalently to the GlcNAc residues of material such as protein or tissue sample or cancer tissue expressing any cancer specific terminal GlcNAc containing structure, preferably any cancer or tumor specific structure according to the invention including the polylactosamine, N-glycan, O-glycan and protein linked terminal GlcNAc-structures. In a preferred embodiment polylactosamine, N- glycan, or O-glycan type of structure is targeted. The invention is specifically directed to glycosylation reactions of preferred terminal GlcNAc structures according to the invention. Preferably the monosaccharide is transferred by a  $\beta$ -glycosyltransferase, more preferably by  $\beta$ -glycosyltransferase which is  $\beta$ 3- or  $\beta$ 4-glycosyltransferase and most preferably by a  $\beta$ 4-glycosyltransferase. In a preferred embodiment the transferase is able to transfer one or several of the monosaccharide residues selected from the group Glc, GlcNAc, Gal and GalNAc and at least one modified derivative thereof. Preferably the transferase is a Hex(NAc) $\beta$ 4-transferase, wherein Hex is Glc or Gal, and r is 0 or r is 1. Preferred glycosyltransferases include animal and human glycosyltransferase. Human transferases are especially preferred for *in vivo* uses.



The most preferred form of glycosyltransferase is an animal  $\beta$ 4-GlcNAc and/or GalNAc-glycosyltransferase comprising structure allowing transfer of 2-modified Gal or GalN or Glc or GlcN. A preferred transferase has been described by Ramakrishnan and Qasba  
5 2002. This bovine  $\beta$ 4-galactosyltransferase enzyme has a mutation at a residue allowing the transfer. The present invention is also directed to similar animal enzymes containing the same or similar peptide structure at the catalytic site and having characterized to transfer GalNAc and/or GlcNAc from UDP-GalNAc or UDP-GlcNAc. In a preferred  
10 embodiment the animal enzyme is a variant of human  $\beta$ 4-galactosyltransferase, preferably human  $\beta$ 4-galactosyltransferase comprising the same mutation.

A preferred enzyme for transferring the substances is a glycosyltransferase capable of transferring of a monosaccharide unit modified to position 2. A mutated animal form of such enzyme was described by Ramakrishnan and Qasba 2002. The present invention is  
15 especially directed to soluble human glycosyltransferases and active fragments thereof, especially mutated galactosyltransferases, capable of transferring 2-modified monosaccharide structures.

Preferred 2-modified carbohydrate conjugates to be transferred

20 The specific diagnostic method is directed to transfer of carbohydrate conjugate to terminal GlcNAc as described by the invention when the carbohydrate to be transferred is modified to position 2. The carbohydrate to be transferred has the structure according to the

Formula C1

25 HexL-S-T

Wherein Hex is hexose preferably Gal or Glc,

L is linking atom on carbon 2 of the hexose preferably oxygen or nitrogen, or carbon or sulphur atom, more preferably L is oxygen or nitrogen, and most preferably nitrogen.

S is spacer group or atom or nothing,

30 preferably the spacer length is at least 3 atoms, more preferably at least four and most preferably at least 6 atoms. The spacer may be nothing if the T group includes a flexible aliphatic or equivalent chain such as polyalkylether-structure, preferably poly(ethylene glycol), PEG.

35 T is the group to be transferred or targeted according to the invention. The transferable group was surprisingly found out to be useful even when larger the acetylgroup naturally present on GalNAc or GlcNAc, even larger than 4 carbon atom substance, even larger than 6- carbon substance or 10- carbon substance, the present invention is directed to transfer of

substances comprising preferably more than 4 carbon atoms, more preferably more than 6 carbon atoms and most preferably more than 10 carbon atoms. According to invention the transferase accepts is also preferred for use in transfer of modified monosaccharides containing more than about 100 Da extra molecular weight, even more than 500 Da, 1000 Da Or even more than 5000 Da. The present invention is directed to use of the full capacity of the preferred glycosyltransferases. The capability of the enzyme to transfer the large group allows the transfer of functional structures such as labels, therapeutic agents or non-immunogenic hydrophilic structures. The capability of transfer even PEG-polymer of about 5000 kDa was even more surprising than the transfer of biotin or similar size labels.

The invention is further directed to the nucleotide sugar conjugates for transferring specific substances T according to the invention according to the Formula C2:

Nu-Hex(L-S-T)

Wherein Hex, L, S and T are as above in Formula C1 and Nu is a nucleotide activating the carbohydrate conjugate according to the invention. Preferred nucleotides includes UDP, GDP, TDP, and ADP depending on the preference of the glycosyltransferase used. Most preferably UDP is used. Preferred glycosyltransferases includes animal and human glycosyltransferase

#### Preferred nucleotide sugar conjugate

Most preferred nucleotide sugar conjugates are according to the Formula C3

UDP-Gal(N-S-T) and

Formula C4

UDP-Glc(N-S-T), wherein the nucleotide is UDP and linking atom is nitrogen and S and T are spacer as described above.

#### Pretargeting methods

Present invention is further directed to transfer linking groups by using modified monosaccharides according to the invention. The linking group can be later modified by a corresponding linking group linked with a group to be transferred according to the present invention. The present invention is especially directed to the transfer of chemoselective and protein/tissue compatible linking groups which are preferably effective in water solutions or aqueous buffers. The chemoselectivity means that linking group reacts to another corresponding linking group with selectivity. The protein and tissue compatibility means that the linking group or its corresponding linking group does not react, or does not essentially react with amino acid residues or other structures present on the material to be

targeted under the conditions of the targeting reaction. The protein and tissue compability depends on the chemical groups present on the material. For example when protein to be targeted does not contain free cysteine side chain, thiol chemistry may be applicable. A preferred pair of chemoselective group is a thiol and a thiol reactive group such as for example maleimide. Another preferred pair of desired linking groups is an aldehyde or ketone to be reacted with an aminooxy group. The aminooxy group reacts selectively and effectively the carbonyl substances in aqueous solution.

The present invention is directed to substances according to the formulas C1-C3 when the T group to be targeted is a chemoselective and protein/tissue compatible linking group. The inventors found out that the preferred modified galactosyltransferase according to the invention transfers at least certain non-carbon atom comprising linking groups even when the spacer is short such as 2-4 four atoms. In a preferred embodiment the invention is directed to substances comprising a short spacer comprising at least 2 carbon, in preferred embodiment at least 3 or 4 atoms, atoms and a linking group, preferably when the spacer has 2 carbon atoms the linking group is N-protected aminooxy group. The aminooxy group is preferably transferred in protected form which is cleaved to reactive aminooxy group under conditions compatible with most proteins. In a specific embodiment a protected linking group according to the invention is used.

In another pretargeting method the invention is directed to transfer of biotin as a non-covalent pretargeting group. Additional groups can be targeted to biotin by avidin or streptavidin. The present invention is specifically directed to transfer of biotin on to tissue or cell as described by the invention, the examples represent useful methods and reagents and actual labelling. Methods to therapeutically target biotin or (strept)avidin pretargeted to cancer for example in vivo in human has been demonstrated. The methods have been effective in clinical trials. Therefore the transfer of biotin to cancer tissue according to invention is especially preferred.

### Therapeutic targeting of carbohydrate conjugate to prevent harmful interactions/ in vitro modification of therapy related agents

In a preferred embodiment the present invention is directed to conjugates which contain a non-immunogenic hydrophilic structure linked to transferable carbohydrate. The non-immunogenic hydrophilic structure is preferably polyalkylglycol or equivalent or a carbohydrate, preferably a non-immunogenic polysaccharide, fragment of a polysaccharide or an oligosaccharide. Most preferably the non-immunogenic hydrophilic structure is a polyethyleneglycol (PEG). The aim of the substance is to target a therapeutic substance such as therapeutic protein or a cell or a tissue away from a source of harmful

interaction. The modification occurs usually in vitro and the therapeutic substances including therapeutic proteins, cells and tissues are collectively called herein therapeutic agents. The modification of cells and tissues may aim for therapy such as transplantation, xenotransplantation or treatment of wounds or tissue damages. The harmful interaction  
5 may be mediated for example by receptor removing a therapeutic protein from blood circulation, by a proteolytic or hydrolytic enzyme degrading therapeutic protein or cell or tissue, by cells such as leukocytes degrading or binding to the or by the structures of kidney removing low molecular weight substances including low molecular weight proteins from blood circulation.

10 The pegylation is generally used for improving the quality of therapeutic proteins. Numerous proteins have been biotechnologically produced and modified by PEG, some of the proteins are in the markets. In most cases the pegylation increases the molecular weight of a low molecular weight protein normally cleared through kidneys. The present  
15 invention is aimed for substances and methods for pegylation of therapeutic protein. Pegylation of tissues or cells may be needed in medical operation such as xenotransplantation. In such case the pegylation is aimed for example for protection of the transplanted tissue from degradation by immune system. Such methods may be used for example in transplantations of neural tissue for treatment of Parkinson's disease or  
20 transplant of pancreatic islet cells for treatment of diabetes.

Methods to modify substrates containing terminal GlcNAc structures in vitro for therapeutic agents

The present invention is aimed for modification of under galactosylated glycoproteins  
25 produced by certain cell line, for example by insect cells. The present invention is especially directed to modification of terminal GlcNAc containing proteins produced under conditions yielding undergalactosylated (and sialylated) glycoproteins. The lack of terminal glycosylation may be induced by cell culture conditions, such as amount oxygen, presence of monosaccharide substrates and proteins. The present invention is further  
30 directed to removal of the terminal glycosylation by expressing galactosidase or sialidase (neuraminidase) or fucosidase or N-acetylhexosaminidase enzyme, preferably a beta-galactosidase and optionally alpha-neuraminidase to the cell culture medium by the same or different production cell line. The alpha neuraminidase may be of general broad specificity or specific for the sialic acid species produced with alpha3-, or alpha6- and  
35 optionally also for alpha8- or alpha 9-linked sialic acid. The glycidase enzyme may be produced as immobilized in the cell wall of yeast or other production cell type.

The present invention is directed to modification of terminal GlcNAc on O-glycan or N-glycan and/or protein linked glycans. The substrate of the modification is usually part of regular N-glycosidic or O-glycosidic core structures. The present invention is specifically directed to substances according to

5 Formula P1:

Hex(L-S-PEG)-GlcNAc $\beta$ -Core-peptide

10 wherein Hex, L and S are as described in Formula C1, Core is a core structure of N-glycan and/or O-glycan, when GlcNAc is part of the core structure the core is the glycan core excluding a terminal GlcNAc residue, PEG is polyethylene glycol, and peptide is protein or peptide to be targeted away from immune system or other harmful interactions. Preferably the peptide is a therapeutic protein known to have been pegylated before. Preferably the therapeutic protein is an antibody or a low molecular weight protein such as  
15 human erythropoietin (EPO), an interferon or an interleukin. In a preferred embodiment the protein is avidin protein aimed for *in vivo* use.

More preferably the present invention is directed to substances according to the Formula P2:

20 Gal(N-S-PEG)-GlcNAc $\beta$ -Core-peptide,

wherein S, PEG-core and peptide are as described above.

In a preferred embodiment the present invention is preferably directed to substances according to the

25 Formula P3:

Glc(N-S-PEG)-GlcNAc $\beta$ -Core-peptide,

wherein S, PEG-core and peptide are as described above.

30

The present invention is further directed to modified cell or tissue material, when the modification is produced by transfer of modified carbohydrate on the surface of the cell and /or tissue according to the invention. Preferred substances are according to the invention as follows.

35 Formula CT1:

Hex(L-S-PEG)-GlcNAc $\beta$ -Core-cell/tiss

wherein Hex, PEG, L and S are as described in Formula D1,  
Core is a core structure of N-glycan and/or O-glycan, optionally excluding a terminal  
GlcNAc residue, Cell/tiss means cell or tissue modifiable.

- 5 More preferably the present invention is directed to tissues according to the  
Formula CT2:

Gal(N-S-PEG)-GlcNAc $\beta$ -Cell /tiss,

- 10 wherein S, PEG-core and peptide are as described above.  
In a preferred embodiment the present invention is preferably directed to substances  
according to the  
Formula CT3:

- 15 Glc(N-S-PEG)-GlcNAc $\beta$ -Cell/Tiss,

wherein S, PEG-core and peptide are as described above.

- 20 The present invention is further directed to modified cell or tissue material, when the  
modification is produced by a transfer of modified carbohydrate on the surface of the cell  
and /or tissue according to the invention.

- The present invention describes therapeutic or diagnostic substances, which can be transferred *in*  
*vivo* covalently to a cell surface, especially to surfaces of a pathogenic entities such as cancer or  
25 tumor cell, bacterium, virus or parasite.

- Furthermore the present invention describes the transfer of the therapeutic or diagnostic  
substances *in vivo* covalently to cell surfaces, especially to the surfaces of pathogenic  
entities such as 1) cancer or tumor cells, 2) microbial pathogens including bacteria, fungi,  
30 viruses and parasites, and 3) pathogenesis or metastasis-inducing receptors. The present  
invention especially relates to the transfer of donor carbohydrate to oligosaccharides  
related to pathogenic conditions, like cancer specific oligosaccharide sequences, or to  
those present on pathogens like viruses, bacteria or parasites. The invention is especially  
directed to the use of carbohydrate conjugated to immunologically active or toxic  
35 therapeutic substances for the treatment diseases like infections, cancers and malignancies.

The invention can be also used to target drugs to cell or tissue surfaces, where these can be  
recycled inside of cells. In a specific embodiment the drug is conjugated to the

carbohydrate to be transferred by a labile bond, which is cleaved inside the cells and the drug is released.

In another specific embodiment, the therapeutic substance is a natural type of monosaccharide, which is covalently transferred to a pathogenesis-inducing carbohydrate receptor *in vivo* and blocks the pathogenesis-inducing carbohydrate receptor. The pathogenesis-inducing carbohydrate receptor may be a carbohydrate receptor of a metastasizing cancer, pathogenic microbe, or a defective glycosylation of tissue causing autoimmune type disorders.

Moreover, the invention describes search of tissue or pathogenesis specific receptors by covalent *in vivo* transfer of substances to surfaces of cells or tissues. The present invention describes methods for the *in vivo* detection of the pathogenic entities and pathogenesis-related receptors. The *in vivo* transfer to tissues is useful for tissue imagining technologies even when the transfer target is not related to pathogenesis. The invention is also directed to the use of carbohydrate conjugates for diagnostics of the pathogenic entities and diseases related to them. The invention is specifically directed to the use of said carbohydrate/carbohydrates for diagnostics of infections, cancer and malignancies.

#### *The in vivo transfer to cell surfaces*

The present invention describes the covalent *in vivo* transfer of a therapeutic or diagnostic molecule to cell surfaces. The transfer is performed by a transferring enzyme, which can transfer a donor substrate molecule to a cell surface or more specifically to an acceptor substrate molecule which is preferentially a cell surface molecule, but can also be a cell surface associated molecule. The donor substrate molecule can be used to block a pathogenesis-associated receptor by *in vivo* synthesis of a tolerated natural structure from the pathogenesis-associated receptor on a cell surface. In another embodiment the donor substrate is a transferable molecule conjugated to a therapeutic or a diagnostic molecule. The conjugation is performed so that it allows the donor substrate conjugate to be recognized and transferred by the transferring enzyme.

For example, the transferring enzyme can be a glycosyltransferase, the donor substrate molecule can be a nucleotide sugar or a lipid donor of a glycosyltransferase enzyme and the acceptor substrate a cell surface carbohydrate or a cell surface associated carbohydrate.

Moreover, as an another example, the transferring enzyme can be a transglycosylating enzyme, the donor substrate is an oligosaccharide or a glycoconjugate donor for the transglycosylating enzyme, and the acceptor substrate is a cell surface carbohydrate acceptor of the transglycosylating enzyme. Preferentially a monosaccharide residue or

conjugate thereof is transferred from a donor to an acceptor substrate. Transglycosylating enzymes and even glycosyltransferases like oligosaccharyltransferase can also transfer oligosaccharides. In both cases the first substrate can be conjugated to a therapeutic or a diagnostic molecule.

5

The invention can be also used to target drugs to cell or tissue surfaces, where these can be recycled inside of cells. In a specific embodiment the drug is conjugated to the modified monosaccharide by a labile bond, which is cleaved inside or on the cells and the drug is released.

10

*Special requirement of in vivo transferring reactions*

The invention is directed to reaction conditions and reagent combinations, which allow glycosyltransfer reactions to achieve transfer of therapeutic or diagnostic carbohydrates to desired targets under novel *in vivo* conditions.

15

A. Glycosyltransferase reactions in vivo

*Transferase reactions.* The invention is directed to use of natural glycosyltransferases present in human and mammalian body fluids and cell surfaces. The functions of extracellular glycosyltransferases are largely unknown, the cell surface forms may be cell adhesion molecules. It is realized in the present invention that the specificities of the glycosyltransferases present in sera allows specific transfer reactions to special precursor oligosaccharides present on pathogenic entities.

20

Furthermore, it is realized that this method could be used for special targeting of therapeutic or diagnostic compounds to surfaces of pathogenic entities, like cancer cells or microbial pathogens. This targeting method differs from previous ones in that the carbohydrate conjugates are transferred covalently to the surface of a pathogenic entity. It is realized that certain cancers for example carry terminal GlcNAc $\beta$ - and GalNAc $\alpha$ -containing acceptors for  $\beta$ galactosyltransferases of human serum.

25

It is further realized that the reactions can be used to transfer toxic or diagnostic agents on surfaces of microbes like *Neisseria* or parasites like *Trypanosoma cruzii*, which are known to transfer sialic acid to their surfaces. The modern recombinant enzyme technologies also allow use of additional glycosyltransferases in body of a patient, for such application the transferase should be preferentially well tolerated like recombinant forms of soluble human transferases. Even glycosyltransferases from microbial pathogens could be useful for specific transfer to surfaces of microbes, but immune reactions against the pathogen type transferases may limit usefulness of long term therapies or change the effect of therapy to more vaccination like in a longer time scale.

30

35



In an separate embodiment the pathogenesis inducing receptor is a tissue saccharide structure of a patient ant the structure is receptor for cancer, microbial pathogen or a toxin secreted by a microbial pathogen or an autoimmune receptor like under glycosylated structures in certain glycosylation disorders. The terminal GlcNAc $\beta$ 3LacNAc- and GalNAc $\beta$ 3LacNAc-structures are potential receptor for the diarrhea causing toxin A from *Clostridium difficile*, these receptors can be blocked by tranasfer of Gal $\beta$ 4- of NeuNAc $\alpha$ 3- to the receptors. Under-sialylation of LDL in atherosclerosis or under-galactosylation of erythrocytes in forms of HEMPAS or in IgG in diabetes are examples of conditions which are treatable *in vivo* according to invention by transfer of normal monosaccharides from regular nucleotide sugars. Cancers can metastasize to liver by terminal Gal-residues which bind to asialoglycoprotein receptor of liver, blocking the receptor by NeuNAc $\alpha$ 3- reduces the liver metastasis in such cancer.

#### Special *in vivo* transferase reaction conditions

The *in vitro* glycosyltransferase reactions are in general carried out in precence of relatively large amounts of MnCl<sub>2</sub>, the Mn<sup>2+</sup> -ion activates most of the known glycosyltransferases. The reagent may be also used to stabilize the donor nucleotide for improving the reaction conditions. Unfortunately, the Mn<sup>2+</sup> -ion is neurotoxic and it is therefore preferred only in for short term use under following conditions: The carbohydrate or the conjugate to be transferred with Mn<sup>2+</sup> -ion is used in limited amounts in 1) gastrointestinal tract 2) in urinary bladder 3) as directly administred close to the pathogenic entity. The limited amounts means that therapy with Mn<sup>2+</sup> -ion levels will not be reach toxic levels. Furthermore the amount of the toxic free Mn<sup>2+</sup> -levels can be controlled by increasing molecules chelating the ion, for example a tolerated chelator used in serum for imagining with with Mn<sup>2+</sup> -ion complex and/or adding chelating protein like transferring. The chelating agent can be used to remove extra Mn<sup>2+</sup> -ions after the desired transfer has been achieved or locally in blood circulation after the cancer or pathogen position where the carbohydrate is targeted. For blood cells or blood components or tissue transplants glycosyltransferase reactions could be performed outside of the body even in presence of Mn<sup>2+</sup> if harmful amounts of the ions are removed before applying the blood or its components or tissue to the body of the patient, however use more tolerated divalent cations as described below is preferred. It is further realized that use of the alternative less toxic divalent cations or removal of Mn<sup>2+</sup> is also preferred in production of glycosylation remodelled therapeutic glycoproteins.

Special conditions for galactosyltransferase/modified *$\beta$ 4-galactosyltransferase reaction in vivo to react with terminal GlcNAc $\beta$ -structures*

The galactosyltransferase activity of human serum was observed to require Mn<sup>2+</sup> ions for activity, other cations did not essentially activate the transferase under assay conditions. It was then tried to add exogenous galactosyltransferase from bovine milk to serum and we found out that the enzyme was active even without manganese ions. Additional activation was achieved by divalent cations zinc, calcium and magnesium. The invention is especially directed to use added  $\beta$ 4-galactosyltransferase in human blood circulation. It is preferred to use Zn<sup>2+</sup>, Ca<sup>2+</sup> and/or Mg<sup>2+</sup> ions for additional activation of the enzyme. It was further found out that phosphorylcholine has stabilizing effect to the donor substrate preventing part of degradation to galactose. The invention is further directed to use of a tolerable phosphoester substance, preferably phosphorylcholine to reduce the degradation of the donor in human blood. The manganese ion was observed to activate endogenous human galactosyltransferase at 1 mM concentration and even at 0.2 mM concentration. Under conditions where use of manganese is acceptable according to the invention, the invention is directed to use of about 0.01 mM to 1 mM Mn<sup>2+</sup>, more preferably 0.02-0.2 mM Mn<sup>2+</sup>.

The invention also finds useful novel reaction conditions wherein no divalent cation is used for with Mn<sup>2+</sup>-activable enzyme. This possible *in vivo* because the highly metabolically active cancer cells, or many stressed cells for example excrete glycosyltransferases and divalent cations complexed with these, the cell surface ion concentrations will allow reactions which are not possible in sole serum. More over the Mn<sup>2+</sup>-ion or other divalent cations can be used together with exogenous glycosyltransferase and the donor carbohydrate as complex so that the free ion concentration remains lower.

It is more preferred to use tolerated alternative ions even though the enzyme activity is lower. According to the invention it is possible to use 4 mM MgCl<sub>2</sub> to activate fucosyltransferases in human whole blood. Short term therapies even bigger Mg<sup>2+</sup>-ion - concentrations to about 6-8 mM could be tolerated by human patients. Additional use of high Ca<sup>2+</sup> concentration like about 1-2 mM gives occasionally better reactivity. In severe diseases like cancer or very lethal infections it may adviseable to try to increase the cation concentrations despite higher risks. When no divalent cation is used in reaction with human whole blood more specific fucosyltransfrase reaction is observed. It is possible to use the cations to regulated specificities of the transfer reactions in vivo. In a specific embodiment organic cation containing molecules like spermine or lechitin or choline can be used to increase the reactivity of the transferase. In some cases other divalent cations

like  $\text{Co}^{2+}$  or  $\text{Ba}^{2+}$  or even  $\text{Cd}^{2+}$  ion could be used for activation of specific glycosyltransferases.

The invention also describes use of *in vivo* tolerable phosphatase inhibitors to increase the reaction. For example in gastrointestinal tract ATP can be used in millimolar concentrations. It must be noted that in gastrointestinal system it is useful to protect the carbohydrate and enzyme if used from the gastric acid.

*Transfer of a carbohydrate conjugated to an immunologically active and/or a toxic carbohydrate*

In a preferred embodiment the carbohydrate is conjugated to an immunologically active and/or toxic, and the conjugate can be transferred to the surface of a pathogenic entity. The modified carbohydrates can be transferred to acceptors especially related to pathogenic conditions, like cancer specific oligosaccharide sequences or oligosaccharides present on pathogens like viruses, bacteria or parasites. The invention is especially directed to the use of modified monosaccharides for the treatment of diseases like infections, cancers and malignancies.

The modified monosaccharide is specifically targeted to the surface of the pathogenic entity by a glycosyltransfer reaction or reactions. The glycosyltransfer reaction is catalyzed by an enzyme, preferentially a transglycosylating enzyme or a glycosyltransferase enzyme, which recognize an acceptor oligosaccharide present on the surface of the pathogenic entity. The transglycosylating enzyme or glycosyltransferase enzyme is preferentially present in the patient, more preferentially the transferase is present in serum (and/or other fluids) of the patient. The transglycosylating enzyme or glycosyltransferase enzyme is preferentially present in a high concentration close to the pathogenic entity, like enzymes effectively secreted or effectively produced as membrane proteins by the pathogenic entity. In a specific embodiment glycosyltransferase or transglycosylating enzyme is used together with the modified monosaccharide. The enzyme may be added to increase the transfer of the modified monosaccharide. When the added glycosyltransferring enzyme is used *in vivo* it is preferentially in soluble form and not antigenic. Preferred glycosyltransferring enzyme include natural serum, urine and other soluble forms of glycosyltransferases of the patient.

In a preferred embodiment the transglycosylating enzyme is a transsialidase enzyme. The glycosyltransferase enzyme is preferentially galactosyltransferase, N-acetylglucosaminyltransferase, N-acetylgalactosaminyltransferase, fucosyltransferase, sialyltransferase, mannosyltransferase, xylosyltransferase, glucuronyltransferase or

glucosyltransferase. More preferentially the glycosyltransferase enzyme is  $\beta$ 4galactosyltransferase,  $\beta$ 3galactosyltransferase,  $\beta$ 3-N-acetylglucosaminyltransferase,  $\beta$ 2-N-acetylglucosaminyltransferase,  $\beta$ 6-N-acetylglucosaminyltransferase,  $\alpha$ 3sialyltransferase,  $\alpha$ 6sialyltransferase,  $\alpha$ 3fucosyltransferase,  $\alpha$ 2fucosyltransferase or  $\alpha$ 6fucosyltransferase. In a specific embodiment the transglycosylating enzyme or glycosyltransferase enzyme transfers a monosaccharide specific for the pathogenic entity like rhamnose, KDO, heptose or furanose monosaccharide residues present on bacteria. Many parasites can also transfer monosaccharides, which are normally not present in human body.

The modified monosaccharides to be used with glycosyltransferases are preferentially nucleotide sugar derivatives or analogs thereof, also other modified glycosides may be transferred by glycosyltransferases. For transglycosylation the modified monosaccharide may be a glycosides like phenyl- or paranitrophenyl-glycoside. The glycosyltransferases are known to tolerate numerous modifications on the donor substrates. Preferentially the nucleotide sugar derivative or analog is derivative of UDP-Gal or UDP-GalNAc where the toxic substance or immunologically active carbohydrate is linked to carbon number 2 or carbon number 6 of the Gal or GalNAc residue or a derivative or analog of UDP-GlcNAc or UDP-Glc where the toxic substance or immunologically active carbohydrate is linked to carbon number 2 or 6 of the Glc or GlcNAc residue or or a derivative or analog of GDP-Fuc where the toxic substance or immunologically active carbohydrate is linked to carbon number 6 of the fucose residue or, an analog or a derivative of CMP-NeuNAc or CMP-sialic acid where the toxic substance or immunologically active carbohydrate is linked to carbon number 5, 7, 8, and/or 9 of the NeuNAc or sialic acid residue. Conjugates of NeuNAc and general methods of making nucleotide sugar conjugates have been further described in WO03031464A2.

The specificity of the transfer reactions is based on the specificity of the glycosyltransferases. The transfer is usually specific for both donor and acceptor substrates. For example specific types of galactosyltransferases or  $\beta$ 1-3N-acetylglucosaminyltransferases are known which can quite specifically transfer to certain O-glycan, N-glycan or polylactosamine structures. Use of soluble patient type glycosyltransferase, which is specific or quite specific for the carbohydrate acceptors present on the pathogenic entity, together with a modified nucleotide sugar is preferred. The patient type transferase means the natural enzyme present in the patient, for example human glycosyltransferases for human use can be produced by biotechnology or less preferentially purified from human serum or tissues. More preferentially the transferase is used in the form naturally present in the part of the tissue where the therapy is used, like

soluble serum form of the enzymes in serum. The specificity of the transfer is also created by specific presence of the acceptor structure for the glycosyltransferring enzyme like a carbohydrate, glycoconjugate, peptide, protein or lipid on the pathogenic entity and/or the localization of transferring enzyme or the carbohydrate to be transferred close to the pathogenic entity. The specificity against the pathogenic entity can be also created by local activation of the toxic or immunologically active carbohydrate after the transfer reaction, for example radioactive substance may be locally activated by specific radiation.

The modified monosaccharides to be used with glycosyltransferases are preferentially nucleotide sugar derivatives or analogs thereof, also other modified glycosides may be transferred by glycosyltransferases. For transglycosylation the modified monosaccharide may be a glycosides like phenyl- or paranitrophenyl-glycoside. The glycosyltransferases are known to tolerate numerous modifications on the donor substrates. Preferentially the nucleotide sugar derivative or analog is derivative of UDP-Gal or UDP-GalNAc where the toxic substance or immunologically active carbohydrate is linked to carbon number 2 or carbon number 6 of the Gal or GalNAc residue or a derivative or analog of UDP-GlcNAc or UDP-Glc where the toxic substance or immunologically active carbohydrate is linked to carbon number 2 or 6 of the Glc or GlcNAc residue or or a derivative or analog of GDP-Fuc where the toxic substance or immunologically active carbohydrate is linked to carbon number 6 of the fucose residue or, an analog or a derivative of CMP-NeuNAc or CMP-sialic acid where the toxic substance or immunologically active carbohydrate is linked to carbon number 5, 7, 8, and/or 9 of the NeuNAc or sialic acid residue.

The specificity of the transfer is preferentially created by specific presence of the acceptor structure for the glycosyltransferring enzyme like a carbohydrate, glycoconjugate, peptide, protein or lipid on the pathogenic entity and/or the localization of transferring enzyme or the carbohydrate to be transferred close to the pathogenic entity. The specificity against the pathogenic entity can be also created by local activation of the toxic or immunologically active carbohydrate after the transfer reaction, for example radioactive substance may be locally activated by specific radiation. The specificity of the transfer reactions is based on the specificity of the glycosyltransferases. For example specific types of galactosyltransferases or  $\beta$ 1-3N-acetylglucosaminyltransferases are known which can quite specifically transfer to certain O-glycan, N-glycan or polylactosamine structures. Use of soluble patient type glycosyltransferase, which is specific or quite specific for the carbohydrates acceptors present on the pathogenic entity, together with a modified nucleotide sugar is preferred.

*Transfer of toxic agents*

The modified monosaccharide may comprise a toxic agent like a toxin, for example a bacterial toxin, a cell killing chemotherapeutics medicine, such as doxorubicin (Arap et al., 1998), or a radiochemical reagent useful for tumor destruction. Such therapies have been demonstrated and patented in the art. The toxic agent may also cause apoptosis or regulate differentiation. The modified monosaccharide can be linked to an additional immunologically active carbohydrate according to the invention, such as A or B blood group antigen not present in the patient, Gal $\alpha$ 3Gal-structure, ligand of other anti-carbohydrate antibodies, including anti-carbohydrate antibodies in patient, or ligand of the defensive lectins of the immune system.

*Transfer of an immunologically active carbohydrate*

The immunologically active carbohydrate can be an oligosaccharide sequence recognized by natural human antibodies. Numerous such antibodies have been described. The antibodies recognize structures like terminal N-acetylglucosamine, N-acetylmannosamine, blood group antigens, or Gal $\alpha$ 3Gal-structures. The functions of the antibodies are not known and these may be caused by infections by bacteria carrying such oligosaccharide sequences. ABO-blood group antibodies restrict blood transfusion and organ transplantations, the antibodies recognize cells from transplant or transfusion and cause its rejection. Similarly anti- Gal $\alpha$ 3Gal-antibodies prevent xenotransplantation for example from pig to human.

The previous invention showed that the terminal N-acetylglucosamine sequence is present in human tumors, indicating potential anticancer reactivity of the natural antibodies. As monovalent compounds the oligosaccharide sequences are not harmful. When the oligosaccharides or carbohydrates, which are recognized by natural antibodies, are transferred in polyvalent form on a cancer cell/tissue surface, these are targeted by the natural antibodies, which leads to the destruction of the cancer cells or tumor. The terminal GlcNAc-structures and Gal $\alpha$ 3Gal-structures are generally applicable as such antibodies occur generally. Blood group antigens can be transferred to pathogenic agents in patients, who have antibodies the specific blood group antigen. For example patients who have blood O usually have antibodies against blood group A and B-antigens, patients who have blood group A usually have antibodies against B-blood group antigens and patients who have blood group B usually have antibodies against A-blood group antigens. Several other blood group antigen systems like P-blood groups are known and could be used according to the invention. The antigenic structures, which are transferred on a pathogenic entity like cancer cells or microbial pathogens like bacteria or viruses or parasite are recognized by antibodies and cause destruction of the pathogen.

Beside the natural anti-carbohydrate antibodies special antibodies can be induced against carbohydrate structures in human. Patients or potential future patients can be and are vaccinated against carbohydrate epitopes of various pathogenic bacteria or parasites.

5 Specific methods to induce immunity against cancer by cancer vaccines are also known. Preferentially the vaccine target carbohydrate structure is not exactly the same as the patient's own, non-cancer associated, carbohydrate structures to avoid autoimmune complications. The transfer of a vaccine carbohydrate epitope on a pathogenic entity as a immunologically active and/or toxic carbohydrate diverts the existing immune response  
10 against the vaccine epitope or immune response which is induced later by vaccination towards the pathogenic agent. The method can be also used as a vaccination method and immune response may necessarily not be needed to be separately induced by vaccination. When the immunologically active and/or toxic carbohydrate causes the destruction of the pathogenic entity, the immune responses against other components on the pathogenic  
15 entity are also induced and cause a vaccination effect. The transfer method is also useful to increase the effect of traditional vaccinations, the immunologically carbohydrate may be the same or different from the one used in the vaccination. The methods according to the present invention can be further used *ex vivo/in vitro* to modify cells such as red cell with specific antigenic structures. In a preferred embodiment the modified red cells are  
20 introduced back to the patient to induce an immune reaction against the antigen. The methods according to the invention can be further used *ex vivo/in vitro* to modify cells or other type of sample from human cancer with immune response inducing or antigenic carbohydrate conjugate to enhance immune reaction against cancer. The invention is further directed to the use of the transfer of modified carbohydrate with covalently  
25 conjugated structure to produce a cell based cancer vaccine from human cancer cells or red cells. The present invention is further directed to *ex vivo/in vitro* modifications of cells with carbohydrate antigens/or structures. These are likely to be effective immunoconjugates.

30 In the most general form of invention it is possibly to transfer any substance recognized by immune system to the surface of the pathogenic entity. Beside carbohydrates such substances include protein or peptide antigens like protein or peptide vaccine substances, non-harmful parts of peptidoglycan or lipid A of bacteria which can be transferred to cell surface of a pathogenic entities. Moreover specific component of immune system like  
35 complement proteins could be transferred. Conjugates of protein substances could create autoimmune problems, which should be considered when planning conjugation chemistry. Inducing immune responses against conjugates of non-natural epitopes like para-nitrophenyl is also known and can be used according to the invention. The non-natural

epitope can be transferred on the pathogenic entity alone or in combination with a vaccination type therapy against the non-natural epitope. Use of non-natural epitopes may reduce risks of autoimmune reactions when the targeting technology is good enough. The non-natural epitope, which can be recognized by immune system, can be used as conjugate of modified monosaccharide as described below.

According to invention carbohydrate receptors of the defensive lectins of a patient can be also used for therapy or diagnostics. The immunologically active carbohydrates according to the invention includes carbohydrate which can be recognized by defensive lectins of a patient like collectins or mannose binding proteins of macrophages or defensive lectins of natural killer cells. Mannose binding proteins may also recognize special GlcNAc and fucose containing molecules, especially when the monosaccharide residues are present in polyvalent form and terminally on glycoconjugates. Natural killer cells have lectins, which also bind polyvalent terminal GlcNAcs. According to invention it is possible to transfer carbohydrate receptors for the defensive lectins on pathogenic entities. Binding of the defensive lectins leads to defensive reaction against the tissue, cell or virus to which it is attached. The defensive reaction may be mediated by complement system or leukocytes like macrophages or natural killer cells or by other defensive means.

The immunologically active carbohydrate can be further conjugated to a toxic agent as described below to increase the reactivity against a pathogenic agent.

#### Humanized antibodies

##### *A preferred cancer target*

When the therapy according to the invention is targeted to cancer and terminal GlcNAc-cancer antigens as described in the present application. Galactosyltransferases like  $\beta$ 4galactosyltransferase or  $\beta$ 3galactosyltransferase can be used to transfer modified Gal from modified UDP-Gal to cell surface of the cancer cells. UDP-Gal is preferentially modified to carbon 6 by a spacer and a Gal $\alpha$ 3Gal-saccharide epitope. In another preferred embodiment UDP-Gal is modified to position 2 of Gal as described by the invention. The modified monosaccharide is transferred on the cancer cells, which are then destroyed by immune response against Gal $\alpha$ 3Gal-saccharide. The transfer can be mediated by  $\beta$ 4galactosyltransferase present in normal serum or additional purified or recombinant human  $\beta$ 4galactosyltransferase. Normal serum also contains a  $\beta$ 3galactosyltransferase transferring to O-glycosidic GalNAc (Tn-cancer antigen), this transfer reaction also targets modified monosaccharides to cancer cells. Several human pathogens contain mammalian type oligosaccharide sequences like *Helicobacter pylori* or several *Neisseria* or *Haemophilus* strains and to these pathogens modified monosaccharides can be transferred



by mammalian glycosyltransferases. Actually *Neisseria* and a parasite *Trypanosoma brucei* are known to transfer sialic acids originating from potential patient to their surfaces under pathogenic conditions.

5 *Detection and diagnostics*

Furthermore the present invention is directed to methods for the detection of the pathogenic entities or activities by the invention. The specific transfer of modified monosaccharides to the pathogenic entities allows the detection of the pathogenic entities.

For this purpose the modification of the monosaccharide need not to be toxic. The  
10 monosaccharide is modified by a label substance like a tag substance including for example an antigen detectable by an antibody, biotin, digoxigenin, digitoxin or a directly detectable substance with examples of fluorescent substance like rhodamine or fluorescein or substance with chemiluminescence activity or phosphorescence substance or a specific molecular mass marker detectable by mass spectrometry.

15 In a preferred embodiment the modified monosaccharide is labeled with two label compounds, which are more preferentially a tag substance and a directly detectable substance and most preferentially a tag substance like biotin and a mass spectrometry label. The label substance is preferentially linked through a spacer to the modified monosaccharide. The invention is also directed to the use of said carbohydrate for  
20 diagnostics of the pathogenic entities and diseases related to them. The invention is specifically directed to the use of said carbohydrate/carbohydrates for diagnostics of infections, cancer and malignancies. The invention is especially directed to the use of immunologically active or toxic carbohydrate for the treatment diseases like infections, cancers and malignancies. Preferentially the cell surface carbohydrates are labeled by the  
25 modified monosaccharide. Modified monosaccharides aimed for detection are useful for detection of certain congenital disorders of glycosylation and under-sialylated LDL. Especially useful are labeled nucleotide sugars.

In a specific embodiment the the modified monosaccharide are labeled with biotin and mass  
30 spectrometric labels. The modified monosaccharide are transferred by glycosyltransferring enzyme or enzymes, preferentially by a  $\beta$ 4galactosyltransferase, to cell preparations, the biotinylated fraction is purified and analyzed by mass spectrometry to reveal difference of expression of the glycosyltransferase acceptors. Preferentially glycopeptides produced by proteolysis of the sample are analyzed and recognized by mass  
35 spectrometry. In a preferred embodiment the method is used to detect difference of O-linked GlcNAc expression levels in cells under different conditions. Preferentially the differences in the same cell or tissue type are detected under different conditions. For the detection of the O-linked N-acetylglucosamine the intracellular proteins should be

accessible in the cell preparation. The O-linked GlcNAc is known to be associated with different pathogenic conditions like diabetes.

5 The target oligosaccharide sequences of the invention can be a part of a glycolipid, a part of a glycoprotein, and/or a part of a N-acetylactosamine chain. The oligosaccharide sequences on glycoproteins can also be a part of N-linked glycans or O-linked glycans of glycoproteins. Defects or changes in biosynthetic and/or biodegradative pathways of tumors lead to the synthesis of the oligosaccharide sequences of the invention both on glycolipids and glycoproteins. Terminal N-acetylglucosamine means that the non-reducing  
10 end GlcNAc residue in an oligosaccharide chain is not substituted by any other monosaccharide. The term oligosaccharide sequence indicates that the monosaccharide residue/residues in the sequence are part of a larger glycoconjugate, which contains other monosaccharide residues in a chain, which may be branched, or natural substituted modifications of oligosaccharide chains. The oligosaccharide chain is normally conjugated  
15 to a lipid anchor or to a protein.

The methods of treatment or the pharmaceutical compositions described above are especially preferred for the treatment of cancer diagnosed to express the cancer specific oligosaccharide sequences of the invention. The methods of treatment or the  
20 pharmaceutical compositions can be used together with other methods of treatment or pharmaceutical compositions for the treatment of cancer. Preferably the other methods or pharmaceutical compositions comprise cytostatics, anti-angiogenic pharmaceuticals, anti-cancer proteins, such as interferons or interleukins, or a use of radioactivity.

#### 25 Transfer of a non-modified carbohydrates for therapy

In a specific embodiment the pathogenesis preventing carbohydrate is a natural type of monosaccharide, which is covalently transferred to a pathogenesis-inducing carbohydrate receptor *in vivo* and blocks the pathogenesis-inducing carbohydrate receptor. The pathogenesis-inducing carbohydrate receptor is a defective glycosylation caused by a  
30 glycosylation disorder, or special glycosylation present in an autoimmune disease, a receptor carbohydrate in a pathogen-host interaction or a receptor carbohydrate present in a cancer-patient interaction, including metastasis. In preferred embodiments the transfer occurs *in vivo* for treatment of a disease. Preferentially a natural type of nucleotide sugar is used. The use of natural types of nucleotide sugars is directed to for treatment of  
35 glycosylation disorders, autoimmune diseases and infections, cancer and malignancies. Preferentially the transfer occurs to the surface of the pathogenic entity or entities.

It is realized in the present invention that it is possible to perform glycosyltransfer reactions *in vivo* and that this is useful for therapeutics. According to present innovation it

is also possible to administer nucleotide sugar or nucleotide sugar and a natural type of glycosyltransferase to a patient suffering from a glycosylation related disease and to at least partially correct the disorder. For example nucleotide sugars administered to blood circulation of patients suffering from some of the congenital disorders of glycosylation can be at least partially treated by administering appropriate nucleotide sugars to the patient, for example especially UDP-Gal, GDP-Fuc and GDP-Man but in some cases also other nucleotide sugars like UDP-GlcNAc, UDP-Glc, UDP-Xyl, UDP-GlcA and CMP-NeuNAc could be useful for such therapies. Part of the glycosyltransferase reactions could occur in serum of patient by transferases of serum.

Special activated salt of nucleotide sugar are described. Essentially pure manganese, magnesium or calcium salts of the nucleotide sugars or modified nucleotide sugars are useful pharmaceutical or therapeutical or nutritional compositions or for preparation of the composition, which can be used according to invention. Also pharmaceutical or therapeutical composition comprising nucleotide sugars or modified nucleotide sugars together with  $Mn^{2+}$ ,  $Ca^{2+}$  or/and  $Mg^{2+}$  ions are preferred according to the invention. These ions can activate glycosyltransferase reactions and/or protect the nucleotide sugars or modified nucleotide sugars from degradation in patient. Special phosphatase resistant, but glycosyltransfer active forms of nucleotide sugars can be used, for example a form of sulphur-substituted phosphate ester. UDP-Gal described in the literature. The manganese salts are tolerable in blood circulation only in very low concentrations, due to neurotoxicity. Low amounts of manganese form of nucleotide sugars can be used in gastro-intestinal system or for example when injected to urinary bladder or directly to the tumor. For systemic use, calcium and/or magnesium ion complexes of the nucleotide sugars or use of tolerable calcium or magnesium salts together with nucleotide sugars is preferred. In a preferred embodiment highest tolerable levels of calcium or magnesium ions, most preferably the  $Ca^{2+}$  and  $Mg^{2+}$  -ions in complex with nucleotide sugar and/or as tolerable salts with the nucleotide sugars are used in natural ratio of  $Ca^{2+}$  and  $Mg^{2+}$  in serum.

In a specific embodiment N-acetylneuraminic acid can be transferred in serum for example from CMP-NeuNAc to under sialylated low density lipoprotein particles (LDL) to prevent diseases caused by undersialylation of LDL.

In a preferred embodiment a nucleotide sugar or nucleotide sugars are used together with a glycosyltransferase to transfer monosaccharides to carbohydrate receptors of host microbe interaction. In a previous application a terminal GlcNAc-containing receptor for gastric pathogen *Helicobacter pylori* was described and the following application described

prevention of the synthesis of the receptor by inhibiting glycosidases. According to present invention it is possible to prevent the adhesion of *Helicobacter pylori* to the receptor by a composition comprising UDP-Gal and galactosyltransferase.

- 5 When the nucleotide sugars or nucleotide sugars and glycosyltransferases are administered orally, these can also perform *in vivo* glycosylation reactions to create probiotic or antibacterial oligosaccharides or glycoconjugates for example from lactose and also create receptor for probiotic bacteria on patients glycoconjugates or mask receptor for pathogenic bacteria.
- 10 Functional food compositions containing nucleotide sugars can be produced according to the invention. In a preferred embodiment the functional food contains both nucleotide sugars and glycosyltransferases. Preferential functional food composition is infant food, more preferentially infant formula. Human milk and other mammalian milks are known to contain nucleotide sugars and glycosyltransferases, therefore natural type of the substances
- 15 of the patients species are useful and well tolerated. Preferred amounts of the nucleotide sugar or nucleotide sugars or these in combination with one or more glycosyltransferases to be used vary from 5- 500 % of average the daily doses/kg obtained from milk. The nucleotide sugars are preferentially GDP-Fuc, CMP-NeuNAc, UDP-GlcNAc and UDP-Gal, other possible nucleotide sugars are GDP-Man,
- 20 UDP-Xyl, UDP-GlcA and UDP-Glc. The monosaccharide residues on the nucleotide sugars are also useful as direct inhibitors of bacterial adhesion. In the present invention it is realized for the first time that nucleotide sugars and their degradation products like monosaccharide-1-phosphates are especially desired natural type glycoconjugates because these do not form non-enzymatic glycation end products, so called advanced glycation end
- 25 products (AGEs) like free monosaccharides. For example, for mammalian species nucleotide monophosphates and nucleotide sugars are major type of monosaccharide conjugates beside glycolipids.

Use of antibodies, preferably from animals, in gastrointestinal and food related  
30 applications

- The present invention is specifically directed to the use of substances and antibodies binding to tumor specific oligosaccharide sequences according to the present invention for therapies in gastrointestinal tract of the patient, preferably in human patient. The therapeutic antibodies for use in human gastrointestinal tract may be antibodies produced
- 35 by animals for example antibodies in milks of domestic animals, for example in milk of domestic ruminants such as cows, sheep, goat or buffalo or antibodies produced in hen eggs. The animals can be immunized tumor specific carbohydrate conjugates as known in the art. The present invention is also directed to other acceptable, preferably food

acceptable proteins which can be used inhibition or destruction of tumors in human gastrointestinal tract, such substances includes plant lectins which are specific for the tumor specific oligosaccharide sequences. The present invention is directed to functional foods and food additives containing antibodies recognizing the tumor specific

5 oligosaccharide sequences according to the present invention in gastrointestinal tract, the present invention is directed also use of other food acceptable substances especially lectins binding to the tumor specific oligosaccharide sequences of gastrointestinal tract in functional foods or as food additives.

#### 10 Screening of substances binding to the tumor specific terminal GlcNAcs

The present invention is specifically directed to the use of the tumor specific terminal-GlcNAc-oligosaccharide sequences for the screening of specific binders with regard to the structures. The screening allows finding of optimal binding substances for the tumor specific oligosaccharide sequences according to the present invention. The specific binders  
15 may be therapeutic or diagnostic antibodies or other molecules binding to the glycans as described by the present invention above.

The screening of the substances binding to the oligosaccharide sequences according to the invention may be performed in an enzyme linked immunoassays (so called ELISA-assays). Direct binding can be measured for example when either the binding substance or  
20 the terminal-GlcNAc-glycan structure is linked to a solid phase matrix.

Free oligosaccharides or oligosaccharide conjugates according to the present invention can be also used as specific inhibitors in the assays. Fluorescence polararization difference and NMR are examples of liquid phase methods to be used for screening of the substances binding to the oligosaccharide sequences according to the invention.

25

#### Cancer vaccines

Furthermore, according to the invention the tumor specific oligosaccharide sequences or analogs or derivatives thereof can be used as cancer or tumor vaccines in man to stimulate immune response to inhibit or eliminate cancer or tumor cells. The treatment may not  
30 necessarily cure cancer or tumor but it can reduce tumor burden or stabilize a cancer condition and lower the metastatic potential of cancers. For the use as vaccines the oligosaccharides or analogs or derivatives thereof can be conjugated, for example, to proteins such as BSA or keyhole limpet hemocyanin, lipids or lipopeptides, bacterial toxins such as cholera toxin or heat labile toxin, peptidoglycans, immunoreactive  
35 polysaccharides, or to other molecules activating immune reactions against a vaccine molecule. A cancer or tumor vaccine may also comprise a pharmaceutically acceptable carrier and optionally an adjuvant. Suitable carriers or adjuvants are, e.g., lipids known to stimulate the immune response. The saccharides or derivatives or analogs thereof,

preferably conjugates of the saccharides, can be injected or administered mucosally, such as orally or nasally, to a cancer patient with tolerated adjuvant molecule or adjuvant molecules. The cancer or tumor vaccine can be used as a medicine in a method of treatment against cancer or tumor. Preferably the method is used for the treatment of a human patient. Preferably the method of treatment is used for the treatment of cancer or tumor of a patient, who is under immunosuppressive medication or the patient is suffering from immunodeficiency.

Furthermore it is possible to produce a pharmaceutical composition comprising the tumor specific oligosaccharide sequences or analogs or derivatives thereof for the treatment of cancer or tumor. Preferably the pharmaceutical composition is used for the treatment of a human patient. Preferably the pharmaceutical composition is used for the treatment of cancer or tumor, when patient is under immunosuppressive medication or he/she is suffering from immunodeficiency. The methods of treatment or the pharmaceutical compositions described above are especially preferred for the treatment of cancer or tumor diagnosed to express the tumor specific oligosaccharide sequences of the invention. The methods of treatment or the pharmaceutical compositions can be used together with other methods of treatment or pharmaceutical compositions for the treatment of cancer or tumor. Preferably the other methods or pharmaceutical compositions comprise cytostatics, anti-angiogenic pharmaceuticals, anti-cancer proteins, such as interferons or interleukins, or a use of radioactivity.

Use of antibodies for the diagnostics of cancer or tumor and for the targetting of drugs to cancer has been described with other antigens and oligosaccharide structures (US 4,851,511; US 4,904,596; US 5,874,060; US 6,025,481; US 5,795,961; US 4,725, 557; US 5,059,520; US 5,171,667; US 5,173,292; US 6,090,789; US 5,708,163; US 5,902,725 and US 6,203,999). Use of cancer specific oligosaccharides as cancer vaccines has also been demonstrated with other oligosaccharide sequences (US 5,102,663; US 5,660,834; US 5,747,048; US 5,229,289 and US 6,083,929).

#### Combination of the therapeutic and diagnostic methods

Present invention is specifically directed to analysis of abnormal and normal glycosylation structures from human tumors and cancers and use of the analytical information for the production of therapeutic antibodies or cancer vaccines according to the invention.

Present invention is specifically directed to treatment of cancer including following steps:

1. analysis of glycosylation of tumor or cancer tissue of a patient
2. analysis of normal glycosylation of the tissue containing the cancer

3. Use of the therapies according to the present invention if the patient has tumor specific oligosaccharide sequences according to the present invention in cancer but does not have the tumor specific oligosaccharide sequences or has these in much lower extent on cell surfaces in the normal tissue.

5 The data in examples shows the usefulness of the combination of analysis of the tumor specific structures according to the invention, because there are individual variations in glycosylation of tumors and normal tissues. The normal tissue close to tumor may also be contaminated partially contaminated by materials secreted by tumor which may be taken to consideration when analyzing the normal tissue data.

10

The substance according to the invention can be attached to a carrier. Methods for the linking of oligosaccharide sequences to a monovalent or multivalent carrier are known in the art. Preferably the conjugation is performed by linking the cancer specific oligosaccharide sequences or analogs or derivatives thereof from the reducing end to a carrier molecule. When using a carrier molecule, a number of molecules of a substance according to the invention can be attached to one carrier increasing the stimulation of immune response and the efficiency of the antibody binding. To achieve an optimal antibody production, conjugates larger than 10 kDa carrying typically more than 10 oligosaccharide sequences are preferably used.

20

The oligosaccharide sequences according to the invention can be synthesized, for example, enzymatically by glycosyltransferases, or by transglycosylation catalyzed by a glycosidase enzyme or a transglycosidase enzyme, for review see Ernst et al., 2000. Specificities of the enzymes and their use of co-factors such as nucleotide sugar donors, can be engineered.

25 Specific modified enzymes can be used to obtain more effective synthesis, for example, glycosynthase is modified to achieve transglycosylation but not glycosidase reactions. Organic synthesis of the saccharides and conjugates of the invention or compounds similar to these are known (Ernst et al., 2000). Carbohydrate materials can be isolated from natural sources and be modified chemically or enzymatically into compounds according to the invention. Natural oligosaccharides can be isolated from milks of various ruminants and other animals. Transgenic organisms, such as cows or microbes, expressing glycosylating enzymes can be used for the production of saccharides.

30 It is possible to incorporate an oligosaccharide sequence according to the invention, optionally with a carrier, in a pharmaceutical composition, which is suitable for the treatment of cancer or tumor in a patient. Examples of conditions treatable according to the invention are cancers in which the tumor expresses one or more of the tumor specific oligosaccharides described in the invention. The treatable cancer cases can be discovered

35

by detecting the presence of the tumor specific oligosaccharide sequences in a biological sample taken from a patient. Said sample can be a biopsy or a blood sample.

5 The pharmaceutical composition according to the invention may also comprise other substances, such as an inert vehicle, or pharmaceutically acceptable carriers, preservatives etc., which are well known to persons skilled in the art.

10 The substance or pharmaceutical composition according to the invention may be administered in any suitable way. Methods for the administration of therapeutic antibodies or vaccines are well-known in the art.

15 The term "treatment" used herein relates to both treatment in order to cure or alleviate a disease or a condition, and to treatment in order to prevent the development of a disease or a condition. The treatment may be either performed in an acute or in a chronic way.

The term "patient", as used herein, relates to any mammal in need of treatment according to the invention.

20 When a tumor specific oligosaccharide or compound specifically recognizing tumor specific oligosaccharides of the invention is used for diagnosis or typing, it may be included, e.g., in a probe or a test stick, optionally in a test kit. When this probe or test stick is brought into contact with a sample containing antibodies from a cancer patient or cancer cells or tissue of a patient, components of a cancer positive sample will bind the probe or test stick and can be thus removed from the sample and further analyzed.

25 In the present invention the term "tumor" means solid multicellular tumor tissues. Furthermore the term "tumor" means herein premalignant tissue, which is developing to a solid tumor and has tumor specific characteristics. The term "tumor" is not referring herein to a single cell cancer such as a leukaemia or to cultured cancer cells or a cluster of such cells. The present invention is preferably directed to primary human cancer samples. It is  
30 well known that glycosylations in cultivated cancer cells vary and are not in general relevant with regard to cancer. It is also known that transfections, cell culture media and dividing solid tumor to single cells may have dramatic effects for glycosylations. When referring to therapies tumor specific oligosaccharides or oligosaccharide sequences (possibly occasionally referred as cancer specific oligosaccharides/oligosaccharide  
35 sequences) are targeted for treatment of all kinds of cancers and tumors. The term cancer includes tumors.



The present invention is specifically directed to the treatment of all types of cancer or tumors expressing the tumor specific oligosaccharide sequences according to the present invention. Examples of preferred cancer types includes cancers of larynx, colon cancer, stomach cancer and lung cancer. These cancer types are especially preferred for the N-glycan type terminal GlcNAc related methods and compositions according to the present invention. Lung cancer is a preferred target for the protein linked GlcNAc related methods and compositions according to the present invention. The O-glycan type substances are especially preferred for use in methods and compositions according to the present invention for ovarian cancer and mucinous carcinomas, especially for ovarian adenocarcinomas. In a preferred embodiment the terminal GlcNAc-structures of poly-N-acetyllactosamine type is used for therapy or diagnostics of hypernephroma cancers. The present invention is also specifically directed to the treatment according to the present invention for any type of cancer or tumor which has surface expression of the terminal GlcNAc-structures according to the present invention.

Glycolipid and carbohydrate nomenclature is according to recommendations by the IUPAC-IUB Commission on Biochemical Nomenclature (Carbohydr. Res. 1998, 322:167; Carbohydr. Res. 1997, 297:1; Eur. J. Biochem. 1998, 257:29).

It is assumed that Gal, Glc, GlcNAc, and NeuNAc are of the D-configuration, Fuc of the L-configuration, and that all monosaccharide units are in the pyranose form. Glucosamine is referred as GlcN and galactosamine as GalN. Glycosidic linkages are shown partly in shorter and partly in longer nomenclature, the linkages  $\alpha 3$  and  $\alpha 6$  of the NeuNAc-residues mean the same as  $\alpha 2-3$  and  $\alpha 2-6$ , respectively, and  $\beta 1-3$ ,  $\beta 1-4$ , and  $\beta 1-6$  can be shortened as  $\beta 3$ ,  $\beta 4$ , and  $\beta 6$ , respectively. Lactosamine or N-acetyllactosamine or Gal $\beta 3/4$ GlcNAc means either type one structure residue Gal $\beta 3$ GlcNAc or type two structure residue Gal $\beta 1-4$ GlcNAc, and sialic acid is N-acetylneuraminic acid or NeuNAc, Lac refers to lactose and Cer is ceramide.

The present invention is further illustrated in examples, which in no way are intended to limit the scope of the invention:

## EXAMPLES

### Example 1.

#### *Culturing and labelling of bacteria*

The recombinant G-fimbriated *Escherichia coli* strain IHE11088 (pRR-5), expressing the GlcNAc-recognizing GafD adhesin (Rhen, M. et al., 1986), was cultured in Luria broth

containing tetracyclin (25 µg/ml) and 10 µl [<sup>35</sup>S]-methionine (400 mCi; Amersham Pharmacia Biotech, Little Chalfont, UK) at 37°C over night. The bacteria were harvested by centrifugation, washed two times with phosphate-buffered saline, pH 7.2 (PBS), and resuspended in PBS to 1 x 10<sup>9</sup> CFU/ml. The specific activities were approximately 100 CFU/cpm.

#### *Labelling of Erythrina cristagalli lectin*

The Galβ4GlcNAcβ-binding lectin from *Erythrina cristagalli* (Teneberg et al., 1994) was purchased from Vector Laboratories Inc., Burlingame, CA. Batches of 100 µg protein were labelled with <sup>125</sup>I, using Na<sup>125</sup>I (100 mCi/ml; Amersham Pharmacia Biotech), according to the IODO-GEN protocol of the manufacturer (Pierce, Rockford, IL). Approximately 5 x 10<sup>3</sup> cpm/µg protein was obtained.

#### *Glycosphingolipid binding assays*

Binding of radiolabeled bacteria and lectin to glycosphingolipids separated on thin-layer chromatograms was done as reported previously (Teneberg et al., 1994, Hansson et al., 1985). Thin-layer chromatography of glycosphingolipids was performed on aluminium-backed silica gel 60 HPTLC plates (Merck, Darmstadt, Germany), using chloroform/methanol/water 60:35:8 (by volume) as solvent system. Dried chromatograms were dipped for 1 min in diethylether/*n*-hexane 1:5 (by volume) containing 0.5% (w/v) polyisobutylmethacrylate (Aldrich Chem. Comp. Inc., Milwaukee, WI). After drying, the chromatograms were soaked in PBS containing 2% bovine serum albumin (BSA) (w/v), 0.1% NaN<sub>3</sub> (w/v) for 2 hr at room temperature. The chromatograms were subsequently covered with radiolabelled bacteria diluted in PBS (2-5 x 10<sup>6</sup> cpm/ml) or radiolabelled lectin in BSA (2 x 10<sup>3</sup> cpm/ml). Incubation was done for 2 hr at room temperature, followed by repeated washings with PBS. The chromatograms were thereafter exposed to XAR-5 X-ray films (Eastman Kodak, Rochester, NY) for 12 hr.

#### *Example 2.*

##### *Demonstration of tumor specificity of terminal GlcNAc structure.*

Thin-layer overlay assays were performed with radiolabelled G-fimbriated *Escherichia coli* to screen various tumors and normal tissues. The *E.coli* strain IHE11088 (pRR-5) specifically recognizes terminal GlcNAcβ-structures (Rhen, M. et al. 1986). Binding active glycolipids were found in non-acid fraction from one of four hypernephroma tumors studied (Fig 1). No binding was observed towards corresponding fraction of non-acid glycosphingolipids from human normal kidney or to other control tissues studied.

## Example 3.

*Characterizations of terminal GlcNAc $\beta$ -structures from human hypernephroma.*

Non-acid glycosphingolipids from human hypernephroma tumor were fractionated and analysed by binding with the GlcNAc $\beta$ -specific G-fimbriated *E.coli* (Fig.1A) and lectin from *Erythrina cristagalli* which recognizes terminal Gal $\beta$ 4GlcNAc $\beta$ -structures (Fig. 2B) by thin-layer overlay assay. The two binding reagents show partially overlapping glycosphingolipid binding species. The data indicates that the terminal GlcNAc-species are mostly present on N-acetyllactosamine type non-acid glycosphingolipids. The terminal GlcNAc-species which do not have an overlap with lectin binding activity have most probably terminal structures where N-acetyllactosamine is derivatized by GlcNAc such as GlcNAc $\beta$ 3Gal $\beta$ 3/4GlcNAc $\beta$ -; diffuse bands probably also indicates the presence of an isomeric form GlcNAc $\beta$ 6Gal $\beta$ 3/4GlcNAc $\beta$ -. The sample also appears to contain minor species where the terminal GlcNAc and N-acetyllactosamine are present in the same glycolipid. This indicates the presence of branched structures such as Gal $\beta$ 3/4GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 3/4GlcNAc $\beta$ - and GlcNAc $\beta$ 3(Gal $\beta$ 3/4GlcNAc $\beta$ 6)Gal $\beta$ 3/4GlcNAc $\beta$ -; the size distribution of the glycosphingolipids probably also indicates species with two or even more terminal GlcNAcs. The binding of the *Erythrina cristagalli* lectin indicates that most of the lactosamine probably has the type two N-acetyllactosamine structure Gal $\beta$ 4GlcNAc.

The glycolipids were partially analyzed by FAB mass spectrometry and by EI massspectrometry after permethylation, which showed presence of terminal HexNAc and that the smallest species with terminal GlcNAc is a pentasaccharide glycosphingolipid probably of lacto or neolacto series. Also 7-meric and larger structures up to 15-mer were observed (Fig. 1). The binding of the lectins indicates that most of the lactosamine probably has the type two N-acetyllactosamine structure.

## Example 4.

*Materials and methods for protein linked structures and labeling by galactosyltransferase*

*Isolation of glycans from formalin-fixed or formalin-fixed and paraffin-embedded tissue samples.* Prior to glycan isolation from formalin-fixed samples, proteins were enriched by chloroform-methanol extraction essentially as described in (Manzi *et al.*, 2000).

Quantitative extraction of glycoproteins was confirmed by radioactively labelled glycoprotein standards (not shown). Prior to glycan isolation from formalin-fixed and paraffin-embedded samples, the samples were deparaffinised. Glycans were detached from sample glycoproteins by non-reductive  $\beta$ -elimination and purified by chromatographic methods.

**MALDI-TOF MS.** MALDI-TOF mass spectrometry was performed with a Voyager-DE STR BioSpectrometry Workstation, essentially as in (Saarinen et al., 1999; Papac et al., 1996; Harvey, 1993).

- 5 *Exoglycosidase digestions.* All exoglycosidase reactions were performed essentially as described in (Nyman et al., 1998; Saarinen et al., 1999) and analysed by MALDI-TOF MS. The enzymes and their specific control reactions with characterised oligosaccharides were:  $\beta$ -N-acetylglucosaminidase (*Streptococcus pneumoniae*, recombinant, *E. coli*; Calbiochem, USA) digested GlcNAc $\beta$ 1-6Gal-R but not GalNAc $\beta$ 1-4GlcNAc $\beta$ 1-3/6Gal-R;
- 10  $\beta$ 1,4-galactosidase (*Streptococcus pneumoniae*, recombinant, *E. coli*; Calbiochem, USA) digested Gal $\beta$ 1-4GlcNAc-R but not Gal $\beta$ 1-3GlcNAc-R;  $\alpha$ -mannosidase (Jack bean; Glyko, UK) transformed a mixture of high-mannose N-glycans to the Man<sub>1</sub>GlcNAc<sub>2</sub> N-glycan core trisaccharide. Control digestions were performed in parallel and analysed similarly to the analytical exoglycosidase reactions.
- 15 *Synthesis of UDP-GalN-biotin.* UDP-galactosamine (UDP-GalN) is formed from UDP-Glc and galactosamine-1-phosphate by the action of galactose-1-phosphate uridylyltransferase (E.C. 2.7.7.12; Sigma, USA). A typical synthesis protocol is described below. The reaction mixture contains 10 mM galactosamine-1-phosphate, 20 mM UDP-Glc, 5 U/ml of
- 20 galactose-1-phosphate uridylyltransferase, 100 mM Na-HEPES pH 8.0, 5 mM MgCl<sub>2</sub>, and 5 mM  $\beta$ -mercaptoethanol. The reaction vessel is incubated at room temperature under nitrogen atmosphere for 3 days, after which nucleotide sugars are isolated from the reaction mixture with a graphitised carbon column essentially as in (Mäki et al., 2002). The nucleotide sugar mixture, containing UDP-Glc and UDP-GalN, is incubated with a
- 25 molar excess of sulfosuccinimidyl-6-(biotinamido)hexanoate (sulfo-NHS-LC-biotin; Pierce, USA) in 50 mM NH<sub>4</sub>HCO<sub>3</sub> at room temperature for 2.5 hours. The product, UDP-GalN-biotin, uridine 5'-diphospho-N-(6-biotinamidohexanoyl)galactosamine, is purified by gel filtration and reversed phase HPLC.
- 30 *Labeling of terminal GlcNAc residues in oligosaccharides and tissue sections with UDP-GalN-biotin.* N-(6-biotinamidohexanoyl)galactosamine can be transferred from UDP-GalN-biotin to a terminal GlcNAc containing acceptor with a recombinant  $\beta$ 1,4-galactosyltransferase similar to the enzyme described in (Ramakrishnan and Qasba, 2002). In a typical procedure, an oligosaccharide acceptor such as GlcNAc $\beta$ 1-3Gal $\beta$ 1-
- 35 4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4Glc, or deparaffinised formalin-fixed paraffin-embedded tissue sections, are incubated at +37 °C with a reaction mixture containing 10 mM UDP-GalN-biotin, 160 U/l enzyme, 100 mM Tris-HCl, and 20 mM MnCl<sub>2</sub>. After washing, the biotin

groups are visualised by standard methods in the art, using streptavidin or avidin coupled reagents, for example streptavidin-FITC.

*Labeling of terminal GlcNAc residues in tissue sections with UDP-[<sup>14</sup>C]Gal.* Formalin-fixed and paraffin-embedded tissue sections were deparaffinised and incubated at +37 °C with a reaction mixture containing UDP-[<sup>14</sup>C]Gal, 200 U/l bovine milk  $\beta$ 1,4-galactosyltransferase (Calbiochem, USA), 50 mM Na-MOPS pH 7.4, and 20 mM MnCl<sub>2</sub>. After washing, the labelled sections were subjected to autoradiography. N-glycans were detached from the tissue sections with *Chryseobacterium meningosepticum* N-glycosidase F (Calbiochem, USA) essentially as in (Nyman *et al.*, 1998). Chromatography was performed as described in figure legends to Fig. 7A and 7B.

#### Example 5

*Cancer-associated terminal GlcNAc containing N-glycans from lung adenocarcinoma samples.* Formalin-fixed samples, from tumor and surrounding healthy tissue, were obtained from a patient with lung adenocarcinoma. There was a significant difference between the neutral glycans isolated from the tumor sample (Fig. 3A) and the healthy tissue sample (Fig. 3B), namely a peak at m/z 1485.48, corresponding to the ion [Hex<sub>3</sub>HexNAc<sub>4</sub>Fuc<sub>1</sub>+Na]<sup>+</sup> (calc. m/z 1485.53). The relative intensity of this glycan peak was elevated over 6.1 times in the tumor sample, as compared to healthy tissue. Furthermore, a peak at m/z 1647.53, corresponding to the ion [Hex<sub>4</sub>HexNAc<sub>4</sub>Fuc<sub>1</sub>+Na]<sup>+</sup> (calc. m/z 1647.59), had a higher signal intensity in the tumor sample. Upon  $\beta$ -N-acetylglucosaminidase digestion (Fig. 3C), the two peaks were completely transformed into peaks at m/z 1079.18, corresponding to the ion [Hex<sub>3</sub>HexNAc<sub>2</sub>Fuc<sub>1</sub>+Na]<sup>+</sup> (calc. m/z 1079.38), and 1444.24, corresponding to the ion [Hex<sub>4</sub>HexNAc<sub>3</sub>Fuc<sub>1</sub>+Na]<sup>+</sup> (calc. m/z 1444.51), respectively, indicating the presence of terminal  $\beta$ -GlcNAc residues. Jack bean  $\alpha$ -mannosidase digestion (Fig. 3D) further transformed these peaks into peaks at m/z 755.19, corresponding to the ion [Hex<sub>1</sub>HexNAc<sub>2</sub>Fuc<sub>1</sub>+Na]<sup>+</sup> (calc. m/z 755.27), and 1282.29, corresponding to the ion [Hex<sub>3</sub>HexNAc<sub>3</sub>Fuc<sub>1</sub>+Na]<sup>+</sup> (calc. m/z 1282.45), respectively. However,  $\alpha$ -mannosidase digestion before the  $\beta$ -N-acetylglucosaminidase digestion did not affect the two peaks, indicating that the  $\alpha$ -Man residues were subterminal to the  $\beta$ -GlcNAc residues. In addition,  $\beta$ 1,4-galactosidase digestion of the original neutral glycan sample completely transformed the peak at m/z 1647.5 into the peak at m/z 1485.5, indicating the presence of a terminal Gal $\beta$ 1-4GlcNAc unit. Taken together, the results suggest that the lung adenocarcinoma tumor sample contained highly elevated amounts of the complex N-linked glycan core structure GlcNAc $\beta$ -Man $\alpha$ 1-

6(GlcNAc $\beta$ -Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc, and slightly elevated amounts of the mono- $\beta$ 1,4-galactosylated (to GlcNAc) derivative of the former structure, as compared to the surrounding healthy tissue.

5

#### Example 6.

*Occurrence of the terminal GlcNAc containing N-glycans in carcinoma samples.* The occurrence of the abovementioned structures in various tumor and healthy control samples was studied by isolating and analysing the neutral glycan fractions by MALDI-TOF MS and exoglycosidase digestions. The analysed tumor-control pairs were: 7 lung cancer sample pairs, and one pair each of colon, stomach, and larynx cancer samples. It turned out that in every case the relative abundance of the two terminal GlcNAc containing N-glycan at m/z 1485.5, was elevated in the cancerous sample. However, there were significant individual differences in the expression levels of this glycan epitope both in the healthy state and in cancer. Table 1 summarizes the differential expression of the m/z 1485.5 N-glycan in relation to the bulk of the isolated neutral glycan fraction.

15

#### Example 7.

20

*Synthesis of UDP-GalN-biotin.* UDP-galactosamine was synthesized as described under Materials and Methods. The product was characterized by MALDI-TOF MS (obs. m/z 564.42 for [C<sub>15</sub>H<sub>25</sub>N<sub>3</sub>O<sub>16</sub>P<sub>2</sub>-H]<sup>-</sup>, calc. m/z 564.31); Fig. 4A) and the expected peak appeared in the mass spectrum one mass unit smaller than the peak of UDP-Glc (obs. m/z 565.37 for [C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>17</sub>P<sub>2</sub>-H]<sup>-</sup>, calc. m/z 565.29); Fig. 4A). The crude nucleotide sugar preparate was reacted with a biotinylation reagent, namely succinimidyl-6-(biotinamido)hexanoate. After the reaction, the expected product could be seen in the MALDI-TOF mass spectrum of the reaction mixture (obs. m/z 902.93 for [C<sub>31</sub>H<sub>50</sub>N<sub>6</sub>O<sub>19</sub>P<sub>2</sub>S-H]<sup>-</sup>, calc. m/z 903.76; Fig. 4B). UDP-Glc did not react at all with the biotinylation reagent. The synthesized UDP-GalN-biotin, uridine 5'-diphospho-N-(6-biotinamidohexanoyl)galactosamine, reacted with GlcNAc $\beta$ 1-3Gal $\beta$ 1-4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4Glc and a recombinant  $\beta$ 1,4-galactosyltransferase similar to the enzyme described in (Ramakrishnan and Qasba, 2002). The product, [N-(6-biotinamidohexanoyl)galactosamine] $\beta$ 1-4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4Glc, was characterized by MALDI-TOF MS (obs. m/z for [M+Na]<sup>+</sup> 1433.38, calc. m/z 1433.55). Taken together, the results indicate that the synthesized product has the expected structure (Fig. 5). The product was chromatographically purified to homogeneity.

30

35

## Example 8.

*Labeling of terminal GlcNAc residues in tissue sections with UDP-[<sup>14</sup>C]Gal and UDP-GalN-biotin.* Deparaffinised formalin-fixed and paraffin-embedded tissue sections were

- 5 radioactively labeled with UDP-[<sup>14</sup>C]Gal and bovine milk  $\beta$ 1,4-galactosyltransferase, as described under Materials and Methods. Autoradiography revealed a clear difference between the tumor and the healthy tissue samples (Fig. 6), indicating that there are highly elevated amounts of terminal GlcNAc residues in the lung adenocarcinoma sample. Similar results were also obtained by using the UDP-GalN-biotin reagent, as described
- 10 under Materials and Methods, streptavidin-FITC, and fluorescence microscopy. Importantly, cancer cells could be labeled with this biotinylation reagent.

## Example 9.

- 15 *Isolation of [<sup>14</sup>C]Gal-labeled oligosaccharides from lung adenocarcinoma sample.* After labeling of lung adenocarcinoma sample and surrounding healthy tissue sections with [<sup>14</sup>C]Gal as described above, the labeled oligosaccharides were isolated by N-glycosidase F digestion and nonreductive  $\beta$ -elimination. In the gel filtration chromatogram of the N-glycosidase F liberated glycans from lung adenocarcinoma (Fig. 7A), only one peak was
- 20 visible and it coeluted with the N-glycan standards Gal $\beta$ 1-4GlcNAc $\beta$ 1-2Man $\alpha$ 1-6(Gal $\beta$ 1-4GlcNAc $\beta$ 1-2Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc and Gal $\beta$ 1-4[GlcNAc $\beta$ 1-2Man $\alpha$ 1-6(GlcNAc $\beta$ 1-2Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc]. The peak was pooled and subjected to HPLC with a porous graphitized carbon column (Fig. 7B), where it was divided into one major and two minor peaks. The major
- 25 peak, containing nearly all of the total radioactivity, coeluted with the N-glycan standard Gal $\beta$ 1-4[GlcNAc $\beta$ 1-2Man $\alpha$ 1-6(GlcNAc $\beta$ 1-2Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc].

- 30 In the gel filtration HPLC chromatogram of the material liberated by nonreductive  $\beta$ -elimination from lung adenocarcinoma (Fig. 7C), a broad peak, containing 45 % of the total radioactivity, was found to elute between the void volume (at 8 ml) and the elution position of the N-glycan standard Gal $\beta$ 1-4[GlcNAc $\beta$ 1-2Man $\alpha$ 1-6(GlcNAc $\beta$ 1-2Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc]. The broad peak was pooled and passed
- 35 through columns of strong cation exchange material and C<sub>18</sub> silica, which would retain all glycopeptidic material, but allow for quantitative elution of free oligosaccharides. Nearly 80 % of the radioactivity in the pooled fractions was retained in the columns, indicating that the broad peak indeed corresponded to alkali-liberated glycopeptides, from which the [<sup>14</sup>C]Gal labeled glycan moieties had not been detached. Major part of the remaining

radioactivity was found to correspond to the N-glycan structure described above, but the presence of other labelled oligosaccharides could not be excluded. The major peak in the gel filtration HPLC chromatogram, containing 55 % of the total radioactivity, coeluted with an N-acetyllactosamine (LacNAc) standard.

5

Example 10.

*Protein linked GlcNAc from cancer samples*

Furthermore, in graphitized carbon column HPLC of the pooled fractions at 15 – 18 min, the major peak coeluted with LacNAc. This suggests that the sample contains base-labile  
10 GlcNAc monosaccharide-protein conjugates, most likely GlcNAc $\beta$ -O-Ser/Thr units. Importantly, the amount of [ $^{14}$ C]-labeled LacNAc was significantly (1.99 times) higher in the lung adenocarcinoma sample as compared to the surrounding healthy tissue sample.

Taken together, these results indicate that about half of the total radioactivity that can be  
15 liberated from UDP-[ $^{14}$ C]Gal labeled lung adenocarcinoma sample tissue sections, represents the [ $^{14}$ C]Gal labeled forms of the cancer-associated N-glycan GlcNAc $\beta$ -Man $\alpha$ 1-6(GlcNAc $\beta$ -Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc. Furthermore, it is evident that also in the UDP-GalN-biotin reaction, the label is transferred into the oligosaccharide structures characterized above.

20

Example 11.

*Isolation of anti-GlcNAc antibodies from human serum.* Human serum from a person who had recovered from mucinous ovarian adenocarcinoma, was passed through Sepharose  
25 columns that contained either GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  or Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  epitopes covalently coupled to the gel. After washing, the columns were firstly eluted with a buffer containing 0.5 M GlcNAc (specific elution), and secondly with acidic buffer (unspecific elution). As a control, an IgG preparation from pooled human sera from healthy donors, i.e. persons who did not have a history of malignant  
30 diseases, was also subjected to the abovementioned chromatographical procedure. Reducing SDS-PAGE analysis was done to the collected fractions (Fig. 8). From the results it can be seen that two bands corresponding to proteins that had similar relative molecular weights to the heavy and light chains of an IgG standard, were eluted in the specific 0.5 M GlcNAc elution of GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  Sepharose, but only in  
35 the serum sample of the person who had recovered from cancer. In contrast, no such specific elution could be detected in Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  Sepharose chromatography of the two samples. According to their relative molecular weight, the specifically eluted proteins are likely to represent the heavy and light chain subunits of



IgG or IgA, but not IgM human antibodies. The present results indicate the presence of elevated levels of terminal GlcNAc specific antibodies in serum of the person who had recovered from cancer, more specifically IgG and/or IgA antibodies that recognize the GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$  glycan epitope.

5

Example 12. Determination and statistical evaluation of decreased neutral N- and O-glycan galactosylation in human carcinomas.

*Galactosylation degree calculation.*

- 10 For galactosylation degree determinations, the non-sialylated glycan fractions from non-small cell lung carcinoma and from control samples from respective healthy lung tissue, were isolated and analyzed by MALDI-TOF mass spectrometry as described above. The galactosylation degrees were calculated as follows. The relative intensities (I) of three peaks in the mass spectra were measured, namely those at m/z 1485.5 (corresponding to the ion [Hex<sub>3</sub>HexNAc<sub>4</sub>dHex<sub>1</sub>Na]<sup>+</sup>, with two non-reducing terminal N-acetylglucosamine residues), m/z 1647.6 (corresponding to the ion [Hex<sub>4</sub>HexNAc<sub>4</sub>dHex<sub>1</sub>Na]<sup>+</sup>, with one non-reducing terminal N-acetylglucosamine group and one non-reducing terminal N-acetylglucosamine residue), and m/z 1809.6 (corresponding to the ion [Hex<sub>5</sub>HexNAc<sub>4</sub>dHex<sub>1</sub>Na]<sup>+</sup>, with two non-reducing terminal N-acetylglucosamine groups).
- 15
- 20 The non-reducing terminal residues of these glycan components were previously determined as either N-acetylglucosamine according to sensitivity to digestion with glucosaminidase from Jack beans, or N-acetylglucosamine according to sensitivity to  $\beta$ -galactosidase digestion. The degree of galactosylation (DG) was calculated as the relation of galactosylated antennae N-acetylglucosamine residues to the total antennae N-
- 25 acetylglucosamine residues, according to the formula:

$$DG = (I_{1647.6} + 2 \times I_{1809.6}) : (2 \times I_{1485.5} + 2 \times I_{1647.6} + 2 \times I_{1809.6}) \times 100 \%$$

*Statistical calculations.*

- 30 Statistical analyses were performed with the SAS Software (SAS System, version 8.2, SAS Institute Inc., Cary, NC, USA), using SAS/STAT and SAS/BASE modules. All tests were performed as two-sided. The distributions of the experimental data were evaluated as 1) normal and symmetric, 2) only symmetric, or 3) non-symmetric and not normal, and the statistical test used was accordingly chosen as 1) Student's *t* Test, 2) Wilcoxon Signed
- 35 Rank Test, or 3) Sign Test. A p value of less than 0.05 was considered statistically significant.

*Galactosylation degree of neutral monofucosylated biantennary N-glycans is significantly reduced in non-small cell lung adenocarcinoma.*

All tumor samples from a randomly picked group of 7 patients with non-small cell lung adenocarcinoma showed a decrease in the galactosylation degrees of neutral monofucosylated biantennary N-glycans, when compared to the respective control samples from the same patients. This difference is statistically significant ( $p = 0.0156$  in Wilcoxon Signed Rank Test). In addition, as described above, the difference seen in the mass spectra between tumor and healthy specimens was correlated to radiochemical staining of tissue sections prepared from the same specimens, when the sections were treated with C-14 labelled uridine diphosphogalactose and bovine milk  $\beta$ 1,4-galactosyltransferase in galactosyltransferase reactions that were designed to quantitate non-reducing terminal N-acetylglucosamine residues in the sample glycoproteins. Moreover, the difference in radiochemical staining between the tumor and healthy control samples was the greatest when the respective difference in the degrees of galactosylation was the greatest, which allows for correlating the total amount of galactosyltransferase-sensitive non-reducing terminal  $\beta$ -N-acetylglucosamine residues in the tumor, with the mass spectrometric results obtained with isolated glycans from the tissue specimen.

*Individual lung carcinoma, a gastro-intestinal carcinoma, and kidney hypernephroma patients show severely decreased non-reducing terminal galactosylation of their glycoproteins.*

In addition to the general decrease in the galactosylation degree in the lung cancer tumor samples, the analyzed samples from the patient group included individuals in which the phenomenon was very drastic. In these samples, the N-glycan peak at  $m/z$  1485.5 was either the most abundant or the second most abundant neutral glycan signal in the mass spectra, indicating that the corresponding glycan structure had been specifically accumulated in the tumor cell glycoproteins. A similar phenomenon was also detected in tumor samples from individual patients of kidney carcinoma and a gastro-intestinal carcinoma, indicating that it is not restricted to lung carcinoma. The accumulation of non-reducing terminal  $\beta$ -N-acetylglucosamine containing N-glycans also characterized the isolated tumor protein-linked glycans from a patient with kidney hypernephroma, which had previously been analyzed for its glycolipid structures and found to contain also glycolipids characterized by decreased galactosylation. The latter correlation between glycoprotein and glycolipid structures further suggests that our observed accumulation of non-reducing terminal  $\beta$ -N-acetylglucosamine containing glycoconjugates is a result of a general defect in galactosylation that occurs in various forms of cancer.

*Tumor sample from an individual lung carcinoma patient that shows severely decreased non-reducing terminal galactosylation of O- and N-linked glycoprotein glycans.*

Tumor sample from a non-small cell lung adenocarcinoma patient was studied in detail to elucidate the structures of various N-acetylglucosaminidase sensitive structures detected in the sample. Compared to healthy lung specimens, the mass spectrum of the non-sialylated glycan fraction from the paraffin-embedded and formalin-fixed tumor sample showed a significantly increased amount of a signal at  $m/z$  609.23 (for  $\text{Hex}_1\text{HexNAc}_2$ , calc.  $m/z$  609.21 for the ion  $[\text{M}+\text{Na}]^+$ ) that can be assigned to a specific mucin-type O-glycan with specific exoglycosidase digestion reactions and MALDI-TOF mass spectrometry of the reaction products, as described below (mass spectra not shown). The abovementioned glycan signal was not sensitive to Jack bean  $\alpha$ -mannosidase digestion, whereas signals corresponding to high-mannose type N-glycans with molecular formulae  $\text{Man}_{3-8}\text{GlcNAc}_2$  and  $\text{Man}_{2-3}\text{GlcNAc}_2\text{Fuc}_1$  present in the same sample were transformed into peaks at  $m/z$  609.16 for  $\text{Hex}_1\text{HexNAc}_2$  and  $m/z$  755.22 for  $\text{Hex}_1\text{HexNAc}_2\text{Fuc}_1$  (calc.  $m/z$  755.27), respectively. Similarly,  $\beta$ -mannosidase digestion had no effect on the specific peak. However,  $\beta$ -N-acetylglucosaminidase from *S. pneumoniae* did cleave the peak at  $m/z$  609.23 that was transformed into a peak at  $m/z$  405.77, corresponding to  $\text{Hex}_1\text{HexNAc}_1$  (calc.  $m/z$  406.13), which indicates for the presence of a non-reducing terminal  $\beta$ -N-acetylglucosamine residue in the glycan structure. In addition, recombinant  $\beta$ 1,3-galactosidase partly transformed the peak into a peak at  $m/z$  447.16,  $\text{HexNAc}_2$  (calc.  $m/z$  447.16). The present data indicates that a major component glycan in the peak at  $m/z$  609.23 contains both non-reducing terminal  $\beta$ -N-acetylglucosamine and non-reducing terminal  $\beta$ 1,3-linked galactose residues, and indicates that it contains the O-glycan Core 2 trisaccharide structure  $\text{GlcNAc}\beta 1-6(\text{Gal}\beta 1-3)\text{GalNAc}$ . Compared to healthy lung tissue specimens, the mass spectrum of the sialylated glycan fraction from the same tumor contained a significantly increased amount of a signal that can be assigned to a sialylated counterpart of the neutral trisaccharide described above, namely at  $m/z$  876.27 for  $\text{NeuAc}_1\text{Hex}_1\text{HexNAc}_2$  (calc.  $m/z$  876.31 for the ion  $[\text{M}-\text{H}]^-$ ). The data indicates that this glycan signal corresponds to the sialylated form of the Core 2 O-glycan epitope detected among the neutral glycans from the same specimen, i.e.  $\text{GlcNAc}\beta 1-6(\text{Neu5Ac}\alpha 2-3\text{Gal}\beta 1-3)\text{GalNAc}$ .

By the action of *S. pneumoniae*  $\beta$ -N-acetylglucosaminidase, the peak at  $m/z$  1485.61 in the non-sialylated glycan fraction of the same sample, corresponding to  $\text{Hex}_3\text{HexNAc}_4\text{Fuc}_1$  (calc.  $m/z$  1485.53), was transformed into the peak at  $m/z$  1079.16, corresponding to  $\text{Hex}_3\text{HexNAc}_2\text{Fuc}_1$  (calc.  $m/z$  1079.38), and the peak at  $m/z$  1647.67, corresponding to  $\text{Hex}_4\text{HexNAc}_4\text{Fuc}_1$  (calc.  $m/z$  1647.59), was transformed into the peak at  $m/z$  1444.24, corresponding to  $\text{Hex}_4\text{HexNAc}_3\text{Fuc}_1$  (calc.  $m/z$  1444.51), which indicates that the

corresponding glycans contain 2 and 1 non-reducing terminal  $\beta$ -N-acetylglucosamine residues, respectively. By the combined action of *S. pneumoniae*  $\beta$ 1,4-galactosidase and recombinant  $\beta$ 1,3-galactosidase, both the peaks at  $m/z$  1647.67 and  $m/z$  1809.72, the latter corresponding to Hex<sub>5</sub>HexNAc<sub>4</sub>Fuc<sub>1</sub> (calc.  $m/z$  1809.64), were converted into the peak at  $m/z$  1485.48, which indicates that the corresponding glycans contained non-reducing terminal  $\beta$ -galactose residues in N-acetylglucosamine terminal structures. Taken together, the glycan signals at  $m/z$  1485.61, 1647.67, and 1809.72 represent a series of differently galactosylated glycan species. The galactosylation degree calculated from these three signals in the present tumor sample is 24 %, which is significantly below the average 33 % of the tumor samples from the group of 7 lung cancer patients described above. Furthermore, the simultaneous presence of the Hex<sub>1</sub>HexNAc<sub>2</sub> and NeuAc<sub>1</sub>Hex<sub>1</sub>HexNAc<sub>2</sub> terminal  $\beta$ -N-acetylglucosamine residue-containing glycans in the present tumor sample indicates that there is a general decrease in galactosylation of non-reducing terminal  $\beta$ -N-acetylglucosamine residues in the protein-linked glycans of the particular tumor sample.

#### Example 13. Protein and water solution-compatible conjugation reagents

##### *Preparation of UDP-GalN-PEG-fluorescein.*

In 100  $\mu$ l total reaction volume, 5 nmol uridine diphosphogalactosamine (UDP-GalN), 500 nmol fluorescein-poly(ethylene glycol)-NHS (MW 5000, Nektar Therapeutics, USA), and 500 nmol O-Benzotriazol-1-yl-N,N,N',N'-bis(tetramethylene)uronium hexafluorophosphate (Aldrich, USA), were incubated in ethylene glycol - dimethylformamide (1:1, v/v) containing 55 mM N-ethyl-diisopropylamine, at room temperature for 60 hours. The reaction mixture was gel filtrated in a Superdex Peptide HR 10/30 column (Amersham Pharmacia Biotech) at 1 ml/min flow rate in 250 mM NH<sub>4</sub>HCO<sub>3</sub> and the effluent was monitored with the UV detector at 214 nm, 261 nm, and 460 nm. Material eluted between 8 and 10 minutes, coeluting with the fluorescein-PEG starting material, was collected and dried. Anion exchange chromatography was performed on a Resource Q 1 ml column (Amersham Pharmacia Biotech) using H<sub>2</sub>O-NaCl gradient. UV absorption at 214 nm, 261 nm, and 460 nm was monitored. Unbound material that contained the fluorescein-PEG starting material was discarded and the material eluting between 10 and 40 mM NaCl concentrations was collected. The fractions were analyzed by MALDI-TOF MS with a Voyager-DE STR BioSpectrometry Workstation in positive ion delayed extraction linear mode using 2,5-Dihydroxybenzoic acid (DHB) as the matrix. Mass spectrometry revealed that polyethylene glycol derivatives were presented in both fractions. Also UV absorption at 460 nm indicated that fluorescein was present in the both

fractions. Taken together, the synthesized UDP-GalN-PEG-fluorescein (Fig. 9) was efficiently purified during the two chromatography steps.

#### *Enzyme reactions.*

- 5 Formalin-fixed and paraffin-embedded tissue sections from human non-small cell lung adenocarcinoma tumor tissue, were deparaffinised and covered with incubation mixture containing UDP-GalN-PEG-fluorescein as a sugar donor, 20 mM MnCl<sub>2</sub>, 10 mM Tris-HCl pH 8.0, and a mutant galactosyltransferase enzyme similar to the one described by Ramakrishnan and Qasba (2002). A negative control reaction contained the same
- 10 incubation mixture without the enzyme. Reactions were incubated at 37 °C for 20 hours, after which the tissue sections were washed with water. The fluorescent samples were analyzed by Olympus AX70 Provis fluorescence microscope. After the reaction, the samples showed clear positive cells at wavelengths 460-490 nm (FITC) within the tumor tissue (Fig. 10.E). The fluorescence was in the cytoplasm as well as in the membrane on
- 15 the positive cells (Fig. 10.C). However, the control samples remained negative (Fig. 10.A) showing only some autofluorescence (Fig. 10.B). However, the samples analyzed at wavelengths 530-550 nm were negative, indicating that the positive results were not due to autofluorescence (Fig. 10.D, 10.F). In conclusion, this example described how the enzyme catalysed the *ex vivo* transfer of GalN-PEG-fluorescein groups from UDP-GalN-PEG-
- 20 fluorescein to non-reducing terminal N-acetylglucosamine (GlcNAc) residues present in glycoprotein glycans of human tumor cells and tumor tissue sections.

#### *Preparation and use of various conjugation reagents*

- In different reactions, carboxylic acid reagents that were successfully incorporated to the
- 25 2-amino group of uridine diphosphogalactosamine through amidation, included S-acetyl-3-mercaptopropionic acid, 4-mercaptobutyric acid, Boc-2-aminooxyacetic acid, and N-maleimido-6-aminohexanoic acid, which are suitable for protein-compatible water-solution coupling of N-maleimido, aldehyde, and thiol group containing reagents or biologically active substances, respectively. The 3-mercaptopropionic acid conjugate was
- 30 primarily produced as acetate protected form and the 2-aminooxyacetic acid conjugate as t-Boc protected form, and the protective groups can be completely removed by incubation in mild alkaline aqueous solution or trifluoroacetic acid, respectively. After purification, the structures of the conjugation reagents were confirmed by MALDI-TOF mass spectrometry and found to contain the desired functional groups attached to the
- 35 galactosamine residue. In test reactions, the reagents were incubated in aqueous solution with a non-reducing terminal N-acetylglucosamine containing glycoconjugate and a modified galactosyltransferase enzyme similar to the one described by Ramakrishnan and Qasba (2002), which resulted in the successful transfer of conjugation reagent-modified

galactosamine residues to the glycoconjugates, evidenced by MALDI-TOF mass spectrometry as a mass increase of the acceptor glycoconjugate, equivalent to the galactosamine-reagent conjugate (mass spectra not shown).

5

Example 14. Increased levels of specific antibodies against non-reducing terminal N-acetylglucosamine containing glycoconjugates in serum of cancer patients.

10

A group of four people with various stages of diagnosed cancer of the gastrointestinal tract or the ovary, was studied by analyzing serum samples for their concentrations of IgG and IgM antibodies against specific carbohydrate epitopes. The assay consisted of binding of specific antibodies from serum to synthetic glycoconjugates, washing, and then detecting the specifically bound antibody levels in ELISA with enzyme-labelled anti-human IgG or anti-human IgM secondary antibodies and quantitation of specific reaction products. The

15

obtained results are depicted in Table 2. Both IgG and IgM levels against a non-reducing terminal N-acetylglucosamine containing N-glycan were elevated in one patient. Antibody levels against the Core 2 trisaccharide GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc were elevated in the whole patient group, but the specific antibody response varied: in one patient both IgG and IgM levels were elevated, in one patient mainly IgG, and in two patients mainly IgM.

20

Antibody response against the GlcNAc $\beta$ 1-3GalNAc disaccharide showed an identical pattern of antibody type response in the patient group. Two patients showed elevated serum levels of mainly IgM and one patient mainly IgG antibodies against an O-glycosidic  $\beta$ -GlcNAc epitope.

25

**Table 2.** Specific antibody responses against carbohydrate epitopes expressed as antibody signal intensities from which the assay background has been subtracted. Saccharide 1: GlcNAc $\beta$ 1-2Man $\alpha$ 1-6(GlcNAc $\beta$ 1-2Man $\alpha$ 1-3)Man $\beta$ 1-4GlcNAc $\beta$ 1-4(Fuc $\alpha$ 1-6)GlcNAc $\beta$ -N-Asn-R, Saccharide 2: positive cancer-associated saccharide, Saccharide 3: GlcNAc $\beta$ 1-6(Gal $\beta$ 1-3)GalNAc $\alpha$ -O-CH<sub>2</sub>-R, Saccharide 4: GlcNAc $\beta$ -O-CH<sub>2</sub>-R, Saccharide 5: GlcNAc $\beta$ 1-3GalNAc $\alpha$ -O-CH<sub>2</sub>-R. R: variable linker.

Saccharide	1	2	3	4	5
Patient 1 IgG	0	0	0,039	0	0,017
Patient 1 IgM	0	0,259	0,091	0,159	0,125
Patient 2 IgG	0	0,022	0,078	0,082	0,094
Patient 2 IgM	0	0,079	0,008	0,029	0,041
Patient 3 IgG	0,006	0	0	0,013	0
Patient 3 IgM	0,01	0,1	0,068	0,122	0,011
Patient 4 IgG	0	0	0	0	0
Patient 4 IgM	0	0,463	0,042	0	0,056

# 10 Example 15.

## Activity of $\beta$ 1,4-galactosyltransferase in human serum and activation of added $\beta$ 1,4-galactosyltransferase under various reaction conditions

- 15 Fresh human blood sample was collected from blood group B -individual (5 ml). After clotting for 30 min it was centrifuged at + 4°C, 2000 rpm for 25 minutes, and the serum was collected for experiments (2 ml, stored on ice).

- 20 Reactions were performed with 50 nmol of acceptor saccharide (GlcNAc $\beta$ 1-3Gal $\beta$ 1-4GlcNAc, from enzymatic synthesis, purified by ion exchange and gel filtration, characterized by NMR and mass spectrometry), 5 nmol UDP-[<sup>14</sup>C]Gal (mixture of nonlabelled and radioactive, radioactivity was 100 000 cpm) and 20  $\mu$ l of fresh human serum (total volume was 20  $\mu$ l). Reaction conditions were varied by adding cations and bovine milk  $\beta$ 1,4-galactosyltransferase ( $\beta$ 1,4GalT).

## Results

By adding 2 mU of  $\beta$ 1,4GalT alone showed clear galactosyltransferase activity, purified galactosylated tetrasaccharide sample had 534 cpm (Table 3). The background is likely radioactive Gal released from donor substrate. Adding 0.1 mM  $Zn^{2+}$  to reaction mixture doubled the product formation. Further addition of 4 mM  $MgCl_2$ , and 2 mM  $CaCl_2$  increased additionally the amount of product.

Similar increasing in product formation was with  $Mn^{2+}$ -addition, but without external  $\beta$ 1,4GalT, other salts used in the experiment did not activate the endogenous galactosyltransferase activity of human serum. Also  $MnCl_2$  at lower concentration than 5 mM was able to activate the endogenous enzyme in the biological solution (not shown). Notable is also that background was lower with  $Mn^{2+}$  and  $Zn^{2+}$  together with fosforylcholine. Fosforylcholine may inhibit enzyme activities of serum which degradate the donor nucleotide.

Table 3

Changes in reaction mixture	Product (cpm)	Background (cpm)
No salt, 2 mU $\beta$ 1,4GalT	534	5104
0.1 mM $ZnCl_2$ , 2 mU $\beta$ 1,4GalT	1022	4446
0.1 mM $ZnCl_2$ , 2 mU $\beta$ 1,4GalT, 4 mM $MgCl_2$ , 2 mM $CaCl_2$	1292	4546
0.1 mM $ZnCl_2$ , 1 mM fosforylcholine 2 mU $\beta$ 1,4GalT	872	2552
5 mM $MnCl_2$	566	1079
1 mM $MnCl_2$	1073	2068
0.2 mM $MnCl_2$	457	4578

## Example 16.

a) The oligosaccharide structure  $GlcNAc\beta 3Gal\beta 4GlcNAc\beta 3Gal\beta 4Glc$  is receptor for the gastric pathogen *Helicobacter pylori*. The structure is changed to 10-fold weaker receptor structure  $Gal\beta 4GlcNAc\beta 3Gal\beta 4GlcNAc\beta 3Gal\beta 4Glc$  by incubating it with UDP-Gal and  $\beta$ 4-galactosyltransferase from bovine milk.

b) The oligosaccharide receptor  $GlcNAc\beta 3Gal\beta 4GlcNAc\beta 3Gal\beta 4Glc$  is incubated with GDP-Fuc and soluble human fucosyltransferase VI corresponding to major the fucosyltransferase from human milk. MALDI-TOF mass spectrometric analysis revealed a major peak corresponding to  $GlcNAc\beta 3Gal\beta 4(Fuc\alpha 3)GlcNAc\beta 3Gal\beta 4Glc$ , the structure is confirmed by NMR-spectroscopy.

c) Erythrocytes from a patient suffering from glycosylation deficiency causing high



levels of terminal GlcNAc-structures including GlcNAc $\beta$ 3Gal $\beta$ 4Glc $\beta$ Cer are incubated with radiolabeled UDP-Gal and  $\beta$ galactosyltransferase. Transfer of labeled galactose on the cell surface is observed. The galactosylation of the cells reduces the reactivity of the cells with anti-GlcNAc-antibodies.


## References

- Ångström, J., and Karl-Anders Karlsson (1996) *Glycobiology* 6, 599-609.
- Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) *Science* 279, 323-4.
- Endo et al. (1996) *Eur. J. Biochem* 236:579-590.
- 5 Ernst, B., Hart, G.W., and Sinaý, P. (eds.) (2000) *Carbohydrates in chemistry and biology*, ISBN 3-527-29511-9, Wiley-VHC, Weinheim.
- Hanisch, F.-G., Koldovsky, U., and Borchard F. (1993) *Cancer Res.* 53, 4791-4796.
- Hansson, G.C., Karlsson, K.-A., Larson G., Strömberg, N., and Thurin, J. (1985) *Anal. Biochem.* 146, 158-63.
- 10 Harvey, D.J., *et al.* (1993) *Rapid Commun. Mass Spectrom.* 7(7):614-9.
- Hounsell, E.F., Lawson, A.M., Stoll, M., Kane, D.P., Cashmore, G.C., Carruthers, R.A., Feeney, J., and Feizi, T. (1989) *Eur. J. Biochem.* 186, 597-610.
- Holmes, E.H., and Greene, T.G. (1991) *Arch. Biochem. Biophys.* 288, 87-96.
- Hu, J., Stults, C.L.M., Holmes, E.H., and Macher, B.A. (1994) *Glycobiology* 4, 251-257.
- 15 Nakamura, M., Tsunoda, A., Sakoe, K., and Saito, M. (1993) *Biochem. Biophys. Res. Commun.* 197 1025-1033.
- Manzi, A.E., *et al.* (2000) *Glycobiology* 10(7):669-89.
- Meichenin M. *et al.* (2000) *Cancer Research* 60:5499-5507.
- Mäki, M., *et al.* (2002) *Eur. J. Biochem.* 269(2):593-601.
- 20 Nyman, T.A., *et al.* (1998) *Eur. J. Biochem.* 253(2):485-93.
- Packer, N.H., *et al.* (1998) *Glycoconj. J.* 15(8):737-747.
- Ramakrishnan, B., and Qasba, P.K. (2002) *J. Biol. Chem.* 277(23):20833-9.
- Papac, D.I., *et al.* (1996) *Anal. Chem.* 68(18):3215-23.
- Rhen M., Klemm P., and Korhonen T.K. (1986). *J Bacteriol* 168, 1234-42 .
- 25 Saarinen, J., *et al.* (1999) *Eur. J. Biochem.* 259(3):829-40.
- Sadamoto, R., Nikura, K., Nishimura, S.-I. (2001) Chemical engineering of bacterial cell wall. Poster C13.8, XVI International Symposium on Glycoconjugates August 19.-24. 2001 Haag Netherlands, *Glycoconjugate J.* no. 1 /2001.
- Spillmann, A., and Finne, J. (1994) *Eur. J. Biochem.* 220, 385-394.
- 30 Symington, F.W, Hendersson, B.A., and Hakomori, S.-I. (1984) *Mol. Immunol.* 21, 877-882.
- Teneberg, S., Lönnroth, I., Torres López, J.T., Galili, U., Ölwegård Halvarsson, M., Verostek, M.F., *et al.* (2000) *Anal. Biochem.* 278:111-122.
- Teneberg S, Ångström J, Jovall P-Å, and Karlsson K-A. (1994) *J Biol Chem* 269, 8554-63
- 35 Viitala, J., and Finne, J. (1984) *Eur. J. Biochem.* 138, 393-397.

What is claimed:


1. A pharmaceutical composition comprising a substance binding to a human tumor specific oligosaccharide sequence containing a terminal specifically protein linked  
5 GlcNAc-structure, for the treatment of a human cancer.
2. The pharmaceutical composition according to claim 1, wherein said human cancer is a human tumor.
- 10 3. The pharmaceutical composition according to claim 1, wherein the composition is for the treatment of a human tumor diagnosed to express or compared to normal tissue expressing said human tumor specific oligosaccharide sequence.
4. The pharmaceutical composition according to claim 3, wherein said human tumor  
15 specific oligosaccharide sequence is expressed on cell surface or tissue surface of human tumor.
5. The pharmaceutical composition according to any one of claims 1 – 4, wherein said oligosaccharide sequence has the sequence according to Formula  
20 
$$[\text{GlcNAc}\beta\text{x}/\text{Gal}\beta 3]_{s1}(\text{GlcNAc}\beta 1-6)_{s2}\text{Sacch}$$

wherein x is 3, when Sacch is Gal(NAc); or  
x is 2, when Sacch is Man; and wherein  
25 s1 and s2 are independently 0 or 1 with the provision that there is at least one terminal GlcNAc; the structure is branched, when both s1 and s2 are 1; Sacch is Gal with the provision that it is not  $\alpha 6$ -linked to another GalNAc; Sacch is GlcNAc $\beta$  with the provision that s1 and s2 is 0 and said GlcNAc $\beta$  is linked to a protein or peptide;  $[\text{GlcNAc}\beta\text{x}/\text{Gal}\beta 3]$  means that terminal residue is either GlcNAc $\beta\text{x}$  or Gal $\beta 3$ .  
30
6. The pharmaceutical composition according to any preceding claim, wherein said substance binding to said oligosaccharide sequence is specific to one or several of the terminal oligosaccharide sequences of a N-glycan type structure according to Formula



wherein  $r_1$ ,  $r_2$ ,  $r_3$ ,  $r_4$ ,  $r_5$ , and  $r_6$  are either 0 or 1 with the proviso that at least  $r_1$  is 1 or  $r_2$  is 1; GN is GlcNAc, with the proviso that when both  $r_1$  and  $r_2$  are 1, one GN $\beta$ Man can be further elongated with one or several other monosaccharide residues such as by galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6 residue and/or Man $\alpha$ 3 residues can be further substituted by GN $\beta$ 6 or GN $\beta$ 4, and/or Man $\beta$ 4 can be further substituted by GN $\beta$ 4.

7. The pharmaceutical composition according to any one of claims 1-5, wherein said substance binding to said oligosaccharide sequence is specific to one or several of the terminal oligosaccharide sequences of a N-glycan type structure according to Formula




wherein  $r_1$ ,  $r_2$ ,  $r_5$ , and  $r_6$  are either 0 or 1, with the proviso that at least  $r_1$  is 1 or  $r_2$  is 1; GN is GlcNAc, with the proviso that when both  $r_1$  and  $r_2$  are 1, one GN $\beta$ Man can be further elongated with one or several other monosaccharide residues such as by galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6 residue and/or Man $\alpha$ 3 residues can be further substituted by GN $\beta$ 6 or GN $\beta$ 4, and/or Man $\beta$ 4 can be further substituted by GN $\beta$ 4.

8. The pharmaceutical composition according to claim 6, wherein said oligosaccharide sequence is

GlcNAc $\beta$ 2Man, GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
 GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
 GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
 GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc,  
 GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man, GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
 GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
 GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc,

Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man, Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
5 GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man,  
GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc, or  
GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc $\beta$ 4(Fuc $\alpha$ 6)GlcNAc

9. The pharmaceutical composition according to any one of claims 1-5, wherein said  
10 substance binding to said oligosaccharide sequence is specific to one or several of the  
terminal oligosaccharide sequences of a O-glycan type structure according to Formula



15 wherein s1, s2, s3, and s5 are independently 0 or 1, with the proviso that at least s1 is 1 or  
s5 is 1 and s3 is 1 or s5 is 1 and s3 is 1, so that the oligosaccharide sequence comprises at  
least one nonreducing end terminal GlcNAc $\beta$ -residue.

10. The pharmaceutical composition according to any one of claims 1-5, wherein said  
20 oligosaccharide sequence is protein linked GlcNAc or a derivative thereof.

11. The pharmaceutical composition according to claim 9, wherein said oligosaccharide  
sequence is

25 GlcNAc $\beta$ 3Gal $\beta$ 3(Gal $\beta$ 4GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc,  
GlcNAc $\beta$ 3Gal $\beta$ 3GalNAc, Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc,  
GlcNAc $\beta$ 6GalNAc, or GlcNAc $\beta$ 3GalNAc

12. The pharmaceutical composition according to claim 3, wherein said substance binding  
30 to said oligosaccharide sequence is specific to one or several of the following terminal  
oligosaccharide sequences:

GlcNAc $\beta$ 3Gal, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcNAc $\beta$ 6Gal, GlcNAc $\beta$ 6Gal $\beta$ 4GlcNAc  
GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal, and GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4GlcNAc

said composition optionally further comprising at least one oligosaccharide sequences  
5 defined in any one of claims 6-11, said composition being for the treatment of lung,  
larynx, colon, gastric or ovarian cancer.

13. The pharmaceutical composition according to any preceding claim, wherein said  
oligosaccharide sequence is not linked by natural glycosidic linkages to other  
10 monosaccharide or oligosaccharide structures.

14. The pharmaceutical composition according to any preceding claim, wherein said  
substance binding to said oligosaccharide sequence is an aptamer, a peptide or a protein.

15 15. The pharmaceutical composition according to claim 14, wherein said protein is an  
antibody, a lectin, or a fragment thereof.

16. The pharmaceutical composition according to claim 14, wherein said protein is an  
enzyme recognizing the terminal GlcNAc-structures, preferably a glycosyltransferase  
20 enzyme or variant thereof.

17. The pharmaceutical composition according to claim 15, wherein said antibody is a  
human or humanized antibody.

25 18. A pharmaceutical composition comprising a human tumor specific oligosaccharide  
sequence containing a terminal beta-linked N-acetylglucosamine residue, GlcNAc $\beta$ , or  
analogues or derivatives thereof for the treatment of human lung, larynx, colon, gastric or  
ovarian cancer.

30 19. The pharmaceutical composition according to claim 18, wherein said human cancer is  
a human tumor.

20. The pharmaceutical composition according to claim 18, wherein the composition is for the treatment of a human tumor diagnosed to express or compared to normal tissue expressing said human tumor specific oligosaccharide sequence.


5 21. The pharmaceutical composition according to claim 18, wherein said human tumor specific oligosaccharide sequence is expressed on cell surface or tissue surface of human tumor.

10 22. The pharmaceutical composition according to claim 18, wherein said composition is antigenic.

23. The pharmaceutical composition according to claim 18 or 19, wherein said oligosaccharide sequence is an oligosaccharide sequence as defined in any one of claims 1 and 5-12.

15

24. The pharmaceutical composition according to claim 23 comprising a polyvalent conjugate of said oligosaccharide sequence wherein position C1 of the reducing end terminal of the oligosaccharide sequence (OS) comprising the tumor specific terminal sequence of the invention is linked ( $-L-$ ) to an oligovalent or a polyvalent carrier (Z), via a spacer group (Y) and optionally via a monosaccharide or oligosaccharide residue (X), forming the following structure



25 where integer m have values  $m > 1$  and n is independently 0 or 1; L can be oxygen, nitrogen, sulfur or a carbon atom; X is preferably lactosyl-, galactosyl-, poly-N-acetyl-lactosaminyl, or part of an O-glycan or an N-glycan oligosaccharide sequence, Y is a spacer group or a terminal conjugate such as a ceramide lipid moiety or a linkage to Z.

30 25. The pharmaceutical composition according to any one of claims 1 - 24 comprising a pharmaceutically acceptable carrier and optionally an adjuvant.

26. A method for diagnosing cancer or tumor in a biological sample taken from a human patient, the method comprising determining the presence in said sample of an

oligosaccharide sequence which comprises a tumor specific terminal specifically protein linked beta-linked N-acetylglucosamine residue, GlcNAc $\beta$ .

27. The method according to claim 26 wherein the determination comprises

5 (a) contacting said biological sample with a substance binding to said oligosaccharide sequence, and

determining the presence of a combination of said substance and said sample, the presence of said combination being an indication of cancer present in said sample, or

(b) releasing the oligosaccharide structures of said biological sample by enzymatic  
10 or chemical methods to form a fraction containing free oligosaccharide structures from said sample, and

determining the presence of said oligosaccharide sequence in said fraction, the presence of said oligosaccharide sequence in said fraction being an indication of cancer present in said sample.

15 28. The method according to claim 26 or 27, wherein said oligosaccharide sequence is a terminal oligosaccharide sequence as defined in any one of claims 1 and 5-12.

29. The method according to any one of claims 26-28, wherein said cancer is a tumor.

20 30. The method according to any one of claims 26-28, wherein a cancer or tumor type is determined.

31. The method according to any one of claims 26-30, wherein normal glycosylation of the  
25 tissue containing the cancer is determined.

32. The method according to any one of claims 26-31, wherein the glycosylations are determined on the surface of cancer or normal tissue

30 33. Diagnostic agent comprising a binding substance as defined in any one of claims 1 – 17 for the diagnosis of human cancer or cancer type.

34. Antigenic substance comprising a terminal oligosaccharide sequence as defined in any one of claims 1 and 5-12 in a chemically or biochemically synthesized polyvalent form.



35. Use of the antigenic substance according to claim 34 or analogs or derivatives thereof to produce polyclonal or monoclonal antibodies.

5 36. Use of the antigenic substance according to claim 34 or analogs or derivatives thereof for the purification of antibodies from serum, preferably from human serum.

37. Use of the antigenic substance according to claim 34 or analogs or derivatives thereof for the detection and/or quantitation of antibodies.

10

38. A cancer vaccine comprising oligosaccharide sequences containing a terminal sequence as defined in any one of claims 1 and 5-12 or analogs or derivatives thereof.

15 39. The cancer vaccine according to claim 38 comprising a pharmaceutically acceptable carrier and optionally an adjuvant.

40. A substance binding to oligosaccharide sequences containing a terminal sequence as defined in any one of claims 1 and 5-12, wherein said substance is an aptamer, human natural or humanized antibody or peptide.

20

41. A method for identifying cancer or tumor specific therapeutics or diagnostic agents comprising the steps of contacting a compound with a oligosaccharide sequence as defined in any one of claims 1 and 5-12 and determining binding to said oligosaccharide sequence by said compound.

25

42. A human anti-GlcNAc antibody obtainable by:  
passing human serum sample through a column containing immobilized terminal  
GlcNAc $\beta$  epitopes;  
washing the column;  
30 eluting the column with a buffer containing high concentration of GlcNAc;  
and collecting the antibody.

43. A functional food or food additive containing antibodies recognizing tumor specific oligosaccharide sequences as defined in any one of claims 1 and 5-12 for the treatment of human cancer or tumor.

5 44. A functional food according to claim 41, wherein said antibody is produced in milk or in hen eggs.

45. The antibody according to claim 42, wherein said antibody recognizes oligosaccharide sequence GlcNAc $\beta$ 6GalNAc $\alpha$ -O-CH<sub>2</sub>-R, GlcNAc $\beta$ 6(Gal $\beta$ 3)GalNAc $\alpha$ -O-CH<sub>2</sub>-R,  
10 GlcNAc $\beta$ 2Man or GlcNAc $\beta$ -O-CH<sub>2</sub>-R or GlcNAc $\beta$ 3GalNAc $\alpha$  | -O-CH<sub>2</sub>

46. Method of treatment or diagnosis of cancer or tumor comprising transferring a modified monosaccharide derivative to cancer cells or tumor by a glycosyl transferase or a transglycosylate enzyme.

15 47. The method according to claim 46 wherein said modified monosaccharide derivative is any type of terminal  $\beta$ -GlcNAc structures defined in any one of the preceding claims.

48. The method according to claim 46 wherein said modified monosaccharide derivative is  
20 according to the formula

UDP-GalN[-S]-D,

wherein

S is an optional spacer group

D is derivatizing group including molecular labels such as for example biotin or a  
25 fluorescent molecule including, or a toxic agent, prodrug or prodrug releasing substance.

49. The method according to claim 48 wherein the modified monosaccharide is UDP-GalN-spacer-biotin or UDP- N-(6-biotinamidohexanoyl)galactosamine.

30 50. The method according to claim 46 wherein the modified monosaccharide is transferred by is a galactosyltransferase which is engineered to transfer effectively 2-modified monosaccharides or a natural GalNAc/GlcNAc-transferase with similar specificity with the said modified galactosyltrasferase from animals.

35 51. The method according to claim 46 wherein said modified monosaccharide derivative is a non-immunogenic hydrophilic structure.

52. The method according to claim 46 wherein said modified monosaccharide derivative is transferred to cell or tissue.

53. The method according to claim 46 wherein said modified monosaccharide derivative is transferred on a therapeutic protein.

54. A substance according to  
Formula P1:

Hex(L-S-PEG)-GlcNAc $\beta$ -Core-peptide

wherein Hex, L and S are as described in Formula C1,

Core is a core structure of N-glycan and/or O-glycan, when GlcNAc is part of the core structure the core is the glycan core excluding a terminal GlcNAc residue,  
PEG is polyethylene glycol, and peptide is protein or peptide.

55. A substance according to  
Formula CT2:

Gal(N-S-PEG)-GlcNAc $\beta$ -Cell /tiss,

wherein S, PEG-core and peptide are as described in Formula C1.

56. Method of synthesis of substance according to claim 54 or 55 comprising transferring a modified monosaccharide by a modified galactosyltransferase.

57. A composition comprising an enzyme substrate, capable of being transferred specifically to a surface of a pathogenic entity or malignant cell or tissue by a transferring enzyme making a covalent linkage between said enzyme substrate and an acceptor structure of said surface, optionally conjugated to an immunologically active substance and/or a toxic substance for use as a medicine.

58. The composition according to claim 57, wherein said enzyme substrate is a carbohydrate substance capable of being transferred specifically to the surface of a pathogenic entity or malignant cell or tissue by the transferring enzyme.

59. The composition according to claim 58, wherein said transferring enzyme is a glycosyl transferase or a transglycosylate enzyme.

60. The composition according to claim 57, wherein said carbohydrate substance is a nucleotide sugar.

61. The composition according to claim 60, wherein said nucleotide sugar is an activated salt of natural type of said nucleotide sugar.

5 62. The composition according to claim 60, wherein said nucleotide sugar is selected from the group consisting of:

UDP-Gal, GDP-Fuc, GDP-Man, UDP-GlcNAc, UDP-Glc, UDP-Xyl, UDP-GlcA and CMP-NeuNAc.

10 63. The composition according to claim 62, wherein the immunologically active substance or the toxic substance as defined in claim 57 is linked to carbon number 2 or 6 of the Gal, GalNAc, Glc or GlcNAc residues of UDP-Gal, UDP-GalNAc, UDP-Glc or UDP-GlcNAc, respectively.

15 64. The composition according to claim 62, wherein the immunologically active substance or the toxic substance as defined in claim 57 is linked to carbon number 6 of the Fuc residue of GDP-Fuc.

20 65. The composition according to claim 62, wherein the immunologically active substance or the toxic substance as defined in claim 57 is linked to carbon number 5, 7, 8 or 9 of CMP-NeuNAc.

66. The composition according to claim 62, wherein UDP-Gal is modified to carbon 6 by a spacer and a Gal $\alpha$ 3Gal-saccharide epitope.

25 67. The composition according to claim 58, wherein said carbohydrate substance is a glycoside being a substrate for a transglycosylate enzyme.

68. The composition according to claim 67, wherein said glycoside is phenyl- or paranitrophenylglycoside.

30 69. The composition according to claim 57, wherein said immunologically active substance is a carbohydrate or a carbohydrate analog or a derivative recognizable by immune system.

70. The composition according to claim 57, wherein said immunologically active substance is recognized by antibodies.

35 71. The composition according to claim 69, wherein said carbohydrate or a carbohydrate analog or a derivative comprises terminal GlcNAc $\beta$ -, Gal $\alpha$ -antigen, or a blood group antigen.

72. The composition according to claim 71, wherein said blood group antigen is blood group A-antigen or blood group B-antigen.

5 73. The composition according to claim 57, wherein said immunologically active substance is recognized by a defensive cell surface receptor.

74. The composition according to claim 57, wherein said immunologically active substance is a carbohydrate recognized by non-antibody defense receptors of a patient.

10 75. The composition according to claim 57, wherein said immunologically active substance is a carbohydrate recognized by defensive lectins of the immune system of a patient or a terminal GlcNAc -recognising antibody substrate.

15 76. The composition according to claim 57, wherein said immunologically active substance is selected from the group consisting of:

proteins, peptide antigens, non-harmful parts of peptidoglycan, non-natural epitopes, and lipid A of bacteria.

20 77. The composition according to claim 76, wherein the protein is a complement protein.

78. The composition according to any one of claims 57-77 further comprising a glycosyl transferase or a transglycosylating enzyme.

25 79. The composition according to claim 78, wherein said transglycosylating enzyme is a transsialidase.

80. The composition according to claim 78, wherein said glycosyl transferase is selected from the group consisting of:

30 galactosyltransferases, N-acetylglucosaminyltransferases, N-acetylgalactosaminyltransferases, fucosyltransferases, sialyltransferases, mannosyltransferases, xylosyltransferases, glucuronyltransferases and glucosyltransferases.

35 81. The composition according to claim 78, wherein said glycosyl transferase is selected from the group consisting of:

$\beta$ 4galactosyltransferase,  $\beta$ 4glucosyltransferase,  $\beta$ 4-N-acetylgalactosaminyltransferase,  $\beta$ 4-N-acetylglucosaminyltransferase,  $\beta$ 3galactosyltransferase,  $\beta$ 3-N-acetylglucosaminyltransferase,  $\beta$ 2-N-acetylglucosaminyltransferase,  $\beta$ 6-N-acetylglucosaminyltransferase,  $\alpha$ 3sialyltransferase,  $\alpha$ 6sialyltransferase,  $\alpha$ 3fucosyltransferase,  $\alpha$ 2fucosyltransferase and  $\alpha$ 6fucosyltransferase.

5

82. The composition according claims 78, 80 or 81, wherein said glycosyltransferase is in soluble non-antigenic form.

10

83. The composition according to claim 57, wherein said pathogenic entity or malignant cell carries a specific carbohydrate structure on its surface, said structure being specifically recognised by said transferring enzyme.


15

84. The composition according to claim 57, wherein said structure of said surface is a pathogenesis or metastasis -inducing carbohydrate receptor.

85. The composition according to any one of claims 57 - 84 further comprising  $\text{Mn}^{2+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Zn}^{2+}$  and/or  $\text{Mg}^{2+}$  ions.

20

86. The composition according to any one of claims 57 – 85 comprising the modified monosaccharide derivative as defined in any one of claims 46-53 and/or the substance as defined in claim 54 or 55.



Autoradiogram after overlaying with  
 $^{35}\text{S}$ -methionine- labeled E.coli  
Specificity: GlcNAc $\beta$

Figure 1.




Figure 2.






Figure 3A.




Figure 3B.




Figure 3C.




Figure 3D.




Figure 4A.




Figure 4B.




Figure 5.




Figure 6.






Figure 7A.




Figure 7B.




Figure 7C.




Figure 8.




Figure 9.




Fig. 10A




Fig. 10B



Fig. 10C




Fig. 10D




Fig. 10E




Fig. 10F

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
**WO 2004/017810 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/00**, 31/70, A61P 35/00, 31/00, G01N 33/574, C07H 5/06
- (21) International Application Number:  
PCT/FI2003/000615
- (22) International Filing Date: 20 August 2003 (20.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
PCT/FI02/00681 20 August 2002 (20.08.2002) FI
- (71) Applicant (for all designated States except US): **BIOTIE THERAPIES CORP.** [FI/FI]; Tykistökatu 6, FIN-20520 Turku (FI).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **NATUNEN, Jari** [FI/FI]; Oolannintie 10 E 18, FIN-01520 Vantaa (FI). **TENEBERG, Susann** [SE/SE]; Postbox 1639, S-43063 Hindås (SE). **KARLSSON, Karl-Anders** [SE/SE]; Nilssonsberg 37, S-41143 Göteborg (SE). **SATOMAA, Tero** [FI/FI]; Maakaari 6 A 11, FIN-00710 Helsinki (FI). **HEISKANEN, Annamari** [FI/FI]; Trumpettitie 8 E 93, FIN-00420 Helsinki (FI).
- (74) Agent: **KOLSTER OY AB**; Iso Roobertinkatu 23, P.O. Box 148, FIN-00121 Helsinki (FI).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:  
10 June 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF

(57) Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer. Further the present invention relates to a method of treatment or diagnosis of cancer by transferring a modified monosaccharide to cancer cells by glycosyl transferase. It also concerns an enzyme substrate composition capable of being transferred to a surface of pathogenic entity for use as medicine.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI/03/000615

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/00, A61K 31/70, A61P 35/00, A61P 31/00, G01N 33/574, C07H 5/06  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, G01N, C07H, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, BIOSIS, MEDLINE, CHEM.ABS.DATA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,X	WO 03016915 A1 (CARBION OY), 27 February 2003 (27.02.2003)	1-45, 46-86 (PARTI- ALLY)
X	British Journal of Cancer, Volume 83, No. 10, 2000, PJ Johnson et al, "Structures of disease-specific serum alpha-fetoprotein isoforms", pages 1330-1337, see specially figure 1, G10 and G11	1-5 (PARTIAL- LY),6-8, 13-86 (PARTI- ALLY)
X	British Journal of Cancer, Volume 81, No. 7, 1999, PJ Johnson et al, "Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour", pages 1188-1195, se specially figure 3, G11 and G10	1-5 (PARTIAL- LY),6-8, 13-86 (PARTI- ALLY)

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 31 March 2004	Date of mailing of the international search report 2004-04-06
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Micael Oswald/BS Telephone No. +46 8 782 25 00



## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0255342 A1 (UNIVERSITY COLLEGE LONDON), 3 February 1988 (03.02.1988), see specially page 1, column 2, lines 32-61  --	1-45, 46-86 (PARTI - ALLY)
X	Eur. J. Biochem., Volume 161, 1986, James W. Dennis et al, "Asn-linked oligosaccharides in lectin-resistant tumor-cell mutants with varying metastatic potential", pages 359-373, the whole document  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	DE 3807594 A1 (REUTTER, WERNER), 21 Sept 1989 (21.09.1989)  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	Cancer Research, Volume 43, November 1983, Katsuko Yamashita et al, "Comparative Study of the Sugar Chains of gamma-Glutamyltranspeptidases Purified from Rat Liver and Rat AH-66 Hepatoma Cells", pages 5059-5063, see specially charts. 4-5  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	J. Biochem., Volume 90, 1981, Katsuko Yamashita et al, "Structural Study of the Sugar Chains of alpha-Amylases Produced Ectopically in Tumors", pages 1281-1289, see specially figures 4-5  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	Histochemical Journal, Volume 24, 1992, Boris E. Chechik et al, "Increased expression of highly branched N-linked oligosaccharides terminating in N-acetylglucosamine residues in neoplastic and sclerodermal chicken fibroblasts", pages 15-20, the whole document  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Molecular Immunology, Volume 24, No. 8, 1989, Gail Nixon Volman et al, "Analysis of Asparagine-linked oligosaccharide structures of chronic lymphocytic leukemia cells", pages 871-888 see specially table 5  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	Eur. J. Biochem., Volume 236, 1996, Tamao Endo et al, "Comparative study of the sugar chains of alkaline phosphatases purified from rat liver and rat AH-130 hepatoma cells Occurrence of fucosylated high-mannose-type and hybrid-type sugar chains", pages 579-590, see specially table 2  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	Clinical Cancer Research, Volume 5, 1999, Abdelhadi Rebbaa et al, "Expression of Bisecting GlcNAc in Pediatric Brain Tumors and Its Association with Tumor Cell Response to Vinblastine", pages 3661-3668  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
P,X	Jpn J. Electroph, Volume 46: 163, 2002, Nobuhisa Ohtani et al, "Abnormality of the oligosaccharide moiety of human immunoglobulin G in sera of patients with either rheumatoid arthritis or cancer", pages 2-6, the whole document  --	1-5 (PARTIAL - LY), 6-8, 13-86 (PARTI - ALLY)
X	Cancer Research, Volume 60, 1 October 2000, Marc Meichenin et al: "Tk, a New Colon Tumor-associated Antigen Resulting from Altered O-Glycosylation 1", page 5499 - page 5507  --	1-5, 9, 11-12, 13-45 AND 46 -86 (PARTIAL - LY)
X	Cancer Research, Volume 53, 15 October 1993, F-G. Hanisch et al: "Monoclonal Antibody 2B5 Defines a Truncated O-Glycan, GlcNAcBeta 1 -3GalBeta 1 4GlcNAcBeta 1-6 (GalNAc), on Mucins from Deep Gastric and Duodenal Glands as Well as Metaplasia and Neoplasia of Gastric Differentiation", page 4791 - page 4796  --	1-5, 9, 11-12, 13-45 AND 46 -86 (PARTIAL - LY)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI/03/000615

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Jpn. J. Cancer Res., Volume 81, April 1990, Jun Nakayama et al: "Griffonia simplicifolia Agglutinin-2-binding Glycoprotein as a Novel Carbohydrate Antigen of Human Colonic Carcinoma", page 388 - page 395  --	1-5,9,11-12, 13-45 AND 46 -86 (PARTIAL - LY)
X	DATABASE WPI Week 199049 Derwent Publications Ltd., London, GB; Class B04, AN 1990-365935 & JP 2264864 A (SHINETSU CHEM IND CO LTD), 29 October 1990 (1990-10-29)  --	1-5,9,11-12, 13-45 AND 46 -86 (PARTIAL - LY)
X	Glycobiology, Volume 4, no. 3, 1994, Jie Hu et al: "Structural characterization of intermediates in the biosynthetic pathway of neolacto glycosphingolipids: differential expression in human leukaemia cells", page 251 - page 257  --	1-5,9,11-12, 13-45 AND 46 -86 (PARTIAL - LY)
X	Archives of biochemistry and biophysics, Volume 288, no. 1, July 1991, Eric H. Holmes et al: "Isolation and Fine-Structure Characterization of Four Monoclonal Antibodies Reactive with Glycoconjugates Containing Terminal GlcNAc Residues: Application to Aspects of Lacto-Series Tumor Antigen Biosynthesis 1", page 87 - page 96  --	1-5,9,11-12, 13-45 AND 46 -86 (PARTIAL - LY)
X	WO 0021552 A1 (UNIVERSITY TECHNOLOGY CORPORATION), 20 April 2000 (20.04.2000),  --	1-5,9,11-12, 13-45 AND 46 -86 (PARTIAL - LY)
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 10, 17 November 2000, (2000-11-17) & JP 20 00191685 A (NIPPON KOUTAI KENKYUSHO:KK), 11 July 2000 (2000-07-11) abstract  --	1-5,9,11-12, 13-45 AND 46 -86 (PARTIAL - LY)

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Chembiochem, Volume 2, 2001, Thomas Bültner et al: "Chemoenzymatic Synthesis of Biotinylated Nucleotide Sugars as Substrates for Glycosyltransferases", page 884 - page 894  --	46-86 (PARTI - ALLY)
X	Glycobiology, Volume 11, no. 7, 2001, Zhao Chun Chen et al: "Synthesis of alpha-gal epitopes (Galalpha 1-3GalBeta 1-4GlcNAc-R) on human tumor cells by recombinant alpha 1,3galactosyltransferase produced in Pichia pastoris", page 577 - page 586  --	46-86 (PARTI - ALLY)
X	Vaccine, Volume 15, no. 11, 1997, Timothy R. Henion et al: "Synthesis of a-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody", page 1174 - page 1182  --	46-86 (PARTI - ALLY)
X	Methods in enzymology, Volume 362, 2003, Reiko Sadamoto et al: "Cell Wall Engineering of Living Bacteria through Biosynthesis", page 273 - page 286  --	46-86 (PARTI - ALLY)
X	Chemistry & Biology, Volume 8, 2001, George A. Lemieux et al: "Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens", page 265 - page 275  --	46-86 (PARTI - ALLY)
X	Annu. Rev. Cell Dev. Biol., Volume 17, 2001, Eliana Saxon et al: "Chemical and Biological Strategies for Engineering Cell Surface Glycosylation", page 1 - page 23  --	46-86 (PARTI - ALLY)

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/FI 0003/000615

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6075134 A (CAROLYN BERTOZZI ET AL), 13 June 2000 (13.06.2000)  --	46-86 (PARTI - ALLY)
X	WO 9114697 A1 (BROSSMER, REINHARD), 3 October 1991 (03.10.1991)  --	46-86 (PARTI - ALLY)
X	WO 0187321 A2 (EUROPEAN MOLECULAR BIOLOGY LABORATORY), 22 November 2001 (22.11.2001)  --	46-86 (PARTI - ALLY)
X	EP 0334962 A1 (ORIENTAL YEAST CO., LTD.), 4 October 1989 (04.10.1989)  -- -----	46-86 (PARTI - ALLY)

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/FI2003/000615**

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **46-53**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see extra sheet**
2. ☒ Claims Nos.: **57-59, 69-70, 73-76, 83-84**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**see extra sheet**
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see extra sheet**

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: **1-45, 46-86 (partially)**
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☒ No protest accompanied the payment of additional search fees.

Box II.1

Claims 46-53 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims.

Box II.2

Present claims 57-59, 69-70, 73-76 and 83-84 relate to compositions defined by reference to desirable characteristics or properties, namely *inter alia* the capability of the enzyme substrate of claim 57 of being transferred to a surface of a pathogenic entity. The claims cover all enzyme substrates having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of compounds. Additionally, previously known compounds may be included in the scope of the present claims. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the composition by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Box III

This International Searching Authority found multiple inventions.

The separate inventions are:

Invention 1.1, (claims 1-5 (partially), 6-8, 13-45 (partially) and 46-86 (partially)) concerns a pharmaceutical composition comprising a substance binding to a terminal N-glycan oligosaccharide sequence according to Formula I or Formula II and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -N-acetylglucosamine (GlcNAc) structure and an enzyme substrate composition.

.../...

Invention 1.2, (claims 1-5 (partially), 9, 11-12, 13-45 (partially) and 46-86 (partially)) concerns a pharmaceutical composition comprising a substance binding to a terminal O-glycan oligosaccharide sequence according to Formula III or according to claim 12 and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -GlcNAc structure and an enzyme substrate composition.

Invention 1.3, (claims 1-5 (partially), 10, 13-45 (partially) and 46-86 (partially)) concerns a pharmaceutical composition comprising a substance binding to a terminal GlcNAc linked to a protein and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -GlcNAc structure and an enzyme substrate composition.

Invention 2.1, (claims 46-86 (partially)) concerns a method of treatment or diagnosis of cancer by transferring a modified monosaccharide derivative to cancer cells by a glycosyl transferase or a transglycosylate enzyme.

Invention 2.2, (claims 46-86 (partially)) concerns a composition comprising an enzyme substrate, capable of being transferred specifically to a surface of a pathogenic entity by a transferring enzyme.

Invention 3, (claims 51-56 (partially) and 86 (partially)) concerns a substance according to Formula P1, a substance according to formula CT2 and a method to synthesise these substances. The pegylated peptides of formula P1 could generally be used for improving the quality of therapeutic proteins. The modification of cells and tissues according to Formula CT2 could generally be used for therapy such as transplantation or treatment of wounds or tissue damage.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

27/02/2004

International Application No.

PCT/FI 2003/000615

WO	03016915	A1	27/02/2003	FI	20011671 A	21/02/2003
EP	0255342	A1	03/02/1988	SE	0255342 T3	
				AT	76512 T	15/06/1992
				AU	601455 B	13/09/1990
				AU	7626787 A	04/02/1988
				DE	3779207 A	25/06/1992
				DK	392387 A	12/02/1988
				ES	2032447 T	16/02/1993
				GB	2195343 A,B	07/04/1988
				GB	8618443 D	00/00/0000
				GB	8717792 D	00/00/0000
				GR	3005450 T	24/05/1993
				IE	59984 B	04/05/1994
				IE	872041 L	29/01/1988
				JP	63119498 A	24/05/1988
				NZ	221230 A	26/04/1990
				US	6391634 B	21/05/2002
				ZA	8705551 A	27/04/1988
DE	3807594	A1	21/09/1989	AT	90793 T	15/07/1993
				DE	3844628 C	19/05/1993
				DE	58904746 D	00/00/0000
				EP	0406259 A,B	09/01/1991
				SE	0406259 T3	
				JP	2693247 B	24/12/1997
				JP	3503281 T	25/07/1991
				US	5625037 A	29/04/1997
				WO	8908845 A	21/09/1989
WO	0021552	A1	20/04/2000	AU	1443900 A	01/05/2000
US	6075134	A	13/06/2000	US	6458937 B	01/10/2002
				US	2003049721 A	13/03/2003
WO	9114697	A1	03/10/1991	DE	4009630 A,C	02/10/1991
				EP	0521941 A	13/01/1993
				JP	5507191 T	21/10/1993
				US	5405753 A	11/04/1995
WO	0187321	A2	22/11/2001	AU	6258901 A	26/11/2001
				EP	1282720 A	12/02/2003
				GB	0012216 D	00/00/0000
				US	2003153056 A	14/08/2003
EP	0334962	A1	04/10/1989	CA	1335071 A,C	04/04/1995
				DE	3853582 D,T	02/11/1995
				JP	11262802 A	28/09/1999
				JP	1065454 A	10/03/1989
				JP	2579497 B	05/02/1997
				US	4994374 A	19/02/1991
				WO	8902474 A	23/03/1989

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>40125</b>	FOR FURTHER ACTION    See Form PCT/IPEA/416	
International application No. <b>PCT/FI 2003/000615</b>	International filing date (day/month/year) <b>20.08.2003</b>	Priority date (day/month/year) <b>20.08.2002</b>
International Patent Classification (IPC) or national classification and IPC <b>A61K39/00, 31/70, A61P 35/00, 31/00, G01N 33/574, C07H 5/06</b>		
Applicant <b>BIOTIE THERAPIES CORP. et al</b>		

<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>19</u> sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> (sent to the applicant and to the International Bureau) a total of <u>11</u> sheets, as follows:</p> <div style="margin-left: 40px;"> <input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).  <input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.         </div> <p style="margin-left: 20px;">b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>	
---	--

<p>4. This report contains indications relating to the following items:</p> <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> Box No. I    Basis of the report  <input checked="" type="checkbox"/> Box No. II    Priority  <input checked="" type="checkbox"/> Box No. III    Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  <input checked="" type="checkbox"/> Box No. IV    Lack of unity of invention  <input checked="" type="checkbox"/> Box No. V    Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  <input checked="" type="checkbox"/> Box No. VI    Certain documents cited  <input type="checkbox"/> Box No. VII    Certain defects in the international application  <input checked="" type="checkbox"/> Box No. VIII    Certain observations on the international application         </div>	
---	--

Date of submission of the demand  <b>17.03.2004</b>	Date of completion of this report  <b>16.12.2004</b>
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. +46 8 667 72 88	Authorized officer  <b>Micael Oswald/ELY</b> Telephone No. +46 8 782 25 00

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/PI 2003/000615

## Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of:

- ☐ international search (under Rules 12.3 and 23.1(b))  
☐ publication of the international application (under Rule 12.4)  
☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

☐ the international application as originally filed/furnished

☒ the description:

pages 1-69 as originally filed/furnished

pages\* \_\_\_\_\_ received by this Authority on \_\_\_\_\_

pages\* \_\_\_\_\_ received by this Authority on \_\_\_\_\_

☒ the claims:

pages \_\_\_\_\_ as originally filed/furnished

pages\* \_\_\_\_\_ as amended (together with any statement) under Article 19

pages\* 70-80 received by this Authority on 2004-12-14

pages\* \_\_\_\_\_ received by this Authority on \_\_\_\_\_

☒ the drawings:

pages 1-16 as originally filed/furnished

pages\* \_\_\_\_\_ received by this Authority on \_\_\_\_\_

pages\* \_\_\_\_\_ received by this Authority on \_\_\_\_\_

☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages \_\_\_\_\_

☐ the claims, Nos. \_\_\_\_\_

☐ the drawings, sheets/figs \_\_\_\_\_

☐ the sequence listing (*specify*): \_\_\_\_\_

☐ any table(s) related to the sequence listing (*specify*): \_\_\_\_\_

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

☐ the description, pages \_\_\_\_\_

☐ the claims, Nos. \_\_\_\_\_

☐ the drawings, sheets/figs \_\_\_\_\_

☐ the sequence listing (*specify*): \_\_\_\_\_

☐ any table(s) related to the sequence listing (*specify*): \_\_\_\_\_

\* If item 4 applies, some or all of those sheets may be marked "superseded."

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP 2003/000615

## Box No. II Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed (Rule 66.7(a)).
- ☐ translation of the earlier application whose priority has been claimed (Rule 66.7(b)).
2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rule 64.1). Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

## 3. Additional observations, if necessary:

The priority is considered valid concerning documents WO 03016915 A1 and Nobuhisia Ohtani et al (2002), cited in the international search report. Therefore, they are of no relevance for this report.

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/PT 2003/000615

**Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application☒ claims Nos. 42-79, 80 (partly)

because:

☒ the said international application, or the said claims Nos. 42-49  
relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 80 (partly)  
are so unclear that no meaningful opinion could be formed (*specify*):

Present claim 80 relates to a composition defined by reference to desirable characteristics or properties, namely, *inter alia*, the capability of the modified monosaccharide derivative of claim 42 to be transferred to cancer cells by glycosyl transferase enzyme. The claims cover all enzyme substrates having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of compounds.

.../...

☐ the claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported by the description that no meaningful opinion could be formed.☒ no international search report has been established for said claims Nos. 50-79☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form

☐

has not been furnished

☐

does not comply with the standard

the computer readable form

☐

has not been furnished

☐

does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in the Annex C-bis of the Administrative Instructions.☒ See Supplemental Box for further details.

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX III

Additionally, previously known compounds may be included in the scope of the present claims. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful examination over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the composition by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful examination over the whole of the claimed scope impossible.

In concern of Invention 2.1, the examination covers modified monosaccharide derivatives according to the examples given in claims 44-45.

## Box No. IV Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.  
☐ paid additional fees.  
☐ paid additional fees under protest.  
☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is:

- ☐ complied with.  
☒ not complied with for the following reasons:

This International Searching Authority found multiple inventions.

The separate inventions are:

**Invention 1.1**, (claims 1 (partly), 2-4, 9-41 (partly), 42-43 (partly), 48-49 (partly)) concerns a pharmaceutical composition comprising a substance binding to a terminal N-glycan oligosaccharide sequence according to Formula I or Formula II and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -N-acetylglucosamine (GlcNAc) structure.

**Invention 1.2**, (claims 1 (partly), 5, 7-8, 9-41 (partly), 42-43 (partly), 48-49 (partly)) concerns a pharmaceutical composition comprising a substance binding to a terminal O-glycan oligosaccharide sequence according to claims 5 or 7-8 and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine,  
.../...

4. Consequently, this report has been established in respect of the following parts of the international application:

- ☐ all parts.  
☒ the parts relating to claims Nos. 1-49, 80 (partly)

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX IV

a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -GlcNAc structure.

**Invention 1.3**, (claims 1 (partly), 6, 9-41 (partly), 42-43 (partly), 48-49 (partly)) concerns a pharmaceutical composition comprising a substance binding to a terminal GlcNAc linked to a protein and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -GlcNAc structure.

**Invention 2.1**, (claims 42-49, 80 (partly)) concerns a method of treatment or diagnosis of cancer by transferring a modified monosaccharide derivative to cancer cells by a glycosyl transferase or a transglycosylate enzyme and modified monosaccharide derivative compositions.

**Invention 2.2**, (claims 53-79 and 80 (partly)) concerns a composition comprising an enzyme substrate, capable of being transferred specifically to a surface of a pathogenic entity by a glycosyl transferase or a transglycosylate enzyme.

**Invention 3**, (claims 50-52 and 86 (partly)) concerns a substance according to Formula P1, a substance according to formula CT2 and a method to synthesise these substances. The pegylated peptides of formula P1 could generally be used for improving the quality of therapeutic proteins. The modification of cells and tissues according to Formula CT2 could generally be used for therapy such as transplantation or treatment of wounds or tissue damage.

**A priori lack of unity** (between Inventions 1.1-1.3, Invention 2.1-2.2 and Invention 3)

Inventions 1.1-1.3 relate mainly to methods for diagnosing and treatment of human cancer that express terminal GlcNAc $\beta$ . Claims 1-41 relate to the problem of creating methods for diagnosing and treatment of human cancer. This problem appears to be solved by diagnosis and treatment of human cancer that express terminal GlcNAc $\beta$ .

.../...



## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX IV

Inventions 2.1-2.2 relate mainly to a method of treatment or diagnosis of cancer by transferring a modified monosaccharide derivative to cancer cells by transferring enzyme and a composition comprising an enzyme substrate, capable of being transferred specifically to a surface of a pathogenic entity by a glycosyl transferase or a transglycosylate enzyme. Claims 42-49 and 53-80 relate to the problem of treatment or diagnosis of cancer or other pathogenic entities. This problem is solved by using a transferring enzyme to transfer an enzyme substrate to the surface of the pathogenic entity.

Invention 3, relates mainly to pegylated peptides according to formula P1 which could generally be used for improving the quality of therapeutic proteins, a modified cell or tissue substances according to formula CT2 which could generally be used for therapy such as transplantation or treatment of wounds or tissue damage and also a method to synthesise these substances. Invention 3 relate to the problem of creating substances that could be used for improving the quality of therapeutic proteins and of creating substances that could be used for therapy such as transplantation or treatment of wounds or tissue damages. This problem appears to be solved by designing substances as described by formula P1 and formula CT2.

As the problems and solutions are technically so different, no single general concept can be formulated based on the technical features of the inventions. Consequently, the requirements of Rule 13.1 PCT are not met.

It was investigated under Rule 13.2 if any further features, either in the claims or derivable from the description, could be considered as a same or corresponding feature and which could be considered a special technical feature establishing a technical link between the three groups of inventions.

No such features were identified. Consequently, the three groups of inventions are not so linked as to form a single general inventive concept as required by Rule 13.1 PCT.

**Â posteriori lack of unity (between Inventions 1.1-1.3)**

Documents cited:

D1: WO 0021552 A1.

D2: Meichenin M, et al. Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. Cancer Res. 2000 Oct 1;60(19):5499-507.

D3: EP 0255342 A1.

.../...

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX IV

The technical features that Inventions 1.1-1.3 have in common are that they all pertain to a pharmaceutical composition comprising a substance binding to a terminal GlcNAc and a method for diagnosing human cancer in a biological sample, comprising determining the presence of the above mentioned terminal GlcNAc.

However, a pharmaceutical composition comprising a substance binding to a substance binding to terminal GlcNAc and to diagnosing human cancer in a biological sample comprising determining the presence of a terminal GlcNAc is known to the art (see D1-D4). In D1 GlcNAc $\beta$ 3GalNAc $\beta$ 6GalNAc and GalNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc oligosaccharides and antibodies thereto and their use in therapy (see specially claims 1, 11, 52 and 54-56) and indicated use in diagnosis (see page 5 lines 10-14) are disclosed. In D2 GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc and GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal oligosaccharides are disclosed as carcinoma-associated antigens and indications for use in therapy and diagnosis for these antigens are made (see the whole document). In D3 indication for diagnosis of terminal GlcNAc is disclosed (see specially page 2, col. 2, lines 32-61).

Hence, The technical features that Inventions 1.1-1.3 have in common novelty.

Therefore, the inventions 1.1-1.3 are not so linked as to form a single general inventive concept as described in Rule 13.1 PCT.

According to Article 34 (3) (a-c) and Rule 13.2, an international application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art.

A search for a new common concept of invention has failed. Therefore, the claims are considered to represent independent subject matter and the invention lacks unity.

**Á posteriori lack of unity (between Inventions 2.1 and 2.2)**

Documents cited:

D4: Chen ZC, Tanemura M, Galili U. Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in *Pichia pastoris*. *Glycobiology*. 2001 Jul; 11(7): 577-86.

D5: Henion TR, Gerhard W, Anaraki F, Galili U. Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. *Vaccine*. 1997 Aug; 15(11): 1174-82.

.../..

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX IV

D6: Sadamoto R, Niikura K, Monde K, Nishimura S. Cell wall engineering of living bacteria through biosynthesis. Methods Enzymol. 2003; 362: 273-86. (Published on the Web 07/13/2002)

The technical feature that Inventions 2.1 and 2.2 have in common is that they concern the treatment of diseases by transferring an enzyme substrate by a glycosyl transferase or a transglycosylate enzyme to the surface of a pathogenic entity.

However, treatment of diseases by transferring an enzyme substrate by a glycosyl transferase or a transglycosylate enzyme to the surface of a pathogenic entity is known in the art (see D4-D6). In D4, the transferring of  $\alpha$ -gal epitopes to human tumor cells for preparation of tumor vaccines is described (see specially the abstract). In D5, the transferring of  $\alpha$ -gal epitopes to influenza virus for preparation of vaccines is described (see specially the abstract). D6 describes bacterial cell surface engineering with modified enzyme substrates for preparing novel drugs and vaccines (see the whole document).

Hence, claims 42 and 53 of the claimed invention lack novelty.

Therefore, Inventions 2.1 and 2.2 are not so linked as to form a single general inventive concept as described in Rule 13.1 PCT. According to Article 34 (3) (a-c) and Rule 13.2, an international application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art.

A search for a new common concept of invention has failed. Therefore, the claims are considered to represent independent subject matter and the invention lacks unity.

...

An international search report has only been established for Inventions 1.1-1.3 and 2.1. Hence, this opinion will only cover those parts covered by the international search report.



## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX V

D12: Hu J, et al. Structural characterization of intermediates in the biosynthetic pathway of neolacto glycosphingolipids: differential expression in human leukaemia cells. Glycobiology. 1994 Jun;4(3):251-7.

D13: Holmes EH, Greene TG. Isolation and fine-structure characterization of four monoclonal antibodies reactive with glycoconjugates containing terminal GlcNAc residues: application to aspects of lacto-series tumor antigen biosynthesis. Arch Biochem Biophys. 1991 Jul;288(1):87-96.

D14: WO 0021552 A1.

D15: JP2000191685.

D16: Penno MB, De Maio A. A murine model for evaluating metastatic potential: characterization of a 90-110-kDa metastasis-binding protein. Exp Gerontol. 1992 Sep-Dec;27(5-6):493-501.

D17: DE 3807594 A1.

Invention 1.1, (claims 1 (partly), 2-4, 9-41 (partly), 42-43 (partly), 48-49 (partly)) concerns a pharmaceutical composition comprising a substance binding to a terminal N-glycan oligosaccharide sequence according to Formula I or Formula II and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -N-acetylglucosamine (GlcNAc) structure.

In D1, the oligosaccharide sequences GlcNAc $\beta$ 2Man $\alpha$ 6 (GlcNAc $\beta$ 2Man)- $\alpha$ 3Man4GlcNAc $\beta$ 4GlcNAc and (Gal $\beta$ 4)GlcNAc $\beta$ 2Man $\alpha$ 6 (GlcNAc $\beta$ 2Man)- $\alpha$ 3Man4GlcNAc $\beta$ 4GlcNAc (see page 1331, figure 1, G10-11) are proposed as cancer specific oligosaccharide structures (see page 1330, col. 2, lines 2-9 (see the Johnson et al, 1999 reference) and page 1331, col. 1, first sentence).

In D2, the oligosaccharide sequence GlcNAc $\beta$ 2Man $\alpha$ 6-(GlcNAc $\beta$ 2Man) $\alpha$ 3Man is proposed as a hepatoma specific antigen (see page 584, table 2, structure 8). It is proposed that the various structural alterations of N-linked sugar chains in alkaline phosphatase as revealed by this study, could be used for the diagnosis and prognosis of liver cancer (see page 589, col. 1, lines 18-28).

In D3, oligosaccharide structures having incomplete outer chains without galactose are proposed as hepatoma specific antigens (see abstract) (e.g. GlcNAc $\beta$ 2Man containing structures (see page 5061, chart 4 and 5)).

.../...

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX V

In D4, terminal GlcNac is proposed as a specific antigen for metastatic tumours (see page 2, col. 2, lines 33-61).

In D5, terminal GlcNac cluster antigens (TGCA) with mannose containing oligosaccharide structures are proposed as neoplastic fibroblast specific antigens (see abstract).

In D6, terminal GlcNac high Mannose containing oligosaccharide structures are proposed as leukemia specific antigens (see table 5).

In D7, terminal GlcNac $\beta$ 2Man oligosaccharide structures are proposed as tumour specific antigens (see oligosaccharides I and II page 1286).

D1-D7 are considered to represent the closest prior art. The distinguishing feature between the subject matter of D1-D7 and present claims 1 (partly), 2-4, 9-41 (partly), 42-43 (partly), 48-49 (partly) is that the disclosed cancer specific oligosaccharides of D1-D7 have not been directly proposed as general cancer specific targets for cancer therapy and cancer diagnosis. They are in most cases limited to specific types of cancers e.g. hepatoma (D4 refer to cancer in general).

However, it is well known in the art that cancer specific oligosaccharides can be used as cancer specific targets for therapy and diagnosis (see *inter alia* D17).

Therefore, it is considered that a person skilled in the art would, with the guidance of D1-D7, use the disclosed oligosaccharides as cancer specific targets for therapy and/or diagnosis.

Hence, it is considered obvious for a person skilled in the art to develop pharmaceutical compositions comprising substances binding to a terminal GlcNac $\beta$ 2Man and to diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharides.

The claims 1 (partly), 2-4, 9-41 (partly), 42-43 (partly), 48-49 (partly) are considered to lack an inventive step according to the motivation stated above.

.../...

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX V

**Invention 1.2**, (claims 1 (partly), 5, 7-8, 9-41 (partly), 42-43 (partly), 48-49 (partly)) concerns a pharmaceutical composition comprising a substance binding to a terminal O-glycan oligosaccharide sequence according to claims 5 or 7-8 and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -GlcNAc structure.

In D8, the oligosaccharide sequences GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc and GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4Glc are proposed as a cancer specific antigens (see page 5506, col. 1, lines 3-8 and page 5507, col. 1, lines 8-11). These oligosaccharide antigens are part of the Tk antigen found on human colorectal carcinomas (see the abstract). It is proposed that the new cancer specific antigen could be an interesting target of immunotherapy (see page 5507, col. 1, lines 3-4).

D9 discloses an antibody (mAb 2B5) that binds to the GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc $\beta$  terminal oligosaccharide (see the abstract). This antibody has been proposed to be of diagnostic relevance due to its selective reactivity to pseudopyloric metaplasia of gallbladder and of pancreatic epithelia or to gastric differentiated carcinoma of the stomach, gallbladder, and pancreas (see page 4791, col. 1, second last sentence).

In D10, terminal GlcNAc is proposed as a colon carcinoma specific antigen (see abstract). GlcNAc $\beta$ 3Gal and GlcNAc $\beta$ 3-(NeuAc)GalNAc are specific oligosaccharide sequences disclosed (see page 393, col. 1, second last paragraph and col. 2 first paragraph).

D11 discloses antibodies specific to terminal GlcNAc and their use in diagnostics of cancer (see abstract).

In D12, terminal GlcNAc $\beta$ 3Gal is proposed as Leukaemia specific antigen (see abstract).

D13 discloses antibodies binding to terminal GlcNAc $\beta$ 3Gal oligosaccharide sequences and their potential use in diagnostics of cancer.

D14 discloses therapeutic use of antibodies binding to terminal GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc and GlcNAc $\beta$ 3GalNAc and oligosaccharides sequences and their potential use in cancer and other diseases.

.../..

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX V

D15 discloses therapeutic use of terminal GlcNac $\beta$ 3Gal oligosaccharide sequence and its use in cancer.

D8-D12 are considered to represent the closest prior art. The distinguishing feature between the subject matter of D8-D12 and present claims 1 (partly), 5, 7-8, 9-41 (partly), 42-43 (partly), 48-49 (partly) is that the disclosed cancer specific oligosaccharides of D8-D12 have not been directly proposed as general cancer specific targets for cancer therapy and cancer diagnosis. They are in most cases limited to specific types of cancers e.g. colorectal carcinoma (See D8).

However, it is well known in the art that cancer specific oligosaccharides can be used as cancer specific targets for therapy and diagnosis (see inter alia D17). Therefore, it is considered that a person skilled in the art would with the guidance of D8-D12 use the disclosed oligosaccharides as a cancer specific target for therapy and/or diagnosis.

Hence, it is considered obvious for a person skilled in the art to develop a pharmaceutical composition comprising substances binding to a terminal GlcNac $\beta$  sequences as disclosed in inventions B and D and to diagnose cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharides.

The claims 1 (partly), 5, 7-8, 9-41 (partly), 42-43 (partly), 48-49 (partly) are considered to lack inventive step according to the motivation stated above.

Invention 1.3, (claims 1 (partly), 6, 9-41 (partly), 42-43 (partly), 48-49 (partly)) concerns a pharmaceutical composition comprising a substance binding to a terminal GlcNac linked to a protein and a method for diagnosing cancer in a biological sample comprising determining the presence of the above described terminal oligosaccharide. It also concerns: other pharmaceutical compositions, a diagnostic agent, an antigenic substance and use thereof, a cancer vaccine, a binding substance, a method for identifying therapeutics or diagnostic agents, a functional food, a method of transferring a modified monosaccharide derivative to a terminal  $\beta$ -GlcNac structure and.

.../...



## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: BOX V

In D16 terminal protein linked GlcNac is proposed as a cancer specific oligosaccharide structure. In the last paragraph of the discussion (see page 500) it is proposed that the knowledge disclosed in the article could be used to develop drugs to inhibit metastatic disease.

D16 is considered to represent the closest prior art. The distinguishing features between the subject matter of D16 and present claims 1 (partly), 6, 9-41 (partly), 42-43 (partly), 48-49 (partly) is that the disclosed cancer specific oligosaccharides of D16 have not been confirmed as human cancer specific oligosaccharides. The results are based on animal models and cell lines experiments.

The problem that this difference solves is that it is of specific interest in the treatment or diagnosis of human cancers to know that the proposed cancer specific oligosaccharides are cancer specific in humans not just in other animals and cell lines. The solution to this problem is to specifically test if the proposed cancer specific oligosaccharides also are specific for humans cancer tissue.

Therefore, it is considered that a person skilled in the art would with the guidance of D16 test if the disclosed oligosaccharide is cancer specific in humans. And the result as the inventors of the application has shown is that they are cancer specific in human also.

Hence, it is considered obvious for a person skilled in the art to develop a pharmaceutical composition comprising a substance binding to terminal protein linked GlcNac, and to diagnosing cancer in a biological sample comprising determining the presence of the above mentioned terminal oligosaccharide.

The claims 1 (partly), 6, 9-41 (partly), 42-43 (partly), 48-49 (partly) are considered to lack inventive step according to the motivation stated above.

**Invention 2.1**, (claims 42-49, 80 (partly)) concerns a method of treatment or diagnosis of cancer by transferring a modified monosaccharide derivative to cancer cells by a glycosyl transferase or a transglycosylate enzyme and modified monosaccharide derivative compositions.

In concern of Invention 2.1, the examination covers modified monosaccharide derivatives according to the examples given in claims 44-45.

.../...

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.  
Continuation of: BOX V

None of cited documents disclose modified monosaccharide derivatives according to claim 80, as defined in the examples given in claims 44-45. Further, the cited prior art does not give any indication that would lead a person skilled in the art to the claimed modified monosaccharide derivatives. Therefore, the claimed invention is not obvious to a person skilled in the art.

Accordingly, the invention defined in claims 80 (partly) is novel and is considered to involve an inventive step. The invention is industrially applicable.

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/FI 2003/000615

## Box No. VI Certain documents cited

### 1. Certain published documents (Rule 70.10)

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 03016915	27.02.2003	20.08.2002	20.08.2001

### 2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)

**Box No. VIII Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:


Article 6 PCT requires among other things that the claims, which define the matter for which protection is sought, are clear and concise. This has to be interpreted as meaning not only that a claim from a technical point of view must be comprehensible, but that it must define clearly the object of the invention, that is to say indicate all the essential technical features, which are necessary to obtain the desired effect, or differently expressed, which are necessary to solve the technical problem with which the application is concerned without undue experimentation.

Claims 1-12, 36 refer to a "substance binding" to a GlcNac-structure. This functional definition of a substance do not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined. The following functional statement does not enable the skilled person to determine which technical features are necessary to perform the stated function.

The claims when referring to a "substance binding" are only fully supported by the description when this term refers to an antibody.

What is claimed:

1. A pharmaceutical composition comprising a substance specifically binding to a human tumor specific oligosaccharide sequence according to Formula



wherein x is 3, when Sacch is Gal(NAc); or  
x is 2, when Sacch is Man; and wherein

s1 and s2 are independently 0 or 1 with the provision that there is at least one terminal GlcNAc; the structure is branched, when both s1 and s2 are 1; Sacch is Gal with the provision that it is not  $\alpha 6$ -linked to another GalNAc; Sacch is GlcNAc $\beta$  with the provision that s1 and s2 is 0 and said GlcNAc $\beta$  is linked to a protein or peptide; [GlcNAc $\beta$ x/Gal $\beta$ 3] means that terminal residue is either GlcNAc $\beta$ x or Gal $\beta$ 3, for the treatment of human cancer.

2. The pharmaceutical composition according to claim 1, wherein said substance binding to said oligosaccharide sequence is specific to one or several of the terminal oligosaccharide sequences of a N-glycan type structure according to Formula



wherein r1, r2, r3, r4, r5, and r6 are either 0 or 1 with the proviso that at least r1 is 1 or r2 is 1; GN is GlcNAc, with the proviso that when both r1 and r2 are 1, one GN $\beta$ Man can be further elongated with one or several other monosaccharide residues such as by galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6 residue and/or Man $\alpha$ 3 residues can be further substituted by GN $\beta$ 6 or GN $\beta$ 4, and/or Man $\beta$ 4 can be further substituted by GN $\beta$ 4.

3. The pharmaceutical composition according claim 1, wherein said substance binding to said oligosaccharide sequence is specific to one or several of the terminal oligosaccharide sequences of a N-glycan type structure according to Formula

$$[\text{GN}\beta 2\text{Man}]_{r1}\alpha 3([\text{GN}\beta 2\text{Man}]_{r2}\alpha 6)\{\text{Man}[\beta 4\text{GN}]_{r5}\}_{r6} \quad (\text{II})$$

wherein r1, r2, r5, and r6 are either 0 or 1, with the proviso that at least r1 is 1 or r2 is 1; GN is GlcNAc, with the proviso that when both r1 and r2 are 1, one GN $\beta$ Man can be


further elongated with one or several other monosaccharide residues such as by galactose, and/or one GN $\beta$ 2Man can be truncated to Man, and/or Man $\alpha$ 6 residue and/or Man $\alpha$ 3 residues can be further substituted by GN $\beta$ 6 or GN $\beta$ 4, and/or Man $\beta$ 4 can be further substituted by GN $\beta$ 4.

5

4. The pharmaceutical composition according to claim 2, wherein said oligosaccharide sequence is

10 GlcNAc $\beta$ 2Man, GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fu $\alpha$ 6)GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man, GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
15 GlcNAc $\beta$ 2Man $\alpha$ 3(Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fu $\alpha$ 6)GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man, Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
Man $\alpha$ 3(GlcNAc $\beta$ 2Man $\alpha$ 6)Man $\beta$ 4GlcNAc $\beta$ 4(Fu $\alpha$ 6)GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man,  
GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc,  
20 GlcNAc $\beta$ 2Man $\alpha$ 3Man $\beta$ 4GlcNAc $\beta$ 4(Fu $\alpha$ 6)GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man,  
GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc, GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc $\beta$ 4GlcNAc, or  
GlcNAc $\beta$ 2Man $\alpha$ 6Man $\beta$ 4GlcNAc $\beta$ 4(Fu $\alpha$ 6)GlcNAc

25 5. The pharmaceutical composition according claim 1, wherein said substance binding to said oligosaccharide sequence is specific to one or several of the terminal oligosaccharide sequences of a O-glycan type structure according to Formula



30 wherein s1, s2, s3, and s5 are independently 0 or 1, with the proviso that at least s1 is 1 or s5 is 1 and s3 is 1 or s5 is 1 and s3 is 1, so that the oligosaccharide sequence comprises at least one nonreducing end terminal GlcNAc $\beta$ -residue.

35 6. The pharmaceutical composition according to claim 1, wherein said oligosaccharide sequence is protein linked GlcNAc $\beta$  or a derivative thereof.

7. The pharmaceutical composition according to claim 5, wherein said oligosaccharide sequence is

5 GlcNAc $\beta$ 3Gal $\beta$ 3(Gal $\beta$ 4GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3Gal $\beta$ 3GalNAc, Gal $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)GalNAc, GlcNAc $\beta$ 6GalNAc, or GlcNAc $\beta$ 3GalNAc

8. The pharmaceutical composition according to claim 1, wherein said substance binding to said oligosaccharide sequence is specific to one or several of the following  
10 terminal oligosaccharide sequences:

GlcNAc $\beta$ 3Gal, GlcNAc $\beta$ 3Gal $\beta$ 4GlcNAc, GlcNAc $\beta$ 6Gal, GlcNAc $\beta$ 6Gal $\beta$ 4GlcNAc  
GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal, and GlcNAc $\beta$ 3(GlcNAc $\beta$ 6)Gal $\beta$ 4GlcNAc

15 said composition optionally further comprising at least one oligosaccharide sequences defined in any one of claims 2-7, said composition being for the treatment of lung, larynx, colon, gastric or ovarian cancer.

9. The pharmaceutical composition according to any preceding claim, wherein said  
20 oligosaccharide sequence is not linked by natural glycosidic linkages to other monosaccharide or oligosaccharide structures.

10. The pharmaceutical composition according to any preceding claim, wherein said  
substance binding to said oligosaccharide sequence is an aptamer, a peptide or a protein.

25 11. The pharmaceutical composition according to claim 10, wherein said protein is an antibody, a lectin, or a fragment thereof.

12. The pharmaceutical composition according to claim 10, wherein said protein is an  
30 enzyme recognizing the terminal GlcNAc-structures, preferably a glycosyltransferase enzyme or variant thereof.

13. The pharmaceutical composition according to claim 11, wherein said antibody is a  
human or humanized antibody.

35

14. A pharmaceutical composition comprising a human tumor specific oligosaccharide sequence as defined in any of claims 1-6, or analogs or derivatives thereof for the treatment of human lung, larynx, colon, gastric or ovarian cancer.

5 15. The pharmaceutical composition according to claim 14, wherein said human cancer is a human tumor.

16. The pharmaceutical composition according to claim 14, wherein the composition is for the treatment of a human tumor diagnosed to express or compared to normal tissue  
10 expressing said human tumor specific oligosaccharide sequence.

17. The pharmaceutical composition according to claim 14, wherein said human tumor specific oligosaccharide sequence is expressed on cell surface or tissue surface of human tumor.

15 18. The pharmaceutical composition according to claim 14, wherein said composition is antigenic.

19. The pharmaceutical composition according to claim 14 or 15, wherein said  
20 oligosaccharide sequence is an oligosaccharide sequence as defined in any one of claims 1-8.

20. The pharmaceutical composition according to claim 19 comprising a polyvalent conjugate of said oligosaccharide sequence wherein position C1 of the reducing end  
25 terminal of the oligosaccharide sequence (OS) comprising the tumor specific terminal sequence of the invention is linked (-L-) to an oligovalent or a polyvalent carrier (Z), via a spacer group (Y) and optionally via a monosaccharide or oligosaccharide residue (X), forming the following structure

30 
$$[\text{OS} - (\text{X})_n - \text{L} - \text{Y}]_m - \text{Z}$$

where integer m have values  $m > 1$  and n is independently 0 or 1; L can be oxygen, nitrogen, sulfur or a carbon atom; X is preferably lactosyl-, galactosyl-, poly-N-acetyl-lactosaminy, or part of an O-glycan or an N-glycan oligosaccharide sequence, Y is a  
35 spacer group or a terminal conjugate such as a ceramide lipid moiety or a linkage to Z.



21. The pharmaceutical composition according to any one of claims 1-20 comprising a pharmaceutically acceptable carrier and optionally an adjuvant.
22. A method for diagnosing cancer or tumor in a biological sample taken from a human patient, the method comprising determining the presence in said sample of an oligosaccharide sequence as defined in claim 1.
23. The method according to claim 22 wherein the determination comprises  
(a) contacting said biological sample with a substance binding to said oligosaccharide sequence, and  
determining the presence of a combination of said substance and said sample, the presence of said combination being an indication of cancer present in said sample, or  
(b) releasing the oligosaccharide structures of said biological sample by enzymatic or chemical methods to form a fraction containing free oligosaccharide structures from said sample, and  
determining the presence of said oligosaccharide sequence in said fraction, the presence of said oligosaccharide sequence in said fraction being an indication of cancer present in said sample.
24. The method according to claim 22 or 23, wherein said oligosaccharide sequence is a terminal oligosaccharide sequence as defined in any one of claims 1-8.
25. The method according to any one of claims 22-24, wherein said cancer is a tumor.
26. The method according to any one of claims 22-24, wherein a cancer or tumor type is determined.
27. The method according to any one of claims 22-26, wherein normal glycosylation of the tissue containing the cancer is determined.
28. The method according to any one of claims 22-27, wherein the glycosylations are determined on the surface of cancer or normal tissue
29. A diagnostic agent comprising a binding substance as defined in any one of claims 1-13 for the diagnosis of human cancer or cancer type.

30. Antigenic substance comprising a terminal oligosaccharide sequence as defined in any one of claims 1-8 in a chemically or biochemically synthesized polyvalent form.
- 5 31. Use of the antigenic substance according to claim 30 or analogs or derivatives thereof to produce polyclonal or monoclonal antibodies.
32. Use of the antigenic substance according to claim 30 or analogs or derivatives thereof for the purification of antibodies from serum, preferably from human serum.
- 10 33. Use of the antigenic substance according to claim 30 or analogs or derivatives thereof for the detection and/or quantitation of antibodies.
34. A cancer vaccine comprising oligosaccharide sequences containing a terminal sequence as defined in any one of claims 1-8 or analogs or derivatives thereof.
- 15 35. The cancer vaccine according to claim 34 comprising a pharmaceutically acceptable carrier and optionally an adjuvant.
36. A substance binding to oligosaccharide sequences containing a terminal sequence as defined in any one of claims 1-8, wherein said substance is an aptamer, human natural or humanized antibody or peptide.
- 20 37. A method for identifying cancer or tumor specific therapeutics or diagnostic agents comprising the steps of contacting a compound with a oligosaccharide sequence as defined in any one of claims 1-8 and determining binding to said oligosaccharide sequence by said compound.
- 25 38. A human anti-GlcNAc antibody obtainable by:  
passing human serum sample through a column containing immobilized terminal  
30 GlcNAc $\beta$  epitopes;  
washing the column;  
eluting the column with a buffer containing high concentration of GlcNAc;  
and collecting the antibody.

39. A functional food or food additive containing antibodies recognizing tumor specific oligosaccharide sequences as defined in any one of claims 1-8 for the treatment of human cancer or tumor.
5. 40. A functional food according to claim 37, wherein said antibody is produced in milk or in hen eggs.
41. The antibody according to claim 38, wherein said antibody recognizes oligosaccharide sequence GlcNAc $\beta$ 6GalNAc $\alpha$ -O-CH<sub>2</sub>-R, GlcNAc $\beta$ 6(Gal $\beta$ 3)GalNAc $\alpha$ -O-CH<sub>2</sub>-R, GlcNAc $\beta$ 2Man or GlcNAc $\beta$ -O-CH<sub>2</sub>-R or GlcNAc $\beta$ 3GalNAc $\alpha$ 1-O-CH<sub>2</sub>
- 10
42. Method of treatment or diagnosis of cancer or tumor comprising transferring a modified monosaccharide derivative to cancer cells or tumor by a glycosyl transferase or a transglycosylate enzyme.
- 15
43. The method according to claim 42 wherein said modified monosaccharide derivative is any type of terminal  $\beta$ -GlcNAc structures defined in any one of the preceding claims.
44. The method according to claim 42 wherein said modified monosaccharide derivative
- 20 is according to the formula  
UDP-GalN[-S]-D,  
wherein  
S is an optional spacer group  
D is derivatizing group including molecular labels such as for example biotin or a
- 25 fluorescent molecule including, or a toxic agent, prodrug or prodrug releasing substance.
45. The method according to claim 44 wherein the modified monosaccharide is UDP-GalN-spacer-biotin or UDP- N-(6-biotinamidohexanoyl)galactosamine.
- 30
46. The method according to claim 42 wherein the modified monosaccharide is transferred by is a galactosyltransferase which is engineered to transfer effectively 2-modified monosaccharides or a natural GalNAc/GlcNAc-transferase with similar specificity with the said modified galactosyltransferase from animals.
- 35
47. The method according to claim 42 wherein said modified monosaccharide derivative is a non-immunogenic hydrophilic structure.

48. The method according to claim 42 wherein said modified monosaccharide derivative is transferred to cell or tissue.
- 5 49. The method according to claim 42 wherein said modified monosaccharide derivative is transferred on a therapeutic protein.
50. A substance according to  
Formula P1:  
10 Hex(L-S-PEG)-GlcNAc $\beta$ -Core-peptide  
wherein Hex, L and S are as described in Formula C1,  
Core is a core structure of N-glycan and/or O-glycan, when GlcNAc is part of the core structure the core is the glycan core excluding a terminal GlcNAc residue,  
PEG is polyethylene glycol, and peptide is protein or peptide.
- 15 51. A substance according to  
Formula CT2:  
Gal(N-S-PEG)-GlcNAc $\beta$ -Cell /tiss,  
wherein S, PEG-core and peptide are as described in Formula C1.
- 20 52. Method of synthesis of substance according to claim 50 or 51 comprising transferring a modified monosaccharide by a modified galactosyltransferase.
- 25 53. A composition comprising an enzyme substrate, capable of being transferred specifically to a surface of a pathogenic entity or malignant cell or tissue by a transferring enzyme, selected from a glycosyl transferase and a transglycosylate enzyme, making a covalent linkage between said enzyme substrate and an acceptor structure of said surface, optionally conjugated to an immunologically active substance and/or a toxic substance for use as a medicine.
- 30 54. The composition according to claim 53, wherein said carbohydrate substance is a nucleotide sugar.
- 35 55. The composition according to claim 54, wherein said nucleotide sugar is an activated salt of natural type of said nucleotide sugar.

56. The composition according to claim 54, wherein said nucleotide sugar is selected from the group consisting of:

5 UDP-Gal, GDP-Fuc, GDP-Man, UDP-GlcNAc, UDP-Glc, UDP-Xyl, UDP-GlcA and CMP-NeuNAc.

57. The composition according to claim 56, wherein the immunologically active substance or the toxic substance as defined in claim 53 is linked to carbon number 2 or 6 of the Gal, GalNAc, Glc or GlcNAc residues of UDP-Gal, UDP-GalNAc, UDP-Glc or UDP-GlcNAc, respectively.

10

58. The composition according to claim 56, wherein the immunologically active substance or the toxic substance as defined in claim 53 is linked to carbon number 6 of the Fuc residue of GDP-Fuc.

15 59. The composition according to claim 56, wherein the immunologically active substance or the toxic substance as defined in claim 53 is linked to carbon number 5, 7, 8 or 9 of CMP-NeuNAc.

60. The composition according to claim 56, wherein UDP-Gal is modified to carbon 6 by a spacer and a Gal $\alpha$ 3Gal-saccharide epitope.

20

61. The composition according to claim 53, wherein said enzyme substance is a glycoside being a substrate for a transglycosylate enzyme.

25 62. The composition according to claim 61, wherein said glycoside is phenyl- or paranitrophenylglycoside.

63. The composition according to claim 53, wherein said immunologically active substance is a carbohydrate or a carbohydrate analog or a derivative recognizable by immune system.

30 64. The composition according to claim 53, wherein said immunologically active substance is recognized by antibodies.

65. The composition according to claim 63, wherein said carbohydrate or a carbohydrate analog or a derivative comprises terminal GlcNAc $\beta$ -, Gal $\alpha$ -antigen, or a blood group antigen.

35

66. The composition according to claim 65, wherein said blood group antigen is blood group A-antigen or blood group B-antigen.
- 5 67. The composition according to claim 53, wherein said immunologically active substance is recognized by a defensive cell surface receptor.
68. The composition according to claim 53, wherein said immunologically active substance is a carbohydrate recognized by non-antibody defense receptors of a patient.
- 10 69. The composition according to claim 53, wherein said immunologically active substance is a carbohydrate recognized by defensive lectins of the immune system of a patient or a terminal GlcNAc -recognising antibody substrate.
- 15 70. The composition according to claim 53, wherein said immunologically active substance is selected from the group consisting of:
- proteins, peptide antigens, non-harmful parts of peptidoglycan, non-natural epitopes, and lipid A of bacteria.
- 20 71. The composition according to claim 70, wherein the protein is a complement protein.
72. The composition according to any one of claims 53-71 further comprising a glycosyl transferase or a transglycosylating enzyme.
- 25 73. The composition according to claim 72, wherein said transglycosylating enzyme is a transsialidase.
74. The composition according to claim 72, wherein said glycosyl transferase is selected from the group consisting of:
- 30 galactosyltransferases, N-acetylglucosaminyltransferases, N-acetylgalactosaminyltransferases, fucosyltransferases, sialyltransferases, mannosyltransferases, xylosyltransferases, glucuronyltransferases and glucosyltransferases.
- 35 75. The composition according to claim 72, wherein said glycosyl transferase is selected from the group consisting of:

5  $\beta$ 4galactosyltransferase,  $\beta$ 4glucosyltransferase,  $\beta$ 4-N-acetylgalactosaminyltransferase,  $\beta$ 4-N-acetylglucosaminyltransferase,  $\beta$ 3galactosyltransferase,  $\beta$ 3-N-acetylglucosaminyltransferase,  $\beta$ 2-N-acetylglucosaminyltransferase,  $\beta$ 6-N-acetylglucosaminyltransferase,  $\alpha$ 3sialyltransferase,  $\alpha$ 6sialyltransferase,  $\alpha$ 3fucosyltransferase,  $\alpha$ 2fucosyltransferase and  $\alpha$ 6fucosyltransferase.

76. The composition according claims 72, 74 or 75, wherein said glycosyltransferase is in soluble non-antigenic form.

10 77. The composition according to claim 53, wherein said pathogenic entity or malignant cell carries a specific carbohydrate structure on its surface, said structure being specifically recognised by said transferring enzyme.

15 78. The composition according to claim 53, wherein said structure of said surface is a pathogenesis or metastasis -inducing carbohydrate receptor.

79. The composition according to any one of claims 53 - 78 further comprising  $Mn^{2+}$ ,  $Ca^{2+}$ ,  $Zn^{2+}$  and/or  $Mg^{2+}$  ions.

20 80. The composition according to any one of claims 53 - 79 comprising the modified monosaccharide derivative as defined in any one of claims 42-49 and/or the substance as defined in claim 50 or 51.